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Abstract 
Botulinum neurotoxin type A (BoNT/A) is implicated in a majority of 
human cases of botulism and causes long-lasting neuromuscular paralysis due 
to the persistence in nerve endings of its light chain protease that cleaves 
synaptosomal-associated protein of 25 kDa (S25). This highly debilitating and, 
often fatal, neuroparalytic condition cannot be adequately treated by traditional 
pharmacological methods due to difficulties in efficiently accessing either the 
pre-synaptic terminals or the cell body of the supplying spinal motor neurons 
and because of the lack of efficient drugs that can block or reverse the 
paralysis. 
A viral vector mediated gene delivery technique was therefore utilised to 
confer protection against toxin-induced blockade of exocytosis by the 
expression of cleavage-resistant S25 (S25-R198T) in susceptible cells. 
Recombinant adeno-associated viral (AAV) vectors expressing a His6-tagged 
S25-R198T (AAV-S25-R198T) were initially used to obtain proof-of-principle of 
this approach in chromaffin cell cultures, neuroendocrine cells that mimic the 
exocytotic pathway found in neurons. Stereotaxic injection of AAV-S25-R198T 
into anterior horns of rat spinal cords resulted in substantial protection against a 
subsequent challenge by BoNT/A injected into the soleus muscle. Interestingly, 
intra-muscular injection of this virus also resulted in protection against 
neuroparalytic action of a subsequently injected toxin. 
In order to obtain more efficient neuronally-targeted, peripherally-
deliverable viral vectors – which would also confer great utility in the treatment 
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of genetic diseases affecting the spinal cord – the more versatile lentiviral 
vectors (LV) were used. Biotinylated LVs were attached to targeting agents, 
different core-streptavidin (CS) tagged protease-inactive BoNT/E (BoTIM) 
mutants, and applied to cerebellar granule neuron cultures. These targeting 
molecules substantially reduced the viral infection of non-neuronal cultures with 
only minimal effects on the transfection of neurons.  
The results obtained in this study demonstrate the applicability of gene 
therapy to ameliorate the neuroparalytic effects of botulism. In addition, the 
novel tools and techniques developed, especially in the targeted, peripheral, 
delivery of viral vectors, could also be adapted to treat genetic disorders of 
motor neurons.  
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1.1. Brief overview of neuromuscular transmission in 
man 
Signals from neurons in the motor cortex (Brodmann’s area 4 – pre-
central gyrus) travel down through the lateral cortico-spinal tract and set up 
excitatory post-synaptic potentials (EPSPs) in dendrites of motor neurons in 
anterior horns of the spinal cord. These EPSPs summate and induce action 
potentials in axons of these neurons which travel down through the anterior 
roots, and via various nerves, to terminate at the pre-synaptic terminals over the 
muscle fibers. Arrival of an action potential to these motor nerve endings opens 
voltage-sensitive Ca2+ channels and the resulting influx of Ca2+ activates the 
putative Ca2+ sensor, synaptotagmin, triggering into action a complex 
machinery of proteins. These include the 3 SNAREs (SNAP receptor) – SNAP-
25, syntaxin and synaptobrevin, inducing fusion of synaptic vesicles containing 
the neurotransmitter, acetylcholine (ACh). The released ACh traverses the 
synaptic cleft and binds to nicotinic ACh receptors (AChR) on the muscle. 
These ligand-gated ion channels open upon binding ACh and let in cations, 
predominantly an influx of Na+, thereby, setting up an end-plate (EP) potential in 
the underlying muscle fibre. This then causes the rapid activation of the 
surrounding voltage-gated Na+ channels, causing an action potential to be 
setup and propagated through the T-tubule network in the muscle fibre. 
Subsequent release of Ca2+ from stores in the sarcoplasmic reticulum elicits the 
contraction of the muscle fibres through a sliding filament model of actin-
myosin, with troponin-tropomysin acting as the Ca2+ sensors.  
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Perturbation of this process at any of the above steps, especially in vital 
respiratory muscles, i.e. the diaphragmatic or intercostal muscles leads to 
serious morbidity and mortality. This can be caused by agents such as the 
botulinum neurotoxin (BoNT – which inhibits the release of ACh) or curare 
(which blocks the AChR), in genetic disorders like Amyotrophic Lateral 
Sclerosis (ALS – caused by the degeneration of motor neurons) and Duchenne 
muscular dystrophy (causing degeneration of muscle fibres) or due to 
immunological conditions such as myasthenia gravis (caused by production of 
auto-antibodies against AChR) and Lambert-Eaton syndrome (auto-antibodies 
against pre-synaptic Ca2+ channels)  .  
1.2. The microscopic architecture of a NMJ 
The NMJ is an area where part of the motor nerve specialized for ACh 
release (pre-synaptic terminal) comes into contact with the part of the muscle 
fibre, that is most sensitive to ACh (post-synaptic membrane).  Upon contact 
with the skeletal muscle fibre, the supplying α-motor neuron (MN) axon divides 
into multiple terminal swellings, called ‘boutons’, devoid of any myelin sheath 
and which project into corresponding depressions in the thickened muscle 
membrane (Sanes and Lichtman, 1999). These circumscribed regions of the 
muscle EP form 1µm deep clefts called ‘junctional folds’, rich in ACh receptors, 
and are mirrored by specialised regions called ‘active zones’ in the pre-synaptic 
nerve terminal, rich in ACh containing vesicles (see fig. 1). Schwann cells 
processes cover and protect the nerve terminal and, also, form myelin sheaths 
covering the pre-terminal axons. Large numbers of mitochondria are found in 
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nerve termini and fulfil the energy requirements inherent in ACh production, 
loading and release. The active zones are specialised for the tethering, docking 
and, most importantly, in regulated Ca2+-dependent fusion of loaded vesicles 
with the plasma membrane (Sanes and Lichtman, 1999). They contain electron-
dense material consisting of proteins such as Rab3-interacting molecules (RIM), 
Munc13, Piccolo, Bassoon, liprins, tyrosine phosphatases and other interacting 
molecules which help to maintain their anatomical and physiological differences 
from the rest of the pre-synaptic membrane (Lonart, 2002; Schoch and 
Gundelfinger, 2006).  
The crests and sides of the junctional folds are richly endowed with 
nicotinic AChRs (>10,000/µm2 – compared to an extra-synaptic density of less 
than 10/µm2), with an average human EP estimated to contain about 15-40 
million receptors (Salpeter et al., 1988; Shyng and Salpeter, 1989; Salpeter et 
al., 1993; Salpeter, 1999). These receptors are predominantly found in the tops 
of the junctional folds with neural cell adhesion molecules (NCAMs) and 
voltage-gated Na+ channels found at the bottom – an architecture fashioned by 
the agrin–MuSK–rapsyn pathway and which has been hypothesized to result in 
increased efficiency of transmission (MuSK - muscle specific kinase) 
(McConville and Vincent, 2002).  
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Fig. 1: The microscopic architecture of a NMJ: A: Schematic showing the main components of 
a mammalian NMJ, with the pre-synaptic terminal on top and the post-synaptic in the bottom 
(Hatched line between the two represents the basal lamina). B: Illustration of the architecture of 
the post-synaptic elements involved in converting end-plate potentials to muscle contraction. 
The horizontally organised thick and thin filaments are the actin/myosin/troponin/tropomysin 
contraction machinery. SR represents the sarcoplasmic reticulum (1: SR Ca2+ channel, 2: ACh, 
3: AChR, 4: Neuronal Ca2+ channel, 5: K+ channel, 6: T-tubule Na+ channel, 7: Muscle Cl- 
channel and 8: Muscle Na+ channel) C & D: Ultrastructure of pre-synaptic frog NMJs. D is the 
reconstruction of multiple electron microscopic images of freeze-fractured active zones. SVs are 
the blue spheres, the active zone proteins are in gold and the plasma membrane is in orange. C 
represents a cartoon of the aspects seen in D, with the plasma membrane shown in white. The 
orderly structure of the active zone is well represented in these images. A & D are adapted from 
(Squire et al., 2003) and B & C are adapted from (Harlow et al., 2001). 
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1.2.1. The pre-synaptic apparatus at the NMJ 
 
Mammalian extrafusal skeletal muscle fibres are innervated by axons 
from α-MNs of the brainstem and spinal cord. These large lower motor neurons, 
are distinguishable by their size and location from gamma motor neurons, which 
innervate intrafusal muscle fibers of muscle spindles. The muscle fibres 
supplied by α-MN forms a motor unit, comprising of biochemically and 
functionally identical fibres, and the α-MNs supplying a single muscle form a 
motor neuron pool, whose cell bodies are usually in close proximity to each 
other in the spinal cord. In the spinal cord, α-MNs are located within the gray 
matter of the anterior horn and their axons exit in the anterior root to form the 
motor component of the various spinal nerves (See fig.: 2). These neurons are 
in turn supplied by upper motor neurons via the corticonuclear, corticospinal, 
and rubrospinal tracts. The corticonuclear and corticospinal tracts are involved 
in the control of voluntary movement and end in glutaminergic synapses on α-
MNs. In addition, α-MNs receive extensive sensory input from Golgi tendon 
organs, muscle spindles and other sensory neurons in the periphery and from 
local inter-neurons in the vicinity, e.g., Renshaw cells. These sensory afferents 
underlie the several types of reflex circuits of differing complexities, like the 
monosynaptic knee-jerk reflex. Some of the inputs from the inter-neurons are 
inhibitory in nature and are involved in the maintenance of proper muscle tone.  
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Sensory afferents
Motor efferents
 
Fig. 2: Spinal control of muscle contraction: Schematic showing the regulatory system 
controlling muscle contraction. The extra and intra-fusal muscle fibres are shown in orange. The 
MNs, α and γ, are shown in green, the sensory input in brown and interneurons in blue. Input 
from the golgi tendon organs and muscle spindles control the excitability of the α MN, while 
input from the γ MN controls the sensitivity of the muscle spindles. Adapted from (Squire et al., 
2003). 
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Arrival of an action potential at the pre-synaptic terminus, from the 
supplying α-MN, results in the opening of Ca2+ channels, and the ensuing Ca2+ 
influx stimulates a fast (<1 ms), regulated (by a complex cohort of proteins) and 
spatially accurate (only at the active zones) fusion of synaptic vesicles to the 
membrane (Katz and Miledi, 1968; Wojcik and Brose, 2007) (See fig.: 3). The 
trafficking of synaptic vesicles from the cytoplasm to the membrane and back 
again is termed the “synaptic vesicle cycle” and can be subdivided into 
sequential steps of vesicle loading, clustering and tethering at the membrane, 
docking at active zones, priming for release and, finally, release of vesicle 
contents by fusion with the membrane (Wojcik and Brose, 2007). These 
vesicles are then recycled and refilled with ACh for repeated rounds of 
exocytosis, through an intermediate process of acidification by a vacuolar 
proton pump followed by active transport of the neurotransmitter into the lumen 
(Sudhof et al., 1993; Sudhof, 2004; Rizzoli and Jahn, 2007). The final steps of 
fusion and recycling differs in various neuron types and can be classified into  a 
“kiss-and-run” type (Heuser and Reese, 1973), where transient opening and 
closure occur through a small fusion pore, and “full fusion”, where the vesicle 
completely merges with the plasma membrane and is endocytosed by clathrin-
coated pits (Ceccarelli et al., 1973; Hurlbut and Ceccarelli, 1974). Another 
process of vesicle fusion has also been hypothesized, where the vesicles 
remain in the readily releasable pool (“kiss-and-stay”) and are refilled with 
neurotransmitters without undocking (Koenig and Ikeda, 1996).  
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Fig. 3: The synaptic vesicle cycle. SVs bud off from endosomes and are then filled with the 
specific neurotransmitter. They are then recruited to the active zone, where they go through 
many intermediate stages before final fusion. Recycling of fused SVs can proceed through 
different pathways like, the “kiss and run” and clathrin-mediated endocytosis. Adapted from 
(Squire et al., 2003). 
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The faster “kiss-and-stay” and “kiss-and-run” methods were thought to be 
used preferentially at faster synapses thereby avoiding the time- and energy-
intensive recycling processes, whereas the slower clathrin-dependent pathway 
was thought to be more prevalent in slower synapses. However, current 
evidence does not show any such preference, especially in light of the fact that 
most neurons only ever undergo exocytosis at a moderate rate and all these 
three types of recycling are adequate under such circumstances (reviewed in 
(Rizzoli and Jahn, 2007)). Upon high frequency nerve stimulation, the initial 
burst of neurotransmitter release is followed by a lower, steady, plateau of 
vesicle release. The total number of synaptic vesicles at a synapse that 
participate in these exo-and-endocytotic processes is referred to as the 
“recycling pool”, comprising an initially released burst called the “ready-
releasable pool” (~20% of vesicles in mammalian NMJs) and a “reserve pool” 
that helps to maintain the later steady-state release (the remaining 80%) 
(Richards et al., 2003; Rizzoli et al., 2003). Some neurons have a third pool of 
vesicles termed the “resting pool”, whose function or absolute number are not 
yet clear (Sudhof, 2000). 
Large dense core vesicles (LDCVs) in neuroendocrine cells such as the 
adrenaline/noradrenaline-secreting adrenal chromaffin cells or insulin-secreting 
beta cells in the islet of Langerhans undergo exocytosis by similar mechanisms, 
differing mainly in the speed of release (up to 20 fold slower) and the lack of 
specialised active zones (Livett, 1984; Livett et al., 1987).  
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1.2.2. Organisation of the post-synaptic NMJ 
The mature mammalian skeletal NMJ consists of the pre-synaptic nerve 
terminal of a spinal motor neuron in close apposition with a striated muscle 
fibre, albeit separated by a thin basal lamina, and is cocooned in Schwann cells 
(Hughes et al., 2006) (See fig.: 1 and 4). The assembly of this complex 
apparatus is initiated by signals from the axon as it approaches an immature 
myotube. While there are many candidates for the actual neuro-chemical 
signals involved in this process, the heparin-sulphate proteoglycan agrin is most 
studied and one whose requirement for this process has been proven in null 
and mutant mice (McConville and Vincent, 2002). Agrin, transported down 
motor axons and released by the immature pre-synaptic terminal, binds to the 
basal lamina and activates a transmembrane receptor tyrosine kinase called 
MuSK on immature muscle cells (Ruegg and Bixby, 1998; Lin et al., 2008).  
This then activates a series of down-stream steps which leads to the activation 
of a membrane associated protein – rapsyn – and finally to clustering of AChRs 
(AChRs), associated 1:1 with rapsyn, and other postsynaptic components like 
utrophins, ankyrins, Na+ channels and many cell adhesion and signalling 
proteins. An immature myotube transcribes α, β, γ and δ AChR genes to form 
the functional pentamer – α2βγδ (the adult counterpart has the ε subtype 
instead of δ). In immature myotubes, the functional AChR protein is found 
distributed throughout the plasma membrane at a concentration of 1000 per 
µm2 – upon contact with the motor axon, this density increases to more than 
10000 per µm2 at the junctional folds and decreases to less than 10 per µm2 
away from them (a process that takes less than 12 h in certain models like 
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chicken and rat NMJs (Bevan and Steinbach, 1977; Froehner, 1991)).  The 
motor nerve terminal not only controls the clustering of AChR, but also 
stimulates their local production through a signalling molecule called neuregulin. 
The innervating motor terminals can also reduce the expression of non-local 
AChRs by distant myocyte nuclei – by changes in the amount of local and free 
intracellular Ca2+ (Sieburth et al., 2005; Hughes et al., 2006).  
The nerve supply to the muscle fibres, while stable, has the property of 
remodelling in response to alterations in synaptic transmission. This is also 
reflected in post synaptic modifications in the size, density and location of the 
AChRs on the muscle fibres. While the molecular signalling mechanisms that 
govern these changes are not fully known, the defined application of toxins 
capable of perturbing neurotransmission at the pre-synaptic (BoNT) or post-
synaptic level (α bungarotoxin - α-BuTx) can help in studying these processes 
at morphological and molecular levels. A more in-depth understanding of these 
processes will not only help in gaining further knowledge of synaptic biology, but 
also in devising treatments for various muscular and neurological disorders.  
The arrival of a nerve impulse at this terminus results in the fusion of ~60 
synaptic vesicles per active zone; each containing ~10,000 molecules of ACh. 
The released ACh then binds to the nicotinic AChRs found in the junctional 
folds resulting in an influx of Na+ and depolarisation of the muscle membrane. 
There is a wide safety margin in the whole process of neuromuscular 
transmission; the amount of ACh released per impulse being far higher than the 
number of AChRs and the number of AChRs being higher than that necessary 
to produce a fully propagated response at the muscle membrane (Ganong, 
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2003; Squire et al., 2003).   
A
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Fig. 4: The Acetylcholine cycle: A: Synthesis of ACh. Free choline in the extracellular fluid is 
taken up and concentrated in the pre-synaptic compartment by a specific choline transporter. 
The enzyme Choline acetyl-transferase (ChAT), then acetylates this free choline using acetyl-
CoA. This is then actively concentrated in the SV by a specific vesicular transporter. Upon 
release, ACh binds to the post-synaptic AChR, setting up an EPP in the muscle membrane. 
Excess ACh is destroyed by basal membrane bound Cholinesterase (AChE) or by the plasma 
pseudo-cholinesterase (pAChE), releasing free choline. B and C: Structure of the nicotinic 
AChR. B shows a schematic with the putative structure as exists in intact membranes. It 
resembles other ligand-gated ion-channel morphology, with a central pore, selectivity filter and 
an ACh binding pocket. C is a three-dimensional computational representation based on 
electron-density maps. B and C are adapted from (Unwin, 2005) 
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The excess released ACh is destroyed by cholinesterase found on the 
basal lamina and by pseudo-cholinesterases in the plasma, priming the 
apparatus for another action potential (See fig. 4). Repeated trains of stimuli, 
before the onset of relaxation in the muscle, results in the activation of 
additional contractile elements and increase in muscle tension in a 
phenomenon known as ‘summation’. With increasing frequency, the tension 
developed increases proportionally till it reaches a plateau, at tetanic frequency 
(Preston and Shapiro, 2005).  
1.2.3. Other important actors involved in nerve-muscle conduction and 
its control – Schwann cells, muscle spindles and spinal inter-neurons. 
Schwann cells are glia-like cells found along the axons of peripheral 
motor nerves involved in the creation of a myelin sheath. The myelin sheath of a 
motor axon is formed of up to 100 layers of the Schwann cell membrane tightly 
wound around the axon interspersed by the nodes of Ranvier – 1 µm 
constrictions devoid of any myelin. Terminal Schwann cells, a specialised 
subset of Schwann cells found near the NMJs, form a closely-fitting cover over 
the pre-synaptic terminals. Schwann cells are important in initial axon guidance 
(Mars et al., 2001; Ullian et al., 2004), in the re-establishment of innervation 
following injury or dismemberment of axons, maintenance and modulation of 
synaptic terminals and neurotransmission (Hughes et al., 2006) and in the 
process of nerve sprouting after perturbation of neuromuscular transmission 
(Son and Thompson, 1995; Son et al., 1996). The portion of the myelin sheath 
which is in tight contact with itself is composed of extracellular domains of a 
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protein called P0 (Protein zero). Mutations of this crucial protein can lead to 
various peripheral neuropathies, especially in certain forms of Charcot-Marie-
Tooth disease.  
 Muscle spindles are an important sensory and calibration system 
involved in the fine control of muscle contraction (See fig.: 1). Also called intra-
fusal fibres, they consist of two morphological distinct, specialised, muscle 
fibres termed as the nuclear bag and chain fibres.  These fibres, innervated 
separately from the rest of the muscle fibres, have a motor supply from small 
motor neurons in the lateral horns of the spinal cord via γ efferent axons (along 
with some innervation from the α motor neurons via β efferent axons). They 
have terminations of sensory afferents from the dorsal root ganglion through 
type Ia fibres. The central termination of neurons supplying the muscle spindles 
end on α motor neurons. Muscle spindles are arranged in parallel to the regular 
muscle fibres and in the classical stretch reflex, stretching causes the sensory 
endings on the spindle fibres to start firing. This causes action potentials to be 
set up in α motor neurons supplying the muscle, thereby, causing its 
contraction. The spindles are also important in gauging changes in the rate of 
stretch of the muscle, in reducing tremors, controlling muscle tone and, through 
inter-neurons in the contralateral side of the spinal cord, in causing relaxation of 
muscle antagonists (Ganong, 2003; Squire et al., 2003). 
 The majority of α motor neurons input is from interneuron in the 
spinal cord, many from those in the same spinal segments. These inter-neurons 
are in turn connected to muscle spindles (on the same and opposite side), golgi 
tendon organs, α motor neurons, sensory neurons and upper motor neurons in 
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the CNS. Inter-neurons act as computational tools that integrate signals from 
various sensory and central sources and distributes them to α motor neurons 
and other inter-neurons. They are crucial in relaying sensory and central 
information to motor neurons that initiate or modulate output and in the 
formation of rhythmic patterns of muscle contraction (Squire et al., 2003). 
1.3. The molecular machinery for fusion of synaptic 
vesicles with the plasmalemma 
Small vesicles, with a phospholipid bilayer and a high protein (>30%) 
content, predominate at mammalian NMJs. While between 20-50nm in size, 
they contain all the proteins necessary for acidification, neurotransmitter 
transport, exocytosis and finally endocytotic recycling (See fig. 5). One of the 
largest proton on the vesicle is the vacuolar protein pump, most synaptic 
vesicles can only contain one of these large transmembrane multi-protein 
complexes containing components responsible for the ATPase activity and 
proton translocation. The proton gradient setup by this pump is exploited by the 
12-transmembrane vesicular ACh transporter to concentrate ACh inside the 
synaptic vesicles (SVs) – exchanging 2 protons for every ACh molecule (Weihe 
et al., 1996; Ojeda et al., 2004).  
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Fig. 5: Synaptic vesicles: A: Molecular constituents of an average SV. Computer generated 3D 
model of all the molecules associated with SVs. The biggest molecule visible is the vesicular 
ATPase (V-ATPase – in blue) and the most abundant molecule is synaptobrevin (in red). 
Adapted from (Takamori et al., 2006). B: Ca2+ microdomains near active zones. The top panel 
shows the Ca2+ concentration upon arrival of an action potential, while the bottom panel shows 
the dispersal of the ionic gradient a few milliseconds after the end of the action potential 
(Gradients of pink represent Ca2+ concentration – higher extra-cellular concentrations diffuse 
inwards through open channels in the top panel). The yellow band represents the lipid bi-layer 
and docked SVs are shown in blue. Adapted from (Squire et al., 2003). 
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These synaptic vesicles are typically congregated in highly organised 
regions of the synapse called active-zones. Another of the most important 
constituents of these active zones are voltage-dependent Ca2+ channels – 
found at a density of more than 100 channels per active zone. These channels 
are crucial in the excitation-secretion coupling in synapses. The normally low, 
and strongly buffered, Ca2+ concentration inside the synapses undergoes a 
rapid, <100µs, and massive, >1000 fold, increase in the local concentration of 
free Ca2+ upon arrival of an action potential at the terminal. This high 
concentration in a spatially localised area is the trigger for synaptic vesicle 
fusion (Katz and Miledi, 1968; Meinrenken et al., 2003). The high buffering 
capacity of the terminals also causes the equally rapid reduction in Ca2+ 
concentrations at the end of the action potential. Recent studies have indicated 
synaptotagmin, with its 5 Ca2+ binding sites and micromolar affinity for Ca2+, 
integrates the Ca2+ entry with fast exocytosis (Schneggenburger and Neher, 
2000) (See fig. 5). 
 
1.3.1. Molecular mechanisms of SNARE-dependent exocytosis  
 SNARE proteins found on the vesicles along with their 
counterparts in the active zone membranes form multi-protein “nano-machines” 
that mediate membrane fusion responsible for neurotransmitter release. This 
family of versatile molecules, which despite their widely divergent sequences 
form similar coiled-coil helical complexes, perform the basic actions of vesicle 
budding and fusion in all eukaryotes. They are also involved in fusion reactions 
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necessary for cell growth, membrane repair and movement. A core complex is 
formed when four characteristic and conserved, 60-70 amino-acid long, SNARE 
motifs assemble into a parallel four-helical bundle (See fig. 6). The currently 
accepted molecular model of SNARE-mediated membrane fusion involves the 
initiation of merger opposing membranes by using energy released during the 
formation of this bundle. These SNARE motifs are usually, but not always, 
flanked by a transmembrane domain at the C-terminal and widely variant 
domains at the N-terminal. Some important exceptions are the synaptobrevins 
(with no N-terminal domain) and SNAP-25 (with no trans-membrane domain 
and two SNARE motifs joined by a palmitoylated linker).  
While SNAREs were originally classified as v-SNAREs (vesicle-
membrane SNAREs) or t-SNAREs (target-membrane SNAREs), the propensity 
of certain members of this family to act as both v-or-t-SNAREs (Sec22 acting as 
both v-and-t-SNARE - (McNew et al., 2000) and (Burri et al., 2003)) has 
resulted in the acceptance of a more refined classification into 4 sub-families. 
Current classification is based on the detailed analysis of core complexes of 
four different classes of SNARE motifs – Qa, Qb, Qc and R – based on the 
identity of highly conserved three glutamine (Q) or one arginine (R) in the 
central ‘0’ layer of the core complexes.  
In vitro SNAREs can interact promiscuously, but in vivo they typically 
only form when a hetero-oligomeric four helical bundle is created containing one 
SNARE motif from each class (Jahn et al., 2003; Jahn and Scheller, 2006). For 
example, exocytosis at mammalian NMJs is mediated by the formation of a core 
complex consisting of the R-SNARE motif from synaptobrevin, the Qa-SNARE 
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motif from syntaxin 1 and the Qb & Qc-SNARE motifs from SNAP-25 (Söllner et 
al., 1993; Sollner et al., 1993; Fasshauer et al., 1998). These SNAREs were 
first identified based on their homology to genes implicated in temperature 
sensitive trafficking mutations in yeast (Wilson et al., 1989). Their absolute 
importance to synaptic exocytosis was first established when they were shown 
to be substrates cleaved by the paralysing botulinum and tetanus neurotoxins 
(Schiavo et al., 1992b; Schiavo et al., 1992a; Schiavo et al., 1995). While there 
is continuing controversy as to whether the SNARE complexes are the minimal 
essential fusion motors or if they are components of a more complex 
machinery, evidence is increasing for the latter hypothesis being probably more 
descriptive of the majority of mammalian synapses.  VAMP knockout mice, with 
a severe deficiency in the Ca2+ triggered fast exocytotic pathway, still show 
~10% of normal release when triggered by other factors such as hypertonic 
sucrose (Schoch et al., 2001). Similarly, SNAP-25 knockout mice also retain 
some amount of exocytosis (Washbourne et al., 2002). Only the deletion of 
Munc18-1/Nsec-1, a syntaxin binding protein from the Sec-Munc (SM) family, 
eliminated release completely ((Verhage et al., 2000) and reviewed in (Jahn et 
al., 2003). Munc18 knockout mice died at birth, showed some synapse 
formation, albeit with early degeneration and demonstrated an absolute lack of 
spontaneous or evoked fusion. 
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Fig. 6: SNAREs and synaptic exocytosis. A: Schematic of the SNARE core complex showing 
VAMP II (blue – R motif), Stx (red – Qa motif) and SNAP-25 (green – Qb and Qc motifs) in their 
four-helix bundle configuration. The left panel shows a side-view of the SNARE complex 
backbone, with the central ionic layer (red) and 15 hydrophobic layers (black) that mediate the 
core interactions highlighted. The right panel shows top-down views of side-chain interactions, 
with important amino acid H-bonds and salt bridges indicated. The central layer shows the 
position of glutamine (Q) or arginine (R) residues that define Q-SNAREs and R-SNAREs, 
respectively. B, C and D: A screen-capture from a Cn-3D rendering of a 2.4Ǻ structure of a 
mature SNARE-complex, showing the top, bottom and side views respectively – this shows the 
tight helix-of-helices structure of a core SNARE complex. Adapted from (Chen and Scheller, 
2001) and (Sutton et al., 1998). 
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Initial clues about the organisation of the central SNARE complex was 
found from in vitro studies which showed that SNAP-25, syntaxin 1 and VAMP 
can form a stable, detergent- and neurotoxin-resistant complex with a 1:1:1 
stoichiometric ratio (Hayashi et al., 1994; Pellegrini et al., 1995). This complex 
dissociates upon addition of NSF and α-SNAP, in the presence of ATP, and 
renders the components susceptible to cleavage by BoNT and TeNT. The 
minimal ternary core complex consists of two domains from SNAP-25, spanning 
residues 1-84 and 143-206, and one domain from syntaxin and VAMP, 
encompassing residues 199-243 and 27-96, respectively. SNAP-25 domains, 
which are separated by a long linker region, are organised in a parallel manner 
in the complex. Furthermore, vesicles containing VAMP were able to fuse with 
those containing SNAP-25 and syntaxin (Weber et al., 1998), albeit at rates 
much slower then those observed in vivo. While important clues were gained by 
pull-down assays and cell free systems, the relative abundance of these 
SNAREs in neurons and their propensity to interact with many different proteins, 
meant that conclusive evidence was not obtainable by such in vitro assays 
(Jahn and Scheller, 2006). However, based on all accumulated knowledge from 
yeast homology studies, neurotoxin mediated neuroparalysis and in vitro 
studies, it does appear that membrane fusion is mediated by these SNAREs, in 
association with other essential proteins like complexins, Stx and Munc-18. The 
progression of SNARE-mediated fusion can be divided into a step-wise process 
involving – a) assembly of free SNAREs into an acceptor complex, a process 
probably mediated by the SM proteins, b) association with VAMP to form a 
loose trans-SNARE complex and c) creation of tight SNARE complexes, 
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probably catalysed by complexins and Stx and, finally, fusion with formation of a 
stable cis-SNARE complex  ((Hanson and Jahn, 1997; Lin and Scheller, 1997) 
and reviewed in (Jahn and Scheller, 2006)). While all these phases can explain 
the processes involved into bringing the two membranes into close proximity, 
there is still some ambiguity about the steps involved in actual membrane fusion 
and lipid mixing. The currently accepted hypothesis is that close membrane 
apposition is brought about by the ‘zippering’ of the coil-coil domains of 
SNAREs, from their N-terminal towards their C-terminal, which clamps the 
membranes together (Fiebig et al., 1999). The “stalk” hypothesis is the most 
favoured one to describe the fusion of lipid bi-layers that then takes place. The 
closely apposed bilayers undergo a transition to a “hemi-fusion” state where the 
outer membranes are continuous but the inner ones are still separate and there 
is no aqueous connection. Later, the inner membranes fuse, followed by the 
release of vesicle contents. After the formation of the hemi-fusion state and 
before complete fusion, the physical constraints imposed by the close 
apposition of these membranes probably imposes strong strains on the linker 
regions that connect the SNAREs to their trans-membrane domains, probably 
resulting in their C-terminal ends being pulled into the hydrophobic core of the 
bilayer . This, and the later complete fusion, results in the formation of a cis-
SNARE complex – being stable even at 80°C, 8M urea or 2% SDS ((Kozlovsky 
et al., 2002; Chernomordik and Kozlov, 2003) and reviewed in (Jahn and 
Grubmuller, 2002)).  As yet, how all these complex processes described above 
fit into the previously described fast and slow, “kiss and run” or “kiss and stay” 
modes of exo-endocytosis, is as yet unclear. 
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1.3.1.1. Recycling of SNAREs for further rounds of exocytosis 
 
 After the formation of the cis-SNARE complex, the individual 
SNAREs need to be redeployed as their free components in the plasma and 
vesicular membranes in order to catalyse a subsequent round of exocytosis. 
Indeed, if the particular muscle is receiving stimulation at tetanic frequencies, 
this needs to happen within milliseconds. While the “reserve pool” of synaptic 
vesicles helps to maintain the later steady-state release (the remaining 80%) 
(Richards et al., 2003; Rizzoli et al., 2003), these will soon be exhausted if the 
vesicles are not quickly and constantly recycled. The cis-SNARE complex, the 
most energetically stable conformation, needs to be disassembled for them to 
regain their fusogenic potential. The study of yeast and Drosophila temperature-
sensitive mutants, that show an accumulation of SNARE cis-complexes at 
restrictive temperatures, has yielded valuable clues about this process (Littleton 
et al., 1998). NSF, a hexameric protein of the AAA+-protein family (ATPases 
associated with various cellular activities – proteins specialised across many 
organisms in dismantling protein aggregates), along with co-factors called 
SNAP (soluble NSF attachment proteins – with three isoforms α, β and γ) are 
involved in this process (Marz et al., 2003). Three SNAP molecules bind to the 
cis-SNARE complexes at approximately their 0-layer - one arginine and three 
glutamines, followed by the activation of NSF (The binding to and importance of 
the 0-layer is controversial with some studies finding no evidence of its 
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importance (Lauer et al., 2006)). The ATPase activity of NSF is utilised to 
generate the energy to separate the highly stable cis-SNARE complex. The 
exact process of disassembly is still not fully known and might need many 
cycles of NSF attachment and ATP hydrolysis to bring to completion. This 
necessity of disassembly, and the absolute dependence on active NSF for in 
vitro fusion, initially lead many into believing that this was an essential step in 
the process of exocytosis - indeed, while cis-SNARE complex disassembly by 
NSF is certainly crucial for maintaining fusion competence, fusion can still take 
place in Drosophila mutants at restrictive temperature until all free SNAREs are 
exhausted (Littleton et al., 1998). 
 The final part of the recycling story, the recycling of lipids that 
went into forming the vesicle, has not yet been fully elucidated with two modes 
proposed  –  “kiss and run” or “kiss and stay” (reviewed in (Rizzoli and Jahn, 
2007)).  The latter, with a large amount of data from yeast homologs, involves 
the fusion and subsequent total collapse of the vesicle into the plasma 
membrane. This is then retrieved by a clathrin-and-dynamin-mediated retrieval 
pathway, similar to regular vesicle fusion in eukaryotic cells (Perrais and 
Merrifield, 2005).  Indeed the uptake of neurotoxins and other proteins from the 
synaptic terminals shows that this process is taking place to a certain extent. 
However, the speed of exo-endocytosis at fast synapses and the discovery that 
peptide blockers of endocytosis do not completely inhibit synaptic transmission, 
implies that this cannot be the predominant mode in all synapses (Zhang, 2003; 
Jockusch et al., 2005; Granseth et al., 2006). On the other hand, the “kiss and 
run” mode has the advantages of easy and rapid recycling and conservation of 
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many essential vesicle proteins. Evidence of such recycling has accumulated 
from studies examining capacitance flickers at synaptic terminals, from studies 
using FM1-43 and other hydrophobic fluorescent dyes and through the use of 
pH sensitive VAMP-GFP chimeric proteins called PHlourins – all these 
demonstrated recapture and re-acidification of synaptic vesicles with 100-
1000ms, a time-scale probably beyond a clathrin-and-dynamin-mediated 
retrieval pathway (Richards et al., 2003; Rizzoli et al., 2003; Rizzoli and Jahn, 
2007). On the other hand, classical imaging studies with electron-micrography 
have not shown clear visual evidence of such activity and the molecular 
machinery that could potentially function in such a rapid process has yet to be 
fully elucidated.  
1.3.1.2. SNAP-25  
The SNAP-25 family of SNAREs consists of a related group of ~23-25 
kDa t-SNARE proteins which contribute the Qb/c-SNARE motifs to a mature 
SNARE complex (Steegmaier et al., 1998). The two SNARE motifs flank a 
central, cysteine-rich, membrane targeting/binding domain which is usually 
palmitoylated. The two neuronal/neuroendocrine specific isoforms, SNAP-25aA 
and SNAP-25b, are highly homologous (with a difference of ~9 AAs (Bark, 
1993; Bark et al., 1995)).  The 23 kDa SNAP-23  protein, showing a 60% 
homology with SNAP-25, has a more ubiquitous tissue distribution and is 
essential for regulated exocytosis in non-neuronal cells (Ravichandran et al., 
1996; Vaidyanathan et al., 2001). The SNAP-25 family also includes the yeast 
homologues sec9p (Brennwald et al., 1994), spo20 (Neiman, 1998) and vam7p 
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(Ungermann and Wickner, 1998). SNAP-25 is usually found associated with 
syntaxin 1 A in neurons.  
 
SNAP-25 is an essential protein and knockout mice die at birth. These 
mice also show an almost complete absence of evoked fusion with a near-
normal quantity of spontaneous fusion events. Palmitoylation, by the palmitoyl-
acyl-transferase enzyme, of the cysteine rich central portion is essential for 
membrane targeting and exocytotic activity of SNAP-25 (Hess et al., 1992; 
Gonzalo and Linder, 1998). This is a dynamic process with the half-life of acyl 
groups being shorter than the half-life of the protein (half-life of SNAP-25 is ~8 h 
and the half-life for its palmitate derivative is ~4 h in PC12 cells; reviewed in 
(Salaun et al., 2004)). Membrane association is highly dependent on the central 
cysteines and removal of any of the four cysteine residues reduces 
palmitoylation and subsequent membrane association (Veit et al., 1996; Lane 
and Liu, 1997). Presence of a 36-amino-acid sequence containing the cysteine-
rich domain, and the 28 amino acids that follow, is sufficient and essential for 
efficient palmitoylation (Gonzalo and Linder, 1998; Gonzalo et al., 1999). While 
spontaneous palmitoylation of SNAP-25 has been shown to occur in the 
presence of syntaxin 1, the functional importance of such a mechanism is as yet 
unknown (Salaun et al., 2004). The N-terminal SNARE domain is probably 
involved in the initial formation of a Ca2+-sensitive binary complex with Stx, 
before VAMP binding and formation of a final SNARE complex (An and Almers, 
2004). BoNT/A cleaves SNAP-25 between Gln197-Arg198, /E between Arg180-
Ile181 and /C1 between Lys253-Ala254 (Blasi et al., 1993b; Montecucco and 
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Schiavo, 1994; Schiavo et al., 2000).    
1.3.1.3. Syntaxin 
The Syntaxin family consists of a homologous group of ~35 kDa t-
SNARE proteins which contribute the Qa-SNARE motif to a mature SNARE 
complex. It is anchored at its C-terminal, through a transmembrane domain, to 
the plasma membrane. The cytosolic N-terminus consists of a conserved 
SNARE domain and a Munc18 binding domain. Despite differences in their 
sequence, the tertiary structures of related syntaxins are very similar and 
consist of an anti-parallel bundle of three α-helices (e.g.: Neuronal Stx, the N-
terminal domain of yeast syntaxin homolog Vam3 and the N-terminal domain of 
syntaxin 6). On their own, SNARE domains of syntaxin (the H3 domain) form a 
homo-tetramers (Misura et al., 2000, , 2001; Misura et al., 2002). Syntaxins are 
expressed as multiple isoforms, with numerous splice variants possible for 
many of them (15 mammalian Stx gene have been identified, with four of them, 
1-4, participating in exocytosis (Teng et al., 2001; Wang and Tang, 2006). 
Syntaxin 1 gets proteolysed by Cl (Blasi et al., 1993a); Syntaxin 1A is cleaved 
between Lys253 and Ala254, whereas syntaxin 1B is cleaved between Lys252 and 
Ala253. Syntaxins 1A and 1B are differentially expressed in the peripheral 
nervous system, with 1B localized to nerve terminals of the NMJ, and 1A to 
perivascular nerve endings (Aguado et al., 1999; Kalandakanond and Coffield, 
2001). BoNT/C1 is unique in that it cleaves both SNAP-25 (Foran et al., 1996; 
Osen-Sand et al., 1996) and many members of the syntaxin family, including 
the neuronal isoforms 1A/1B, 2 and 3 (Blasi et al., 1993a; Schiavo et al., 1995). 
      
 
 
46
1.3.1.4. VAMP  
Synaptobrevin or vesicle-associated membrane protein (VAMP) is the 
smallest member of the group of neuronal SNAREs. It consists of a family of 
~13 kDa transmembrane proteins located on SVs and large dense core vesicles 
(LDCV) (Sudhof et al., 1993). Two neuronal isoforms VAMP 1 and 2 and 
cellubrevin (Cbr), a non-neuronal homologue, have been identified (McMahon 
et al., 1993; Rossetto et al., 1996; Advani et al., 1998). These v-SNAREs 
provide the R-SNARE motif for a SNARE complex. VAMP 2 knockout mice die 
at birth, form synapses with reduced spontaneous fusion and show no evoked 
exocytosis. It consists of very short C-terminal end which protrudes into the 
lumen of the vesicle. This is attached to a trans-membrane domain, followed by 
a conserved SNARE core and is capped by an unstructured, proline-rich and 
isoform-specific N-terminal in neuronal VAMPs (Cornille et al., 1995). Some 
non-neuronal synaptobrevin homologs have conserved N-terminal domains 
called longin domains (Brunger, 2005). These conserved longin domains 
probably play a role in vacuolar and sub-cellular targeting. TeNT and BoNT/B 
cleave VAMP 2 and Cbr but not rat Vamp 1 (Volchuk et al., 1994). TeNT and 
BoNT/B cleave VAMP2 between Gln76-Phe77 and Cbr between Gln59-Phe60; 
BoNT/D cleaves VAMP1/2 between Lys59-Leu60 and Cbr between Ala67-
Asp68 and possibly Lys42-Leu43; and BoNT/F cleaves VAMP1/2 between 
Gln58-Lys59 and Cbr between Gln41-Lys42 (Schiavo et al., 2000; Aoki, 2004). 
Clostridial neurotoxins require a 15-20 amino acid recognition/buffer sequence 
spanning the cleavage site for efficient proteolysis (Foran et al., 1994). 
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1.3.2. Other important molecular actors in the synaptic vesicle cycle – 
synaptotagmin, Rab3, Munc18, SV2, etc. 
 
It has been known for a long time that the fast, evoked, release at nerve 
terminals is strongly tied to an increase in intra-neuronal Ca2+ concentration 
(Katz and Miledi, 1968). Other studies showed that time-scale of exocytotic 
fusion of vesicles can best be explained in terms of Ca2+ binding to a sensor 
with at least five binding sites of micromolar affinity, thereby, causing 
downstream activities that result in fusion (Geppert et al., 1994; Li et al., 1995; 
Catterall, 1999; Lawrence and Dolly, 2002).  The group of Ca2+-binding proteins 
called synaptotagmins (Syt) best fit this role. While more than 14 different 
isoforms have been identified, Syt 1 and 2 are found in high abundance in 
neuronal tissues and have the Ca2+ binding properties that match the putative 
sensor (Ullrich et al., 1994). Syt 1 is a transmembrane protein that also contains 
two Ca2+-binding C2 domains (conserved region-2 of protein kinase C domains) 
and, when bound to Ca2+ can interact with SNAREs and/or membrane 
phospholipids. Through a putative syn-print motif, Ca2+-channels can interact 
with Syt 1 (Sheng et al., 1997) and syntaxin1A/B (Keith et al., 2007) – thus 
filling another blank in the Ca2+-fast-exocytosis puzzle (Catterall, 1999). Syt 1 
knockout mice die within 48 h after birth, form synapses with elevated 
spontaneous fusion and reduced evoked fusion (Geppert et al., 1994). 
Structurally, Syt 1 contains two cytoplasmic C2 domains - the C2A domain 
binds three and the C2B domain binds two Ca2+ ions (Schneggenburger and 
Neher, 2000). While the binding affinities of the free C2 domains are very low 
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(0.5–5 mM), this increases >1000-fold upon binding to phospholipids 
membranes; this corresponds quite accurately with the hypothesized neuronal 
Ca2+-sensor. In addition, Syt 1 knockout mice show a selective loss of fast, 
Ca2+-triggered exocytosis in hippocampal synapses and in chromaffin cells with 
a small elevation of the rate of spontaneous fusion. Mutations affecting Ca2+ 
affinity of Syt 1 corresponded with an identical shift in the Ca2+ affinity of fast, 
evoked, exocytosis (reviewed in (Stevens and Sullivan, 2003; Meldolesi and 
Chieregatti, 2004; Yoshihara and Montana, 2004)). 
Munc18 knockouts, lethal at birth, are the only ones that show a 
complete absence of fusion activity in synapses – both spontaneous and 
evoked fusion is abolished in these animals which synaptic degeneration 
(Verhage et al., 2000). Belonging to the group of Sec1/Munc18 (SM) proteins, 
they are conserved in many species and play a central role in synaptic and non-
synaptic exo-endocytosis. Munc18-1, the isoform predominantly expressed in 
neuronal and neuroendocrine tissues, interacts and co-localises in vivo with 
monomeric (closed) Stx and with SNARE complexes. Munc18 has been 
hypothesised in almost all aspects of synaptic fusion – the transport, docking, 
tethering, priming and fusion of SVs, in the creation of specific and accurate 
SNARE complexes by reducing promiscuity and, even in synaptic plasticity 
(Toonen and Verhage, 2007). The synaptic function of Munc18 is correlated 
with its interaction with Stx1 – initially, it was thought that since Munc18 binds to 
the closed form of Stx1, its dissociation from Stx must be necessary for SNARE 
complexes to form and, therefore, Munc18 must act as a negative regulator of 
exocytosis (Dulubova et al., 1999). But more recent evidence which showed 
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that Munc18 can also bind SNARE complexes, at physiological concentrations 
and in vivo, has complicated this picture (Dulubova et al., 2007). Further 
studies, and analysis of Munc18 knockout mice, have revealed that it plays 
crucial roles in regulating vesicle translocation to active zones, on vesicle 
preparation (tethering, docking, priming) for fusion and in increasing the fusion 
rate (reviewed in (Toonen and Verhage, 2007)).  
Rab3 proteins, especially Rab3A, are the most abundant of the GTP-
binding Rab proteins in the brain. They regulate general intracellular transport 
and are found on synaptic vesicles. Initial clues about the importance of Rab3 
proteins in exo-endocytosis was found when it was discovered that they 
undergo a cycle of vesicle association-dissociation that parallels exo-
endocytosis (Fischer von Mollard et al., 1991). They are attached to synaptic 
vesicles in the GTP-bound state via covalently-linked geranylgeranyl moieties. 
After Ca2+-triggered fusion, Rab3A binds to a GDP-dissociation-inhibitor that, by 
utilising the GTP, dissociates it from the vesicle. This cycling of Rab3A probably 
has important implications if the finer aspects of synaptic function like synaptic 
plasticity and memory (Thakker-Varia et al., 2001; Ring et al., 2006).  
Synaptic vesicle protein 2 (SV2) is a conserved membrane glycoprotein 
specifically localized to SVs and neuroendocrine secretory vesicles. The three 
homologous SV2 isoforms (SV2A, SV2B, and SV2C – 60-80% homology) found 
in mammals contain 12 potential transmembrane domains, with cytoplasmic N- 
and C-termini and a large glycosylated loop that protrudes into the vesicle 
lumen – this loop gets exposed to the extracellular environment upon vesicular 
fusion (Bajjalieh et al., 1994). The N-terminal half of SV2 shows considerable 
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homology to a family of eukaryotic carbohydrate transporter proteins, while the 
C-terminal shows homology to neurotransmitter transporters. The antiepileptic 
drug, Levetiracetam, has been shown to specifically bind to, and modulate, the 
function of SV2A (Lynch et al., 2004; Lambeng et al., 2005; Matveeva et al., 
2008). The major isoform SV2A, and to a lesser extent SV2B, is widely 
distributed in the CNS, in peripheral NMJs and in neuroendocrine cells; SV2C 
has a more unique and restricted pattern of distribution (Bajjalieh et al., 1994). 
Phenotypically, SV2A and SV2A/SV2B knockout mice exhibited severe seizures 
and died after birth; the electrophysiological consequence of this deletion was 
the accumulation of presynaptic Ca2+ during consecutive action potentials (Janz 
et al., 1999). While evidence points to SV2 being a Ca2+ transporter in synaptic 
vesicles, this has not yet been fully corroborated (Xu and Bajjalieh, 2001).  
Many other proteins play essential roles in synaptic neurotransmission.  
Munc13, Rab3-interacting molecule, ELKS/Rab3-interacting molecule, α-liprins, 
synapsins, sec6/8 tethering complexes, SNAP-25-interacting proteins such as 
SNAPin and SNIP, synapsins and synaptophysin are just a few of them  
(Sudhof, 2000, , 2004).  
Despite the huge amount of knowledge and experimental data that has 
accumulated on all these different molecular actors at the synapse, a complete 
and final picture of evoked vesicle exocytosis and recycling has yet to emerge. 
1.4. Etiology and clinical symptoms of human botulism 
Botulism is a group of related neuroparalytic diseases caused by the 
action of neurotoxins produced by the anaerobic bacillus, Clostridium botulinum. 
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This group of gram-positive, spore-forming bacteria produces one of the seven 
antigenically distinct neurotoxin serotypes - /A, /B, /E, /F, /C1, /D & /G (Brin, 
1997; Dolly and Aoki, 2006). Of these, the first four are implicated in human 
disease (Sobel et al., 2004) and types /C1 and /D are known to cause similar 
paralytic conditions in other mammals and birds; type /G is not known to cause 
any human or animal disease. While rare, some strains of C. butyricum and C. 
baratii have also been known to produce type /E and type /F, respectively 
(Simpson, 2004). 
The clinical manifestation of botulism, derived from the Latin word for 
sausage - ‘botulus’, was first described by the German physician and poet, 
Justinus Kerner in early 19th century Würrtemberg. The isolation of the 
Clostridium bacilli and the discovery of its association with the clinical condition 
of botulism was achieved by Emil Ermengem in Belgium in 1895 (see (Erbguth, 
2007) for a more detailed history of botulism). Botulism presents in humans as 
an acutely developing, symmetric flaccid paralysis that starts usually in cranial 
nerves and manifest within 18-36 h as diplopia, dysphagia, slurred speech and 
dryness of the oral mucosa (CDC, 1998; Cherington, 1998; Shapiro et al., 1998; 
Cherington, 2004; Sobel, 2005). The paralysis then progresses to respiratory 
muscles, upper and lower limbs and, if untreated, this ultimately leads to 
respiratory paralysis and death (Arnon et al., 2001). Type /A causes the longest 
lasting paralysis in humans, mice and rats (Sloop et al., 1997; Dolly, 2003; 
Foran et al., 2003; Meunier et al., 2003) and is responsible for more than half of 
all reported human cases in the US. The minimal lethal dose of the toxin varies 
from less than a microgram in adults to nanograms in infants (extrapolated from 
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primate studies); type /A, which is the most potent serotype, has a LD50 of 0.001 
µg/kg (Arnon et al., 2001; Arnon et al., 2006). Botulism can be contracted by 
ingestion of neurotoxin contaminated food (food botulism), ingestion of 
Clostridial spores by infants (infant botulism) or by direct bacterial infection of 
wounds (Shapiro et al., 1998; Sobel et al., 2004). While food-borne botulism is 
now seldom found, it is an important public health emergency, especially in 
poorer countries, due to the explosive epidemic nature of occurrences. This 
form of transmission results from the ingestion of food containing preformed 
toxin. With the advent of scientific food processing techniques, the most 
common cause of botulism in rich countries is infant botulism. This is caused by 
the ingestion of Clostridial spores, which due to the low acidity of gastric 
mucosa in infants pass unscathed, colonise the intestines and release the toxin 
after a short germination. While this form of botulism is predominantly found in 
infants less than 1 year old, it can also rarely be seen in individuals suffering 
from a natural or iatrogenic deficiency of gastric acid secretion. In general, while 
botulism is now a relatively rare cause of mortality, the toxin’s exquisite potency 
and lethality means that it poses a considerable threat as a bio-weapon (WHO, 
2002).  
The closely related Clostridial toxin, tetanus neurotoxin (TeNT), is 
produced by Clostridium tetani and causes the disease tetanus. First identified 
by Kitasato, the spores of this strict anaerobe are widely distributed in nature. 
Upon entry into wounds, the spores germinate, grow and produce TeNT. 
Following lysis of the bacilli, the released TeNT causes spastic paralysis 
characteristic of tetanus and which can lead to death, indirectly, from 
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exhaustion or respiratory/cardiac failure (Schiavo et al., 2000). Tetanus is far 
more common, and more easily recognised in its milder forms, than botulism. 
Despite the development of a very efficacious vaccine, tetanus still claims many 
lives, especially in under-developed countries (Galazka and Gasse, 1995).  
The common pathophysiological mechanism underlying the paralytic 
activity of all these toxins is the irreversible blockade of ACh exocytosis by 
proteolytic cleavage of one of the three SNARE partners essential for 
productive fusion of synaptic vesicles at the peripheral neuro-muscular junctions 
(Schiavo et al., 1993c; Schiavo et al., 1993d; Schiavo et al., 1993b; Schiavo et 
al., 1995; Verderio et al., 2006) (Described in detail in Section. 2. See also 
Figure 7. See Dolly et al., 2008 for a detailed review). 
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Fig. 7: CNTs inhibit exocytosis in neurons by site-specific cleavage of SNAREs. The SNAREs 
affected by CNTs are shown in this schematic, with the proteolytic cleavage sites for the 
different toxins indicated by arrows (BoNT /A, /E and /C1 cleave SNAP-25; BoNT /B, /G, /D, /F 
and TeNT cleave VAMP II and BoNT /C1 cleaves Stx). The SNARE core domains on the 
different proteins are indicated in red. N and C refer to the terminals of the different proteins, SV 
is the synaptic vesicle, P is the plasma membrane and the squiggles represent the palmitoyl 
groups on SNAP-25. 
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1.5. Viral vectors for gene therapy 
Mammalian post-mitotic neurons are by their very nature incapable of 
replicating to provide substitutes in case of death or injury of existing neurons. 
In addition, the extensive macro- and microscopic axo-dendritic network, built 
up slowly over the life of the animal and which defines the functional capacity of 
every neuron, cannot be reproduced with other advanced therapies like 
introduction of stem-cell based substitute neurons. Therefore, a direct approach 
to manipulate gene expression in the mammalian neurons can lead to the 
development of novel therapies to treat neurodegenerative diseases or to repair 
physical, chemical, toxicological, bacterial and even viral injuries in them. This 
also offers new approaches to probe the patho-physiological basis of neural 
disorder and to identify new molecular targets for intervention. 
Two of the most promising candidates for the role of neuronal gene 
delivery vectors are the non-enveloped Adeno-Associated Viral vectors (AAVs) 
and lipid enveloped Lentiviruses (LVs). These vectors, derived from common 
human viral pathogens, have an outstanding safety profile, show relative ease 
of production, have been engineered to have a broad tropism and have defined, 
minimal, genomes. They differ in their transfection rates, target specificity and 
the timescale and efficiency of transgene production (Kay et al., 2001) (See 
Table 1 for a comparison of the properties of the two main viral vectors used in 
gene therapy).  
Viruses have evolved efficient strategies over millions of years of 
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evolution for transferring genes essential to their function and reproduction into 
mammalian cells.  Harnessing this capability, while eliminating their deleterious 
features has yielded viral vectors that can act as agents for gene delivery for the 
introduction and expression of genes encoding therapeutic proteins. They can 
thus be used to rectify phenotypes induced by known genetic mutations or to 
counteract progressive neurological diseases by introduction of known 
protective genes. To be useful, viral vectors needs to be replication-deficient (to 
limit the gene expression in the area of interest and to eliminate cell death that 
is the usual consequence of replication), non-immunogenic (to prevent the host 
immune system from mopping up all the introduced viral vectors and to prevent 
the immune-mediated culling of transfected cells) and non-toxic (by the 
elimination of non-essential and deleterious proteins found in the viral genome), 
while still retaining their capability to deliver genetic material to the nucleus of a 
target cell (thereby ensuring continuous expression of necessary proteins 
without the necessity of repeated administration). But, an ideal vector system is 
a difficult task to engineer and all currently used ones involve compromises in 
one or the other facet. The early candidate vectors used for gene therapy, 
herpes-virus and adenoviral vectors, contained large fragments of their native 
genome, expressed non-essential and toxic/immunogenic viral proteins and 
suffered from immunogenicity and neuronal toxicity. Also, they were 
occasionally found contaminated with native, and replication-competent, viruses 
or could recombine with those wild-type viruses that can be often found 
naturally infecting mammals (Davidson and Breakefield, 2003).  
Viral vectors bind to specific receptors on the target cell surface and 
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undergo internalisation. Non-enveloped, capsid shrouded viruses harness the 
host cells receptor-mediated endocytosis pathways. Upon endosomal 
acidification, the capsid breaks down and the DNA or RNA released into the 
cytoplasm, binds to nucleus-seeking proteins and the genetic material is 
delivered into the nucleus through the nuclear pore. Some of the capsidated 
viruses might be transported along the cytoskeleton before nuclear delivery. On 
the other hand, enveloped virions usually undergo membrane fusion at the cell 
surface or in endosomes, depending on the nature of the envelope . While there 
are neurotropic viruses, e.g., herpes, rabies and polioviruses, that specifically 
bind to pre-synaptic terminals and undergo retrograde transport into neuronal 
cell bodies, they have their own drawbacks like enhanced toxicity and 
immunogenicity, The natural binding processes can be exploited to redirect viral 
tropism by introducing receptor ligands into capsid proteins, by exchanging 
capsid/lipid-glycoprotein proteins between serotypes, or by using bi-functional 
neurotoxins or neuron specific antibodies that bind both to the virus and 
presynaptic targets (e.g., capsid proteins of AAVs and the lipid envelope 
glycoproteins of lentiviruses) (Schaffer et al., 2008).  
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Feature AAV Lentivirus 
Packaging 
capacity 
Low, ~4.9 kb High, ~8 kb 
Host range Very broad, infects neurons 
and glia 
Very broad, infects neurons 
and glia 
Long-term 
expression 
Yes Yes 
Genomic 
integration 
Yes, 19q11 Yes, random 
Bio-safety Very-high High, esp. later generations 
Size 20-25nm ~100nm 
Yield/Titer Very high High 
Cellular entry HSPG + co-receptor; 
receptor-mediated 
endocytosis 
VSV-G mediated fusion of 
virus followed by entry of 
genomic content and core 
Oncogenesis risk No (very low) Yes (depends on MOI and 
cell type) 
Replication 
competent virus 
risk 
No Minimal 
Immunogenicity Low Very low 
Envelope Protein Lipid with proteins embedded 
Retrograde 
transport 
Yes (In CNS and from 
periphery) 
Yes (In CNS, periphery 
unknown) 
Expression onset Slow Faster 
Purity Very high High 
 
Table 1: Comparison of AAV and LV gene delivery systems. (HSPG: Heparan sulphate proteo-
glycan) 
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Fig. 8: AAV and LV structure A: Computer generated surface topology map of AAV-2. The 
generated view is colored according to the distance from the center of the AAV. Adapted from 
(Xie et al., 2002). B: Computer generated surface topology map of a model retrovirus. This is a 
surface rendered tomogram of an individual virion. Proteins on the lipid membrane are 
represented in magenta and  the lipid surface of the virus is shown in purple (Some 
discontinuities are seen in the lipid membrane exposing the yellow interior). Adapted from 
(Forster et al., 2005). 
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1.6. Model systems used to study botulism and to 
assess the efficacy of various therapies 
The gold standard to assess the effects of CNTs is their natural target, 
the cholinergic NMJ. In vivo murine model systems accurately mimic the 
physiological and anatomic effects of CNT intoxication. But due to the difficulties 
inherent in this system i.e., the limited amount of tissue and the need for large 
number of animal subjects, necessitated the use of other in vitro and ex vivo 
models systems. The in vitro models – protease assays with purified SNAP-25 
substrates and permeabalised cell preparations - were used to study enzymatic 
activity of natural and modified BoNT/A, /E and /C1 on susceptible and 
cleavage-resistant SNAP-25. These systems, enabled and accurate and high-
throughput measurement of the relative cleavage resistance of SNAP-25 
mutants and of the innocuousness of toxin mutants. Ex vivo models – using 
bovine chromaffin cells and rat cerebellar granule neurons or mouse hemi-
diaphragms – enabled a more physiological measure of the effectiveness of 
viral delivery of cleavage resistant SNAP-25 genes or of the binding, 
internalisation and SNARE-cleaving properties of native and mutant BoNT 
toxins and chimeras. Finally, the benchmark in vivo models for studying the 
effects of toxins and efficacy of the counter-acting therapeutic strategies - 
mouse LD50, rat/mouse digit abduction scoring and efficiency of neuromuscular 
transmission (ENT) in rat soleus – enabled a near-accurate mimicking of clinical 
botulism.  
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1.7. Principal goals of this study  
A major challenge facing gene therapy for motor neuron disorders __ a 
group of rare yet debilitating and ultimately fatal diseases affecting spinal motor 
neurons __ is targeted, minimally-traumatic delivery. Due to the limited number 
of motor neurons (e.g. rat sciatic nerve has only ~2000 efferents) (Nicolopoulos-
Stournaras and Iles, 1983), insults that are merely sub-lethal in other cells can 
be extremely deleterious (e.g. in superoxide-dismutase mutant mice, which 
ubiquitously express the damaged protein, motor neurons are the most affected 
(Bruijn et al., 2004)). Their anatomical structure, with a relatively inaccessible 
cell body in the spinal column and an elongated axon, complicates therapies 
including gene transfer by viral vectors. Those that transfect motor neurons 
(Adeno-associated, Lenti and Herpes viruses) do so most efficiently when in 
direct contact with the cell body (Mannes et al., 1998). As intra-spinal injection 
is difficult under clinical conditions, the use of peripherally-deliverable vectors 
would be desirable; moreover, such an advance requires a model that allows 
accurate measurement of the graded improvements currently achievable.  
An ideal system to evaluate such therapies is the blockade of 
neuromuscular transmission by botulinum neurotoxin type A (BoNT/A), by 
specific cleavage of SNAP-25. This toxin is also implicated in the clinical cases 
of botulism, which, while relatively rare, is a serious condition with no known 
pharmacological therapies. While some prophylactic vaccines do exist to 
combat botulism, they are increasingly out of favour due to the recognised 
therapeutic application of BoNT/A and /B for a variety of neuromuscular 
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conditions. Furthermore, they only confer a limited period of protection, are not 
licensed for use in the general population and are ineffective after exposure to 
the toxin (Shapiro et al., 1998). Anti-toxin serum, especially those generated in 
humans against multiple toxin serotypes (human botulism immune globulin),  is 
a valuable aid if administered within 24 h of exposure in infants preventing 
further deterioration of the exposed patient’s condition and shortening the 
duration of hospitalisation, esp. the amount of time spent on mechanical 
ventilation (Tacket et al., 1984; Arnon et al., 2006). Unfortunately, these anti-
toxins have very limited utility after the initial 24 h due to the intracellular action 
of the toxin’s LC and are complicated by factors such as hypersensitivity, for the 
equine anti-serum (Black and Gunn, 1980),  and the currently limited 
applicability, of the human anti-serum, for any outbreaks in adult populations. 
The ineffectiveness of current treatments in combating botulism necessitates 
the development of a refined therapy with the ability to abrogate the prolonged 
convalescence, high mortality and morbidity associated with this condition. The 
finding that protection from BoNT/A mediated exocytotic blockade can be 
achieved by expression of a toxin-resistant S25 mutant gene was an important 
step in realising this goal (O'Sullivan et al., 1999). Thus the twin goals of 
developing efficient gene transfer tools to motor neurons and of finding novel 
therapies for botulism can be simultaneously considered (See fig. 9).  
In this study, neuromuscular paralysis by BoNT/A was attenuated using 
Adeno-associated (AAV) vectors that give long-term expression of a cleavage-
resistant S25 mutant (S25-R198T), having all the properties of the wild-type 
including ability to substitute for truncated S25 and recover exocytosis in 
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intoxicated chromaffin cells (O'Sullivan et al., 1999). AAV vectors provide an 
efficient and relatively safe way to ensure prolonged expression of genes in 
neurons (Burger et al., 2005), and botulism in rats provides a much more valid 
model for evaluating this gene therapy. Injection of AAVs encoding S25-R198T 
into the spinal anterior horn innervating the soleus muscle protected 
neuromuscular transmission from subsequent inhibition by BoNT/A. Moreover, 
muscles treated in this way showed a decreased amount of nerve sprouting 
compared to unprotected controls. Finally, administering the therapeutic AAVs 
directly into the soleus muscle resulted in their retrograde transport to motor cell 
bodies and a consequential reduction of BoNT/A-mediated blockade of 
neurotransmission at peripheral synapses. These findings provide the first 
evidence for the potential applicability of gene therapy to the intractable 
problems posed by botulism and, possibly in the longer-term, genetic disorders 
of motor neurons.  
The specificity of BoNTs and TeNT for NMJs makes their non-toxic 
derivatives valuable as transporters for the delivery of therapeutic agents into 
the motor-neurons (Johnstone et al., 1990). Steps in this direction have been 
taken through the production of recombinant toxins in which the protease site 
has been inactivated to create variants that are still able to undergo binding, 
internalisation and translocation at cholinergic motorneurons (Zhou et al., 1995). 
The utilisation of such 'cholinergic transporter' molecules might be useful in 
targeting viral vectors for the prevention of conditions affecting motor neurons. 
For this purpose, the dichain form of BoTIM was utilized. This has been shown 
to be essential for productive uptake into motor nerve endings (Dolly et al., 
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1994; Daniels-Holgate and Dolly, 1996) while yielding more efficient 
internalisation than can be achieved with HC alone (Bade et al., 2004). The 
creation of a core-streptavidin-BoTIM/E chimera (CS-BoTIM) with the targeting 
properties of BoTIM and the biotin binding properties of CS should yield a 
versatile molecule that could be attached to biotinylated cargo in the desired 
stochiometry (Pahler et al., 1987; Sano et al., 1995). The CS-BoTIM also offers 
the advantage of a smaller conjugate, ease of production, control of positioning 
of the attachment site and attachment to a single biotin molecule. BoTIM was 
conjugated at the genomic level to a monomeric streptavidin domain – the 
minimal streptavidin core (12-16kDa) was cloned into the N-terminus of the 
His6BoTIM single chain gene, expressed in E.coli and the resultant CS-BoTIM 
purified using a Ni-NTA column. Retention of neuronal targeting ability by CS-
BoTIM was tested after application to rat CGNs and HEK-293s in culture; 
immuno-histochemical visualization of stronger binding to the former confirmed 
the neuronal preference of binding. Application of active BoNT/E, conjugated as 
before to CS at the genomic level, resulted in SNAP-25 cleavage and exocytotic 
blockade, confirming the binding, internalisation and release of LC.  
The next refinement of the gene replacement methodology involved the 
attempted targeting of lentiviral vectors to neurons by availing of the unique 
selectivity of CS-BoTIM. This potentially opens up routes of peripheral 
administration due to the therapeutic becoming concentrated on to the pre-
synaptic membrane at the NMJ. Such a targeted virus would have a huge 
number of applications not just in the treatment of botulism but, also, in 
hereditary motor neuron diseases (e.g. spinal motor atrophy, amyotrophic 
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lateral sclerosis) and those caused by viruses, physical and biochemical 
trauma. A second-generation LV system was exploited to create high titer 
viruses expressing GFP, which were later biotinylated with a reducible linker 
interface. Proof of principle for this exciting new strategy was obtained by the 
successful coupling of the CS-BoTIM protein to the viral vectors, followed by 
their later application onto CGN and HEK-293 cells. To determine optimal 
coating conditions, CS-BoTIM was mixed with different ratios of the test and 
control viruses in order to generate viral particles coated with the targeting 
agent. The optimally coated viruses, preferentially binding to neuronal terminals, 
showed a reduction in their promiscuous infectivity to HEK-293 cells, with only a 
small attenuation of their natural neuronal infectivity.  
These devised tools and therapies, targeted initially at botulism, should 
provide a strong foundation for the later development of sustained motor neuron 
gene therapies applicable centrally or peripherally. 
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Fig 9:  Overview of gene therapy against botulism. A motor neuron, with its nucleus, dendrites, 
axons and cholinergic terminals is represented here. The hexagonal structures represent viral 
vectors, clear J-shaped structures - native SNAP-25, shaded J-shaped structures – multi-toxin-
resistant SNAP-25 (MTR) and labelled boxes attached to viral particles – targeting agents and 
the green genomes – specific promoter. The dotted red line represents the path of the virus to 
the MN nucleus and the solid blue line the path of the SNAP-25 protein. The virus can be 
delivered spinally or peripherally (in which case it has to undergo retrograde transport). Once in 
the host nucleus, the viruses start producing cleavage-resistant SNAP-25 mRNA, and thus the 
protein. Once the MTR SNAP-25 protein is transported down to the cholinergic terminals, they 
can no longer be inactivated by the introduced CNTs (BoNT A/ E /C1). Thus the treated 
terminals are able to retain exocytotic activity, in the face of a later challenge with these CNTs, 
or can retain activity quicker, in the case of a prior treatment with these toxins. Further 
refinements can be introduced by the addition of targeting molecules (BoTIM/E or TeTIM) 
and/or by the addition of a cholinergic/neuron-specific promoter.  
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2. Attenuation of BoNT-induced blockade of 
exocytosis at peripheral NMJs by viral vector 
mediated gene transfer into spinal motor neurons 
 
The characteristic symptoms of botulism are caused by the BoNT-
mediated blockade of neurotransmission in cholinergic nerve terminals, 
especially NMJs. The processes involved in blockade of neurotransmitter 
release by Clostridial neurotoxins involve – targeting to the NMJ, binding, 
internalisation, translocation of light chain to the cytoplasm and, finally, 
proteolytic cleavage of the requisite SNAREs. The Clostridial neurotoxins share 
many properties and, upon entry into the bloodstream, target to pre-synaptic 
nerve terminals. The HCs mediate selectivity by targeting to high-affinity 
membrane ecto-acceptors located exclusively on cholinergic (motor/autonomic) 
nerve endings (Dolly et al., 1984a; Black and Dolly, 1986b; Black and Dolly, 
1987; Daniels-Holgate and Dolly, 1996). Upon uptake into the target vesicles, 
the heavy chain helps form a transmembrane pore which allows the light chain 
to escape into the cytoplasm. Upon intracellular entry, the light chains cleave a 
defined member of the SNARE family and cause an inhibition of evoked 
exocytosis (Schiavo et al., 1993a; Schiavo et al., 2000) (The targets and the 
cleavage sites are described in detail in Section. 1.3). When the rate of 
synthesis of the new SNARE molecules and/or turnover of the handicapped 
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SNAREs overwhelms the enzymatic activity of remaining BoNT, normal 
neuromuscular transmission returns (de Paiva et al., 1999). 
2.1.1. Trafficking of Clostridial neurotoxins (CNTs) to their site of 
action 
The Clostridial bacilli producing the different BoNT toxins are quite 
fastidious anerobes; the growth conditions vary between different serotypes and 
are sensitive to changes in temperature, pH and oxygenation. Therefore, the 
usual method of contact with the toxin is through consumption of contaminated 
food, which already contains previously produced toxin. As the BoNTs are 
sensitive to the harsh proteolytic conditions found in the gastric lumen, they are 
packaged with other non-toxic proteins, which protect a proportion of toxin until 
it reaches the small intestine. Those that protect and contain BoNT/A can be 
purified as 19 S, 16 S, or 12 S stable complexes. The non-neurotoxic 
components consist of non-hemagglutinins, with Mr ~120 kDa, and 
hemagglutinins, consisting of a combination of five different proteins of 52, 35, 
20, 19, and 15 kDa (Inoue et al., 1996). In the small intestine, the slightly 
alkaline pH causes dissociation of the toxin complexes and the free neurotoxin 
undergoes transcytosis across intestinal epithelial cells and reaches the 
bloodstream.  
The process of migration of CNTs to the extra-cellular space surrounding 
the NMJ has not yet been completely characterised – a journey that takes the 
toxin molecule across capillary endothelial and basal laminar barriers while, 
presumably, evading the body’s immune and scavenging systems and 
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simultaneously preserving its activity for the final target. The clinical importance 
of this migratory stage, especially in relation to prophylactic treatments such as 
vaccination or injection of antibodies, is discussed later. Such is the exquisite 
specificity of the toxin to NMJs that, at physiological doses, the only effect of the 
toxin is the perturbation of neuromuscular transmission – despite the ready 
presence of potential substrates in non-neuronal secretory cells. Indeed, in 
cultured neuroendocrine cells which share the same SNARE targets as the 
NMJ, permeabalisation or treatment with non-physiological buffers is necessary 
for the uptake of the toxin. Once near the pre-synaptic motor terminals the toxin 
undergoes a series of steps that culminates in the delivery of the LC protease to 
near the SNARE targets. For BoNTs, this process can be divided into a three 
step model – binding and internalisation of the holo-toxin, pore formation by the 
HC and, finally, translocation of the LC into the cytoplasm (Dolly et al., 1992; 
Verderio et al., 2006; Brunger et al., 2007; Fischer and Montal, 2007a, 2007b) 
(See fig. 10).  
The evidence accumulated points to a “dual-receptor”, “dual-affinity” 
mode of entry of BoNTs. The “double specificity” conferred by such an ecto-
acceptors can help in explaining the CNT’s remarkable specificity for NMJs. 
Gangliosides, especially the sialylated glycosphingolipids containing N- and O 
substituted neuraminic acid residues, are hypothesized to act as an intial, 
accumulatory, ecto-acceptor component for CNTs. The accumulated CNTs then 
bind to specific protein receptors on the pre-synaptic terminal surface and 
undergo endocytosis. These two ecto-acceptor families are the most probable 
candidates for the physico-chemically determined, low–affinity  (e.g.: 
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synaptosomes: Kd ~26 nM, Bmax ~7.5 fmol/mg protein; presynaptic plasma 
membrane: Kd ~30 nM, Bmax ~52 fmol/mg protein for labelled BoNT/A in electric 
organ of Torpedo) and high-affinity (e.g.: synaptosomes: Kd = 0.11 +/- 0.03 nM, 
Bmax = 50 +/- 10 fmol/mg protein; presynaptic plasma membrane: Kd = 0.2 +/- 
0.05 nM, Bmax = 150 +/- 15 fmol/mg protein for labelled BoNT/A in electric organ 
of Torpedo) receptors (Dolly et al., 1984b; Blasi et al., 1992; Daniels-Holgate 
and Dolly, 1996).  
The ganglioside-binding part of the theory is now well established (See 
(Simpson and Rapport, 1971; Nishiki et al., 1996; Bullens et al., 2002; Dong et 
al., 2003; Rummel et al., 2004a; Mahrhold et al., 2006; Rummel et al., 2007) 
and is reviewed in (Verderio et al., 2006)). The importance of gangliosides on 
acceptor membranes for the uptake of BoNT and TeNT was confirmed when it 
was shown that pre-incubation with ganglioside GT1 inhibited their uptake in 
chromaffin cells (Stoeckel et al., 1977), while pre-treatment of cells with the 
polysialogangliosides GD1a, GT1b and GD1b enhanced the toxin-mediated 
blockade of exocytosis (Marxen et al., 1991).  Also, ganglioside depletion in 
neuroblastoma cells impairs BoNT/A internalization, treatment with 
neuraminidase decreases BoNT binding and knockout mice defective in a-
series and b-series ganglioside production showed highly reduced sensitivity to 
BoNT/A and BoNT/B (lacking the complex gangliosides GM1, GD1a, GD1b, GT1b 
and GQ1b because of disrupted β1,4-N-acetylgalactosaminyltransferase (GM2/GD2 
synthase; EC 2.4.1.92) gene) (Bullens et al., 2002, , 2003; Kitamura et al., 
2005). The current understanding is that polysialogangliosides, richly distributed 
on the presynaptic motor nerve terminal, bind BoNTs HCC, a sub-domain which 
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shows a high degree of homology to the carbohydrate-binding domain found in 
plant lectins; BoNT/A and /B has been shown to bind GT1b through a conserved 
H…SXWY…G peptide motif in this region (Poulain et al., 1989; Miller et al., 2008; 
Stenmark et al., 2008; Tsukamoto et al., 2008) while binding property of 
BoNT/C to GD1b, and GT1b and BoNT/D to phosphatidylethanolamine has also 
been shown to reside in the HC region (Tsukamoto et al., 2005). 
However, and complicating matters quite substantially, these same 
studies showed that ganglioside-binding is not an essential, or the only, pre-
requisite for toxin uptake, since the amount of inhibition obtained was not 
complete when antagonising just the ganglioside part of binding (Stoeckel et al., 
1977; Marxen et al., 1991). In addition, neuraminidase treatment of chromaffin 
cells did not completely abolish CNT activity and ganglioside knockout mutants 
were still capable of being paralysed by BoNT/A and TeNT, albeit at a far 
slower rate (Kitamura et al., 1999; Kitamura et al., 2005). So, ganglioside 
binding alone cannot completely explain the specificity of BoNTs for the 
cholinergic motoneurons. The best studied protein receptor candidates are Syts 
and SV2. Studies have shown that binding of BoNT/B to Chinese hamster ovary 
and PC12 cells is dependent of expression of Syt2 (Dong et al., 2003). In vitro 
pull-down assays have also shown that BoNT/B and /G interact with Syt1 and 
Syt2 and pre-treatment with peptide fragments corresponding to the luminal 
domains of these proteins can inhibit toxin-mediated blockade in mouse hemi-
diaphragm assays (Rummel et al., 2004b). The binding to BoNT/B was activity 
dependent, hinting at the luminal region being involved. Truncation analysis of 
Syt2 revealed that residues adjacent to the transmembrane domain, amino 
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acids 40–60, are critical for toxin binding. Interestingly, Syt2 binds to 
gangliosides through residues 61-267, thereby linking the initial binding of CNTs 
to sialogangliosides and the later binding to Syt2 (there is a high homology 
between Syt1 and 2 in these regions (Dong et al., 2003)). This finding also 
explains the frequent finding that CNT uptake in neurons is activity-dependent; 
the luminal domain of Syt will only be exposed upon fusion of SVs. The dual-
receptor hypothesis for  CNTs in general and BoNT/B and /G in particular, has 
been further established by mutation studies that showed a strong and, 
sometimes, near-complete inactivation of the toxin’s activity in vivo upon 
introduced changes in the putative binding regions (Rummel et al., 2007).  
The protein receptor for BoNT/A has also been recently identified – the 
intra-vesicular luminal domain, L4, of SV2 has been shown to be critical for 
BoNT/A binding (Dong et al., 2006). Proof for this specific interaction has been 
obtained by pull-down assays with fragments of SV2 (L4- 529-566AA) and by 
competition assays. BoNT/A binding to hippocampal neurons cultured from 
SV2B-/- mice was reduced by 28%, by 53% in SV2A+/-SV2B-/- mice and binding 
was almost completely abolished in SV2A-/-SV2B-/- mice (Dong et al., 2006). 
Uptake was restored by the expression of SV2A in SV2A/2B double knock-out 
mice. BoNT/A was also shown to bind the least prevalent SV2C isoform as well; 
indeed, its reported affinity was higher than that for SV2A or 2B (Mahrhold et 
al., 2006).  
Once the ganglioside-protein-receptor-toxin complexes form, they 
undergo receptor mediated endocytosis, most probably involving clathrin-coated 
vesicles (the energy- and temperature-dependent uptake of these neurotoxins 
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is discussed in (Dolly et al., 1984a; Black and Dolly, 1986b, 1986a)).  The onset 
of neuroparalysis induced by CNTs can be shortened under condition of 
increased SV recycling, a process that is intimately connected with SV fusion 
[Dolly >>]. While the HC domains of CNTs have been shown to be essential and 
sufficient for the internalization into vesicles (Lalli et al., 1999), it is not yet 
known if they, or other parts of the CNTs, in any way influence the endocytotic 
process, or if they are mere passengers.  
 Once internalised, the vesicles containing the CNT-receptor 
complex are sorted in a TeNT- or BoNT-specific manner, leading to the distinct 
symptoms associated with each disease. While the cholinergic NMJ is the final 
target of BoNTs, TeNT undergoes retrograde transport back to the spinal cord, 
transcytoses across the synaptic junction and targets inhibitory glycinergic inter-
neurons in the spinal cord; BoNT/A is >1000 fold more effective than TeNT in 
blocking release from the peripheral cholinergic nerve endings (Habermann et 
al., 1980), while the reverse is true at the inter-neurons (Habermann and 
Erdmann, 1978; Bigalke et al., 1985). The differential sorting of CNTs in the 
endosomes of NMJs could be a property of the protein/ganglioside receptor or 
due to a determinant on the HC. The former is supported by studies that show 
that TeNT co-segregates with p75NTR while the latter model is supported by 
hybrid toxin studies which show that when the HC of BoNT/A is linked to the LC 
of TeNT, the hybrid has the binding and sorting features of BoNT/A (Poulain et 
al., 1991; Weller et al., 1991). The putative mechanism by which TeNT 
undergoes retrograde axonal transport into the spinal cord is described in the 
next section. 
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Fig. 10: Mechanism of action of BoNT. The different phases in BoNT action are schematically 
represented here. After initial binding to specific receptors (A), the holotoxin undergoes 
internalisation into endosomes (B). Upon endosomal acidification (C), the HC forms a pore 
through which the LC is extruded into the cytoplasm (D). The LC now targets its specific  
SNARE substrate, SNAP-25 (F), VAMP (G) or Stx (H). 
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Fig. 11: Crystal structure of BoNT/A. A: A screen-shot of a Cn-3D rendering of the determined 
3.3Ǻ structure of BoNT/A holotoxin shows the different, biochemically identified, domains. At the 
C-terminus, comprising mainly of β-sheets, is the HCC which is involved in specific binding to 
receptors on cholinergic terminals. This is followed by α-helix rich HCN and the N-terminus LC. 
(β-sheets are in gold and α-helices are in green, with intermediate AAs in blue. Also seen is the 
Zn2+ ion at the catalytic site). B and C: Structure of BoNT/A LC bound to its SNAP-25 
substrate. The complex inter-play between the different α and β exosites on SNAP-25 and the 
toxin’s LC can been seen in this 2.1 Ǻ structure. The LC is shown in gold (β-sheets) and green 
(α-helices) and the SNAP-25 substrate is shown in yellow (with one α-helix in green). Panel B 
shows both the LC and the substrate, while C shows only the substrate for increased clarity. 
Also seen are the Zn and Cl ions. Based on data from (Lacy et al., 1998) and (Breidenbach and 
Brunger, 2004). 
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Since the substrates for the CNTs are in the cytoplasm, the process of 
transfer of the LC into the cytoplasm is critical to their in vivo activity. Extensive 
clues about this process can be gained by studying similar processes involved 
in the entry of bacterial and plant toxins, like Shiga, Diptheria and Cholera 
toxins (Sandvig and van Deurs, 2005). This translocation requires the HC, is 
triggered by low vesicular pH and requires a reducing environment in the 
cytoplasm (Boquet and Duflot, 1982). The pH sensitivity of this process has 
been demonstrated by studies that showed abolition of the toxin’s activity upon 
pre-treatment  with drugs such as bafilomycin (inhibitor of the proton pump) or 
lysosomotropic drugs like chloroquin or methylamine (Simpson, 1982, , 1983; 
Lawrence et al., 2007). The HN terminal of BoNT/A consists of two long 
amphipathic α-helical coil-coil domains, analogous to some viral proteins (Lacy 
et al., 1998; Lacy and Stevens, 1999). This amphipathic HN domain of CNTs, 
exposed under low pH conditions, inserts into the endosomal membrane to form 
cation-selective conductance channels (Schmid et al., 1993). Simultaneously, 
the LC which is attached to the HC by a di-sulphide bridge, partially unfolds at 
low pH and slides into the pore formed by the HC. Upon contact with the 
reducing environment in the cytoplasm, the di-sulphide bond is reduced and LC 
liberated (Koriazova and Montal, 2003). If non-reducing conditions or 
holotoxins, with the LC and HC still attached, are used, the LC does not free 
itself upon insertion and continues to block the HC pore. Once in the cytoplasm, 
the free LC now refolds back to its native configuration. The process of 
translocation has been studied using electrophysiological tools in great detail in 
Neuro 2a neuroblastoma cells and reconstituted liposomes, mimicking the 
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natural endosomal environment (Montal et al., 1992; Fischer and Montal, 
2007a, 2007b; Fischer et al., 2008). In such conditions, the HC forms channels 
which open in bursts interspersed between periods of inactivity. These channels 
are open at negative voltages and show a main conductance of 105 +/- 5 pS or 
65 +/- 4 pS in 200 mM CsCl or NaCl, respectively (Fisher and Montal, 2006). 
2.1.2. Proteolytic cleavage of specific SNAREs by the LC of CNTs 
The protease activity of the CNTs resides in the LC and this alone can 
mediate the subsequent paralysis of neuromuscular transmission. Direct 
introduction of the LC, by permeabilisation (Ahnert-Hilger et al., 1989) or by 
liposomes (de Paiva and Dolly, 1990), results in cessation of synaptic 
exocytosis identical to that elicited by the whole molecule. The elucidation of the 
different CNTs amino-acid sequences and solving of their crystal structure, with 
or without their attached substrates, has enabled a deeper understanding of the 
mechanisms underlying their enzymatic activity. The LC sequences show a 
metalo-protease domain with a HExxH+E consensus Zn2+-binding site 
(Jongeneel et al., 1989; Kurazono et al., 1992). Three residues co-ordinate the 
catalytic Zn2+ in the active site (H222, H226 and E261) while E223 ensures its 
hydration  (Lacy et al., 1998; Lacy and Stevens, 1999). The importance of Zn2+ 
was shown when its removal inactivated the toxin and prevented neuroparalysis 
(Schiavo et al., 1992b; de Paiva et al., 1993). The identity of their synaptic 
targets was first revealed when VAMP2 was shown to be the target for BoNT/B 
and TeNT (Schiavo et al., 1992c) (See section 1.3 for more details about the 
cleaved SNAREs and their cleavage sites. See also Figure 7). The identification 
      
 
 
78
of critical SNAREs as targets for the different CNTs fits well with the 
electrophysiological observation that inhibition of SV fusion is a prime 
consequence of toxin mediated neuroparalysis.  
The mechanisms underlying the enzymatic activity of CNTs are now 
better understood due to recently solved structures of different LCs bound to 
their substrates (Hanson and Stevens, 2000; Breidenbach and Brunger, 2004, , 
2005). Unlike classical metallo-proteases, the LCs, though significantly 
homologous at their active sites, have no common recognition motif on the 
SNAREs. While they are generally promiscuous in their requirement for 
particular side-chains flanking the scissile bond, they do require long stretches 
of their target SNAREs for optimal efficiency (Foran et al., 1995; Schmidt and 
Bostian, 1995, , 1997; Breidenbach and Brunger, 2004, , 2005).  Also, point 
mutations in regions remote from the scissile bond can reduce proteolytic 
efficiency of these LCs. All these clues point to a bi-partite mode of action of the 
LCs, with regions spatially separated from the scissile bond, exosites, being 
important in binding and recognising the SNAREs and bringing them into a 
conformation where the active site can access the scissile bond.  
SNAP-25 interacts quite extensively with BoNT/A LC and upon binding 
abandons its native helical configuration and wraps round most of the LC’s 
circumference (Breidenbach and Brunger, 2004, , 2005). The part of the LC 
opposite the active site plays an important role in identifying the correct 
substrate and the C terminus of the correctly bound SNAP-25 probably induces 
a conformational change in the catalytic motif of the LC, increasing its catalytic 
efficiency. Thus, while only nine residues from the C-terminus of SNAP-25 are 
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actually cleaved, 60 residues in the C-terminal are needed for efficient 
proteolysis, encompassing the structurally-identified a and b exosites on the LC. 
Truncated forms, with only 40 C-terminal residues, and mutations, including 
I156E and M167E, substantially decrease the catalytic efficiency by depriving 
the a-exosite of its binding partner. The b-exosite on the other hand binds at the 
far C-terminal of SNAP-25; versions of S25 truncated below M202 are cleaved 
at a very slow rate.  
These processes probably occur in a sequential manner – SNAP-25 first 
binds to BoNT/A at the a-exosite, fastens around the LC molecule, binds at the 
b-exosite and induces conformational changes at the active site potentiating its 
catalytic activity. As these disruptions in SNAP-25 structure, caused by the 
multiple interactions with LC, also bring the Gln197-Arg198 bond near the 
HExxH+E catalytic domain, allowing efficient and rapid proteolytic cleavage of 
the terminal 9 residues. This bi-partite multi-site binding strategy can be used to 
explain the selectivity of CNTs and the necessity of a large extent of substrate 
for efficient proteolysis. This also explains quite elegantly the finding that 
proteolysis of SNAP-25 is retarded if it is already incorporated into a ternary 
SNARE complex (Breidenbach and Brunger, 2004). The identification of these 
non-scissile substrate binding sites on the surface of BoNT/A, such as the a- 
and b-exosites, also presents new opportunities for novel peptide inhibitors. 
The specific residues flanking the scissile bond influences toxin 
susceptibility. Amino acids at either the P1 or P’1 site are important for cleavage 
of VAMP II by BoNT/B (Foran et al., 1994; Regazzi et al., 1996) and SNAP-25 
by BoNT/A, /C1 and /E (Schmidt and Bostian, 1997; Schmidt et al., 1998); for 
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BoNT/E,  other sites also contribute to the efficacy of cleavage (P5 to P’3) 
(Vaidyanathan et al., 1999). The multi-site binding strategy employed by 
BoNT/A accounts for the extreme selectivity of this enzyme, both in terms of the 
particular SNARE that is cleaved as well as the particular cleavage site. Due to 
their high homology, most of the CNT LCs probably use similar mechanisms for 
substrate recognition (e.g., the similarity between BoNT/A and /B is very high, 
the overall root mean square deviation between the holotoxins is 2.1 Å, and 
between the LC active sites is 1.4 Å (Swaminathan and Eswaramoorthy, 2000)).  
2.1.2.1. Unique trafficking properties of TeNT  
After TeNT enters the motor nerve terminal, it is internalised into a 
vesicle and transported retrogradely along the axon into the motor neuron cell 
body, at 7.5mm/H, and to the dendrites and released into the synaptic cleft 
(Burke et al., 1971). The released TeNT is then taken up by inhibitory inter-
neurons where it blocks transmission, tipping the balance between excitatory 
and inhibitory control of the motor neuron towards the latter, resulting in 
“tetanic” muscle spasms characteristic of the disease. The differential specificity 
and targets of TeNT and BoNT is determined by the different vesicles that they 
enter at the NMJ. TeNT enters non-acidified vesicles undergoing retrograde 
transport while BoNT enters acidified vesicles and thus remains within the 
motorneuron presynaptic terminal (Lalli and Schiavo, 2002; Lalli et al., 2003; 
Bohnert and Schiavo, 2005). An alternate hypothesis is that TeNT could be 
perverting the course of regular endosomal vesicles and causing them to 
undergo retrograde axonal transport. An interesting finding is that TeNT uptake 
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is independent of pre-synaptic activity, unlike BoNT uptake – potentially opening 
up avenues to target not only active neurons, but also paralysed ones 
(Deinhardt et al., 2006). The peripheral effects of TeNT are very minimal, unless 
very high doses are injected. TeNT co-localises with the receptor for NGF 
(p75NTR), segregates to non-acidified vesicles, requires F-actin, microtubules, 
dynein, kinesins, V-ATPase and myosin to successfully undergo retrograde 
transport (Lalli and Schiavo, 2002; Lalli et al., 2003). 
2.1.3. The structure of purified CNTs  
The solved structures of CNT holotoxins reveal a domain organization 
consisting of the receptor binding domain (HCC), the translocation domain 
(HCN), and the light chain (LC) protease domain (Lacy et al., 1998; Lacy and 
Stevens, 1999) (See fig. 11). The sequence homology and functional similarity 
between the CNTs is reflected in their structural resemblance as well - the 
overall root mean squared deviation between /A and /B holotoxins is 2.1 Å, and 
between the LCs is 1.4 Å.  These CNTs are synthesised as single proteins with 
a molecular weight of 150 kDa and subsequent proteolytic cleavage by 
endogenous or exogenous proteases creates a C-terminally located heavy 
chain (HC) and a N-terminally located light chain (LC), with molecular weights of 
100 kDa and 50 kDa respectively. Despite cleavage, they persist as a very 
stable di-chain molecule due to the presence of a disulphide bond and tight 
non-covalent protein-protein interactions between the chains (Dolly and Aoki, 
2006). The solved crystal structure for BoNT/A, accurate to within 3.2 Å , shows 
that it has an extended structure with dimensions of 45 X 105 X 130 Å in which 
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the HCN domain, composed of two 105 Å α-helical domains, separates the L 
domain from the HCC domain. The LC domain, a compact structure measuring 
55 X 55 X 62 Å, is composed of a mixture of α-helical and β-strands and is 
linked to the HCN via a long loop which wraps around the LC (Lacy et al., 1998). 
Despite the overall similarity, small differences in surface residues probably 
contribute to the significant substrate specificity of different CNTs. The solved 
BoNT/A-SNAP-25 complex structure has revealed that the LC depends on an 
extensive array of exosites to provide the substrate specificity, to orient the 
scissile peptide bond correctly in relation to the enzyme’s catalytic motif and  to 
boost the catalytic efficiency (reviewed in (Breidenbach and Brunger, 2004). 
See fig. 11).  
2.1.4. Recovery of cholinergic transmission at the NMJs after 
Clostridial toxin poisoning  
The speed of recovery from CNT-induced neuromuscular paralysis is 
strongly serotype dependent. Muscle can remain paralysed for many months 
after BoNT/A and /C1, while patients exposed to BoNT/B, /D, /E or /F recover 
from poisoning within a matter of weeks (Cherington, 1998). The response of 
the pre-synaptic membrane to blockade of exocytosis is proposed to 
significantly affect the speed and extent of recovery – for example: a higher 
plasticity and regenerative capacity after injury in younger animals could 
contribute to the faster recovery compared to adults (Pestronk et al., 1980; 
Verdu et al., 2000; Chen et al., 2002). At murine muscle endplates, the nerve 
endings sprout vigorously after exposure to BoNT/A and, in the initial post-
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paralytic period, only these sprouts are capable of exocytotic function at newly-
formed synapses (Duchen and Strich, 1968; de Paiva et al., 1999). Such 
sprouting, which has also been detected in juvenile rats (Pestronk and 
Drachman, 1978b), depends on the amount of toxin introduced and the muscle 
type; fast muscles show less sprouting and predominantly axonal outgrowths 
compared to the terminal sprouts seen in slow muscles (Brown et al., 1980). 
The final phase of recovery involves exocytosis returning to the original synapse 
and regression of the sprouts. While the stages of this functional recovery have 
been characterised, it is not known whether the fine control of sprouting and 
regression are related to the toxin’s persistence, its cleavage product (truncated 
SNAP-25) or if it is controlled solely by the loss of neural stimulation of the 
muscle resulting from disablement of the SNARE function. The relative 
importance of the muscle or Schwann cells in either of these complementary 
processes remains poorly defined (Tam and Gordon, 2003). The up-regulation 
of synaptic protein production has been observed in paralysed NMJs and could 
be the key to recovery or merely be a response to an unknown ‘switch’ for 
sprouting (Jung et al., 1997). BoNT/A intoxication has also been found to induce 
the extension of Schwann cell processes, which play important roles in the 
regeneration by providing paths along which the sprouts extend (Son and 
Thompson, 1995; Son et al., 1996). However, the matter is complicated by the 
finding that BoNT/A can cause sprouting in nerve-muscle co-cultures deficient 
in Schwann cell (Bonner et al., 1994). Hormonal and signalling factors, and their 
receptors, like insulin-like growth factor (IGF) could also play an important role 
in sprouting (Caroni and Grandes, 1990; Caroni et al., 1994; Caroni, 1997). 
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 The extended duration of synaptic stasis associated with BoNT/A 
poisoning causes prolonged convalescence and considerable morbidity. This 
could be due to the persistence of the toxin LC in the pre-synaptic terminal or 
the prolonged destabilisation of the SNARE machinery by the cleaved SNAP-25 
or due to the time taken to replenish the incapacitated SNAP-25. The latter can 
be ruled out as BoNT/E, which cleaves the very same substrate as /A, has a 
very short duration of action (Meunier et al., 2003). The inhibitory effect of the 
BoNT/A cleavage product of SNAP-25 was demonstrated in chromaffin cells, 
where over-expression of SNAP-25-197 caused an inhibition of Ba2+-evoked 
hGH secretion (O'Sullivan et al., 1999). Another important clue to explain the 
prolonged duration of BoNT/A action was the finding that the BoNT/A-LC is 
distributed in a punctate manner in the plasma membrane and co-localizes with 
SNAP-25-197, while BoNT/E LC was predominantly cytoplasmic (Fernandez-
Salas et al., 2004a; Fernandez-Salas et al., 2004b). Furthermore, this 
localisation of BoNT/A-LC to a slow recycling compartment at the plasma 
membrane may make it less susceptible to degradation or ubiquitination while 
cytoplasmic BoNT/E-LC could be more accessible to removal, thus, accounting 
for their different time scales of paralysis. There is also some evidence for the 
first eight amino acids at the N-terminal of LC/A or a di-leucine motif present at 
the C-terminal could contain a signal for plasma membrane localization 
(Fernandez-Salas et al., 2004a; Fernandez-Salas et al., 2004b). 
The microscopic manifestation of synaptic re-organisation following 
intoxication with BoNT/A are well known. Blockade of ACh release for 3 days or 
more by BoNT serotypes induced nerve sprouting with the formation of 
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functional extra-junctional synapses whilst the original remains inoperative. 
Initially, thin amyelinated neuritic processes emanate from their original parent 
nerve endings (terminal sprouting) or from the last node of Ranvier (nodal 
sprouting) and extend outside the area occupied by the parent nerve terminal. 
In time, these sprouts gain the components necessary for a functioning 
synapse, and the AChR clusters on the opposing muscle surface that go with it, 
and start to exhibit exo- and endocytosis (de Paiva et al., 1999; Meunier et al., 
2003). At their peak, they are much larger than the, currently quiescent, parent 
synapse, but after 9 weeks, the growth of the sprouts ceases. Activity starts to 
return to the parent nerve ending and, by 3 months, the sprouts undergo 
retraction accompanied by complete resumption of the normal level of neuro-
exocytosis to the fully-remodelled endplate that is then virtually indistinguishable 
from the original (de Paiva et al., 1999). This is a very striking and extensive 
cascade of events which illustrates how such neuronal plasticity can cope with a 
toxin insult and highlights the role of the activity mediated by the sprouts in 
allowing and, probably, promoting rehabilitation of the synapse. 
2.1.5. Engineering SNAREs resistant to cleavage by CNTs 
Extensive work has been undertaken to define the important residues in 
the SNARE substrates that affect the rate of their cleavage by different CNTs. 
As with any other enzymatic proteolytic process, substitutions in and around the 
cleavage site strongly affect the Kd and Vmax of the reaction. For e.g., Q76V, 
F77W mutations in VAMP2, the P1 and P1’ residues respectively, confer 
resistance to TeNT inhibition of hGH release in PC12 cells and insulin secretion 
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in HIT-T15 cells (Regazzi et al., 1996; Quetglas et al., 2002). Similarly, Q76V or 
F77V or F77L mutations of VAMP2 confer resistance to BoNT/B (Shone and 
Roberts, 1994) and K59R or K59A mutations induce resistance to /F (Schmidt 
and Stafford, 2005). Mutated SNAP-25 isoforms have been engineered to resist 
cleavage by BoNT/C1 (R198T or R198E (Vaidyanathan et al., 1999)), /A 
(R198T (O'Sullivan et al., 1999)) and /E (I181F (Vaidyanathan et al., 1999) or 
D179K, M182T (Koticha et al., 2002)).  
2.1.6. Adeno-associated viruses (AAV)  
AAV is a non-pathogenic single-stranded DNA containing replication-
deficient parvovirus, with a stringent requirement of co-infection with a helper 
adenovirus or herpes virus to complete its lytic life-cycle (McLaughlin et al., 
1988; Berns and Linden, 1995; Linden et al., 1996; Samulski, 2000; Xie et al., 
2002; Burger et al., 2005). While these dependo-viruses are widely prevalent as 
a latent infection in many mammals, including humans, they rarely cause overt 
clinical symptoms. AAVs are protein enveloped viruses with a capsid diameter 
of 26nm. Inside this capsid can be found a single-stranded DNA genome 
containing all the cis-acting elements needed for AAV replication and packaging 
and flanked by inverted terminal repeats (ITR). Of the 11 known serotypes, 
AAV1-5 are the best studied and AAV-2 is widely used in clinical gene therapy 
(Choi et al., 2005). 
The wild-type AAV-2 genome consists of rep and cap genes encoding 
genes necessary for replication and capsid protein production respectively. 
Utilizing two promoters and alternative splicing, AAVs generate four rep proteins 
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- Rep78, Rep 68, Rep 52 and Rep 40. Transcripts from another promoter 
generates the three structural viral capsid proteins, 1, 2 and 3 (VP1, VP2 and 
VP3), through alternate splicing and translation start sites (Berns and Linden, 
1995; Linden et al., 1996; Linden and Berns, 2000). These differ only in their N-
terminals while sharing 533 amino acids in a common C-terminal – generating 
VP1, VP2 and VP3 proteins of molecular weights 87, 73 and 62 kDA 
respectively (the former two contain additional N-terminal sequences of 202 and 
65 amino acids, respectively). The intact AAV viral particle contains a total of 60 
copies of VP1, VP2, and VP3 at a 1:1:20 ratio, arranged in a T=1 icosahedral 
symmetry (McLaughlin et al., 1988). Wt-AAVs (wildtype AAVs) exist as 
quiescent integrated forms in the host genome and only replicate in the 
presence of helper viral infection. 
AAVs need to undergo multiple steps prior to synthesizing its genome 
contents – the introduced AAV first binds to cellular surface receptors (usually 
heparan sulphate proteoglycans) and is later endocytosed. After uncoating, the 
viral particle releases the ss-DNA genome which is trafficked to the nucleus. 
The conversion of the genome from single-stranded to double-stranded DNA is 
followed by transcription of its constituent proteins in the nucleus. In the 
absence of the helper virus, wt-AAVs integrate into the host chromosome, 
usually 19q11, with the assistance of Rep proteins and through the interaction 
of their ITR with the host chromosome (AAVs replicate epi-chromosomally 
under replication permissive conditions and integrate into the host genome at a 
rate of 5–10% under non-permissive conditions (Linden et al., 1996)). The 
efficiency of infection and the rate of protein production is determined by many 
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factors such as – the abundance of cellular surface receptors for viral 
attachment and internalization, the effectiveness of release from endosomes 
and lysosomes, the efficiency of unpacking and nuclear trafficking, the rate of 
conversion of single-stranded to double-stranded DNA template and, finally, for 
a sustained long-term expression, the amount of integrated viral genome. All 
these factors differ between the serotypes and are strongly affected by the host 
cell, but they might be manipulated to facilitate more efficient or more specific 
transduction of cells or tissues for gene therapy (Burger et al., 2004; Choi et al., 
2005). 
The properties of this versatile virus have been exploited to produce 
recombinant AAV (rAAV) gene delivery vectors. A helper-virus free system for 
the production of infectious rAAV can be fashioned by removing the two viral 
genes (rep and cap) and inserting a transgene expression cassette between the 
two ITRs, with Rep and Cap provided in trans. The absence of the constitutively 
expressed native viral genes reduces the toxicity, eliminates the reproductive 
capability and lessens the possibility of immune recognition.  
A commercially available rAAV helper- free system from Stratagene has 
been used widely for scientific and pre-clinical applications (Kay et al., 2001) 
(see Fig. 12). In this system, the stripped down human AAV-2 genome, bereft of 
all except the ITRs and a coding cassette, is co-transfected into HEK-293 
variant (AAV-293) cells with two other plasmids, pHelper and pAAV-RC. The 
essential helper adenoviral genes, E2A, E4, and VA RNA genes, required for 
the production of infective AAV particles are supplied in trans (through a co-
transfection with the plasmid pHelper). The AAV-293 host cells, which stably 
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express the adenovirus E1 gene, and the plasmid pAAV-RC, producing the Rep 
and Cap genes are the other essential requirements supplied in trans. The 
removal of the AAV rep and cap genes also makes space for insertion of a gene 
of interest, upto 3 kb and driven by a cytomegalovirus (CMV) promoter, in the 
formed AAVs. In addition, some variants can also be generated to co-express a 
marker Green Fluorescent protein (GFP) through the use of a bovine Internal 
Ribosome Entry site (IRES) (with a consequent reduction in the maximum insert 
size to 1.7kb). 
Elimination of live helper virus, removal of all non-cis genes from the 
genome and splitting of the trans components, into two plasmids and one cell 
line, provides a safer, purer, replication-deficient, recombination-free and more 
convenient alternative to Herpes and Adenoviral gene delivery systems (Buning 
et al., 2008).  The broad host range, high titer virus production capacity, ability 
to infect post-mitotic cells and long-term gene transfer potential render them 
promising tools for gene delivery and expression in neuronal populations 
(Martinov et al., 2002; Ruitenberg et al., 2002; Burger et al., 2005). There is, 
however, some evidence to suggest that AAVs have a preference for certain 
types of neurons, a preference strongly mediated by the serotype used (Burger 
et al., 2004).  There is also strong evidence to suggest that they can undergo 
retrograde transport from spatially separated pre-synaptic terminals to neuronal 
nuclei and even from NMJs (Kaspar et al., 2003).  
Thus, the positive results obtained from ability of a toxin-resistant SNAP-
25 isoform to counteract BoNT/A in chromaffin cells, encouraged the 
development of gene therapy strategies to achieve a similar goal in neurons, in 
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vitro and in vivo. Incorporation of this proven gene into the available AAV 
system was the first goal of this project. After the creation of such a viral vector, 
it was tested in chromaffin cells, in CGNs and finally in vivo, in rat models of 
botulism.  
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2.2. Experimental strategies employed 
BoNT/A, purified to a specific neurotoxicity of 1 mouse LD50 = 5 pgs as 
described previously, was used (Shone and Tranter, 1995). The following 
reagents were purchased: AAV vector Helper-free plasmids (pAAV-MCS, 
pIRES-hrGFP, pHelper and pRC) and cell lines (Stratagene), heparin agarose, 
benzonase, mouse anti-NF200 antibody and basic laboratory chemicals 
(Sigma-Aldrich), Tissue-tek (Sakura), anti-S25 SMI-81 antibody (Sternberger 
Monoclonals), mouse anti-His6 antibody (Amersham), α-bungarotoxin (α-BuTx) 
conjugated to Alexa-488 or rhodamine (Invitrogen), West-Dura ECL developer 
(Pierce), gel extraction and plasmid purification kits (Qiagen), enzymes for DNA 
production and purification (NEB), stereotaxic table with rat spinal immobilizers 
(Stoelting), micro-surgical implements (WPI), micro-syringes and needles 
(Hamilton). The constituents of the different prepared buffers and solutions can 
be found in Appendix 1. 
2.2.1. Animal husbandry, LD50 determination and DAS scoring 
Female Wistar rats (8 weeks old, ~200g) and female TO mice (20g) were 
acquired, under license, from Trinity College Bioresources Unit or Harlan (UK). 
Animals were housed in certified facilities and handled by trained animal 
technicians. They were given ad libitum access to water and commercial rodent 
food. All techniques were approved by the Environmental Health Unit in the 
Department of Health and Children in Ireland and conformed to relevant EU 
regulations. Experiments were approved by the University Ethics Committee 
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and supervised by a consultant veterinary surgeon. Animals that were treated 
with drugs/toxins, or operated on, were segregated from the normal population. 
Data sheets were maintained on these animals and details of their weight, feed, 
excreta, digit abduction scores (DAS) and general condition noted regularly. All 
potentially painful procedures were done under sedation or anaesthesia. Any 
animal that seemed to be in pain was given adequate analgesics or, in extreme 
conditions, euthanized. 
The two main procedures involving live animals were LD50 determination 
and viral vector administration (The latter is described in detail in Section 2.2.5). 
In both cases, every effort was taken to minimise the number of animals by first 
performing in vitro assays to give an approximation of the activity of the toxins 
or the dose of virus needed. LD50 in mice is the only method capable of 
quantifying the composite activity of the BoNT and TeNT toxins (i.e. extra- and 
intra-cellular stability in the animal, binding to neuronal acceptors, acceptor-
mediated toxin uptake, translocation and enzymatic cleavage of their targets in 
the conformations existing within neurons). A mouse bioassay is the ultimate, 
most reliable and, thus, the only internationally-accepted measure of toxin 
activity for human uses (see (Schantz and Kautter, 1978) and (Schantz and 
Johnson, 1990)). This entails a single intraperitoneal injection followed by 
monitoring of generalised neuromuscular paralysis (Union, 2000). The toxin 
paralyses the respiratory muscles leading to death by asphyxiation; however, 
the mice were not subjected to prolonged suffering and were euthanised at the 
onset of confirmed respiratory paralysis. After the injection, they were observed 
every 3 h during the day, every 6 h at night and more often when symptoms 
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become evident, for the length of the procedure. The animals were examined 
for signs of lethargy, which indicates early stages of botulism, and when the 
animals ceased to “run away” from the handler, the extent of respiratory distress 
was carefully assessed.  Signs of distress include cyanosis in the tail and 
“drawing in” of its stomach (abdominal contraction). When there was clear 
evidence that the animal would not survive from respiratory distress, it was 
humanely killed. In early stages, mice sometimes demonstrated signs of 
dysphagia and difficulty in accessing food and water and, therefore, the animals 
were fed with easily accessible water-soaked food pellets.  Another checkpoint 
monitored was body weight; if loss exceeded 20%, the mice were humanely 
killed.   
The speed of onset of the symptoms can differ depending on the dose. 
The different subtypes of BoNT to be used have distinct patterns and time 
courses of paralysis.  For example, an animal injected with BoNT/A will show 
serious symptoms on day 1-2 whereas those injected with BoNT/E or other 
short-acting forms display symptoms on day 2, yet are likely to recover. Four 
days after toxin injection the experiment was ended and animals were 
euthanized by cervical dislocation, according to the EU guidelines.  
The same monitoring procedures were used for experiments involving 
the intra-muscular injection of BoNT and viruses.  
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Fig. 12: The AAV vector production process. This flowchart represents the different plasmids 
and steps involved in the production of a functional virion and the processes implicated in its 
integration into the target cell. pAAV-gene: the transfer construct containing the expression 
cassette with the necessary flanking cis-acting promoter and poly-adenylation sequences. 
pAAV-RC: Containing the Rep and Cap genes of the AAV2 virus (Rep: AAV2 replication genes. 
CAP: AAV2 capsid genes). pHelper: Containing the E2A, E4 and VA sequences from 
adenovirus. HEK-293: human embryonic kidney cell line. CMV: cytomegalovirus promoter. 
hGHpA: human growth hormone polyadenylation sequence. ITR: inverted terminal repeats. 
E2A, E4 and VA: Adenoviral genes that along with the E1A and E1B genes from HEK-293 
enable the successful production of an AAV2 particle. 
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Fig. 13: Cloning of pAAV-His6-S25 and pAAV- His6-S25MTR: The top half of the figure shows 
the PCR amplification of wild-type S25 using an N-terminal primer containing a BamHI site, 6 
repeats of CAT (coding for His) & a start codon, and a C-terminal primer containing a XhoI site 
with a stop codon. After restriction digestion, the PCR product is inserted into a BamHI and XhoI 
digested pAAV-MCS vector (Middle). The lower panel shows amplification of the S25R198T 
gene using two sets of primers (containing the necessary D179K and M182T mutations) 
resulting in the production of two overlapping PCR products. Using them as templates, PCR 
with the two initially used outer primers yielded the multiple toxin resistant His6-S25MTR gene 
which, after digestion with BamHI and XhoI, was inserted into the pre-digested pAAVMCS 
plasmid. Lane 1 & 2 – undigested & Bam H1/Xho1 digested pAAVMCS; 3 – digested His6-S25 
PCR product; 4- digested His6-S25 MTR PCR product. 
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Name of Primer Sequences 
bGlobulin For ATTCTGAGTCCAAGCTAGGC 
hGH pA Rev TAGAAGGACACCTAGTCAGA 
T3 For ATTAACCCTCACTAAAGGGA 
T7 Rev TAATACGACTCACTATAGGG 
left ITR For CCTCTGACTTGAGCGTCGAT 
right ITR Rev TACTATGGTTGCTTTGACGT 
SNAP-25-XhoI-Rev ATCCGCTCGAGTTAACCACTTCCCAGC 
SNAP-25BamHIHis6For CGGGATCCATGCATCATCATCATCATCATGCCGAGGACGCAGACA
TGCG 
SNAp-25RTXhoIrev AGATCTCTCGAGTTAACCACTTCCCAGCATCTTTGTTGCAGTTTGG
TTGGCTTCATCAATTC 
CMV Taqman            5'FAM-CCGCTATCCACGCCCATTGATG-3'TAM   
CMV_TFor              TGGAAATCCCCGTGAGTCAA 
CMV_TRev              CATGGTGATGCGGTTTTGG 
EF-1 short for TGCCGCCAGAACACAGGTG 
WPRE rev TAGTTAAGAATACCAGTCAATCTTTCAC 
EF1-a for CCATTTCAGGTGTCGTGAGGA 
IRES Rev CATATAGACAAACGCACAC 
S25D-K M-T For AAGAGGATCACAGAGAAGGCTGACTC 
S25D-K M-T Rev TGTGATCCTCTTAATCTGGCGATTCTG 
S25T-For GGCTGATGAGTCCCTGGAAA 
S25T-Rev CGCCTTGCTCATCCAACAT 
S25Taqman 5'FAM-AGCTGGTTGAAGAGAGTAAAGATGCTGGC-3'TAMRA 
GAPDH For  TGCCAAGTATGATGACATCAAGAAG 
GAPDH Rev  TAGCCCAGGATGCCCTTTAGT 
GAPDH Taqman  5'FAM-TGGTGAAGCAGGCGGCCGAG-3'TAMRA 
b-actin for  AGGGAAATCGTGCGTGACA 
b-actin rev  GTCTAGGGCAACATAGCACAGCTT 
pQE For GTATCACGAGGCCCTTTCGTCT 
pQE Rev CATTACTGGATCTATCAACAGGAG 
CS-For ATGATGAGATCTCTCGAGGGTGGC 
CS-Rev GCCGCCAGATCTCTCGAGGGATC 
Botim Clon1 For: ACTGGATCCCCGACCATTAATAGTTTTAATTATAATGATCCTG 
Botim Clon1 Rev: CAGGGATCCACCGGTACGCGTAGAATCGAGACCG 
LCE For: ATTTCAAGTTAAATGTAGGCAAAC 
HCE Rev: CATAATTATTATTTGAAGTTACTGTATC 
LCE Rev: GTACCAATTACATTTCTCTCTGG 
HCE For: TGGAAATAATATTGGGTTGTTAGG 
 
Table 2: Sequences of the different primers used: All sequences are represented 5’-3’. The 
taqman probe, CMV_Taqman is labeled with the reporter dye FAM (6-carboxy-fluorescein) at its 
5’ end and the quencher TAMRA (6-carboxy-tetramethyl-rhodamine) at its 3’ end. 
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2.2.2. Construction, production and purification of recombinant AAVs 
expressing BoNT/A-resistant S25 (S25RT), wild-type S25, markers 
hrGFP or hrGFP with S25RT 
An AAV vector Helper-free system consisting of three plasmids – transfer 
construct (e.g.: pAAV-hrGFP, pAAV-His6SNAP-25RT etc); pAAV-RC, 
containing the rep and cap AAV genes and pHelper, expressing the necessary 
adenoviral-proteins – was used to produce replication-deficient AAV virions 
(See fig. 12 and 13). PCR, using the S25BamH1His6-For and S25XhoI-Rev 
primer pair, was undertaken to generate a His6-tagged S25 product from a 
pcDNA1.1 plasmid containing the mouse S25 gene His6-tagged (see Table 2 for 
primer sequences). After restriction digestion with Bam HI and Xho I, the 
product was purified using a Qiagen gel extraction kit and inserted into the 
pAAV-MCS plasmid, pre-digested with the same enzymes, to yield pAAV-His6-
S25 plasmid (see fig. 13 for more information on the cloning process). 
Confirmation of cloning and correct orientation of the insert was obtained by 
sequencing, using the β-globin-For and hGHpA-Rev primers.  
A similar technique, with the substitution of S25RTXhoI-Rev for S25XhoI-
Rev, was used to create pAAV-His6-S25-R198T encoding a functional S25 
which is resistant to cleavage by BoNT/A. For generating a S25 gene resistant 
to cleavage by /A, /C1 and /E splicing by overlap extension PCR was used to 
introduce two further mutations into the S25R198T gene – D179K and 
M182T(Koticha et al., 2002). Briefly, PCR using the pAAV-S25R198T plasmid 
with the two primer pairs, β-globin-For & S25DKMT-Rev and S25DKMT-For & 
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hGHpA-Rev yielded two overlapping fragments of 680 and 200 bps. When 
purified and mixed together in a PCR reaction with β-globin-For & hGHpA-Rev 
primers, these generated a full-length 860bp S25 MTR (multi-toxin resistant) 
containing BamHI and XhoI restriction sites at its 5’ and 3’ ends. Insertion into 
the pre-digested pAAV-MCS plasmid yielded the pAAV-His6-S25-MTR plasmid 
containing the triply-mutated S25 gene – R198T, D179K and M182T (Figure 
13). Using the same strategies and cloning methods, a second set of plasmids 
was created which could co-express these previously described genes along 
with a hrGFP marker gene, that is driven by an internal ribosome entry site 
(IRES) sequence (pAAV-His6-S25-IRES-hrGFP, pAAV-His6-S25-R198T-IRES-
hrGFP and pAAV-His6-S25-MTR-IRES-hrGFP). Isolation of all these plasmids, 
along with the pAAV-hrGFP control, to a high purity was then scaled up using a 
Qiagen Giga-prep kit. These different plasmids, along with the commercial AAV-
hrGFP, were used to create their respective AAVs as described in Zolutukhin et 
al, 1999 (Zolotukhin et al., 1999).  
The cis-construct plasmids, along with pAAV-RC and pHelper, were 
transfected into HEK-293 cells using calcium phosphate. An aliquot (10 µg) of 
each plasmid was mixed together and used to transfect 70% confluent HEK-193 
cells. After 12-18 hr, the medium was replaced and the cells were washed with 
PBS and harvested on day 3. The collected cells were subjected to 2-3 cycles 
of freeze/thaw, digested with benzonase (an endonuclease from Serratia 
marcescens) at 37oC for 15 mins and incubated with  0.5% sodium 
deoxycholate for a further 30 mins, before clarification  by centrifugation at 200 
g for 10 mins. The cleared lysate, sequentially filtered through a 5µm and 0.8µm 
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filters, was then loaded onto pre-equilibrated Heparin-Agarose resin (~200µl per 
15 cm plate of HEK-293 cells) and, after repeated washing, the bound virus was 
eluted using PBS + 0.5M NaCl. The resultant viruses were concentrated, and 
buffer exchanged, using a low-protein binding 100kDa cut-off filter, aliquoted, 
snap-frozen and stored at -80 oC.  
2.2.2.1. Titration of produced AAVs – PAGE, RT-QPCR, Western 
blotting and FACS-based assays 
The purity of these preparations was assessed on a Coomassie stained 
SDS-PAGE gel, and viral (protein) yield measured by comparing the surface 
proteins (VP1, 2 &3) to a bovine serum albumin (BSA) standard. Using the CMV 
Taqman probe and CMV_TFor & CMV_TRev primers, real-time quantitative 
PCR comparison with known quantities of the respective plasmids gave an 
accurate quantification of the number of genomic copies (GC) per preparation 
(Table 2 shows the sequence of primer and probes used).  A dilution series of 
these viruses was then used to infect HEK-293 cells and the number of 
transducing units (TU) per preparation calculated by extrapolating the two 
highest dilutions where infected cells could be identified, by green fluorescence 
(for the hrGFP containing viruses) and by an antibody- based detection (for 
those expressing S25). By these methodologies, large quantities of highly pure 
AAV viral particles (VP) were successfully prepared; for example, AAV-hrGFP 
virus was >95% pure and showed a concentration of ~1011 VP/ml and ~ 1x109 
TU/ml (See fig. 14). The disparity between these values is due to the presence 
of some empty and damaged virions but is within permissible limits. 
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Furthermore, this prepared virus gave strong expression of hrGFP in widely 
different cells like bovine adrenal chromaffin cells (See fig. 14 and 15). Cell 
viability assays on a Beckman-Coulter FACS apparatus further demonstrated 
the innocuous nature of these viruses in HEK-293 cells (See fig. 15B). Using 
the CMV Taqman probe and CMV_TFor & CMV_TRev primers (Table 2), real-
time quantitative PCR comparison with known quantities of the respective 
plasmids gave an accurate quantification of the number of genomic copies (GC) 
per preparation.  A dilution series of these viruses was then used to infect HEK-
293 cells and the number of transducing units (TU) per preparation calculated 
by extrapolating the two highest dilutions for which infected cells could be 
identified, using green fluorescence (for the hrGFP containing viruses) and by 
an antibody-based detection (for those expressing His6-S25).  
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Fig. 14. Efficient production, purification and concentration of AAV-hrGFP virus: 
A: Coomassie stained SDS-PAGE gel of aliquots taken at different points in the production 
process: M-prestained markers, 1-lysate, 2-deoxycholate extract, 3-Heparin agarose column 
flow-through, 4-eluate, 5- concentrator FT and 6-concentrated AAV-hrGFP. VP1, 2 and 3 are 
AAV surface proteins. B: Western blot of a duplicate of the gel in A, developed with an ECL 
reagent following detection with a rabbit anti-AAV and anti-rabbit-HRP. C: Overlay of a phase 
contrast and flourescent microscopic views of HEK-293 cells infected with AAV-hrGFP at an 
MOI of 1. 
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Fig. 15: The purified and concentrated AAVs show high infectivity without causing any 
deleterious effects. A: The produced viruses can efficiently infect bovine adrenal chromaffin 
cells and have only a minimal effect on HEK-293 cell viability. B: Cell death was determined by 
the ratio of propidium iodide (PI) stained to unstained cells on a Beckman-Coulter FACS 
apparatus, 5 days after treatment with various volumes of AAV-hrGFP, containing 1x109 TU/ml, 
or PBS. The percentage of PI positive cells was plotted as a ratio of the total cell number. An 
average of 4 runs, and standard deviation, is plotted in the graph 
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Fig. 16: The introduced His6-tagged S25 is efficiently expressed and partially localized to the 
membrane. A: HEK-293 cells were infected with AAV-His6-S25 virus for 5 days before lysis by 
freeze/thawing. Lysate was centrifuged at 18,000g for 1 hr; the supernatant (lane1) and pellet 
(lane 2) were separated and run on a 15% SDS-PAGE gel. After transfer, the Western blot was 
probed with mouse anti-His6 antibody,  followed by anti-mouse HRP conjugate and developed 
with an ECL-plus reagent. B: Representative picture showing some membrane-associated 
protein: HEK-293 cells infected with AAV-His6-S25R198T were formalin fixed and methanol 
permeabalised before sequential application of mouse anti-His6 and anti-mouse-Alexa 488 
secondary antibodies. The photo was taken on an Olympus inverted fluorescent light 
microscope with a 40X objective. C: Co-expression of His6-S25R198T with hrGFP: HEK-293 
cells infected with AAV-His6-S25R198T-IRES-hrGFP were treated as before except for the 
substitution of an anti-mouse-phycoerythrin secondary. Images corresponding to the His6-
S25R198T-red fluorescence (left) and hrGFP-green fluorescence (middle) were obtained and 
overlaid (right); yellow indicates cells expressing both these proteins. 
      
 
 
104
2.2.2.2.  Subcellular localisation of produced S25 by confocal 
microscopy 
For AAV-His6-S25 virus, sufficient expression and membrane association 
of the introduced protein was confirmed by Western blots on the membrane and 
cytosolic fractions, using a monoclonal anti-His6 antibody followed by detection 
with an anti-mouse-HRP conjugate (See fig. 16). Briefly, the cells were lysed 
with 1% Triton X-100 in PBS, the cellular and membrane fractions separated, 
aliquots denatured in Laemmli gel loading buffer and run on 12% pre-cast 
PAGE gels from Invitrogen. The separated proteins were transferred onto PVDF 
membranes over-night at 4oC. The blots were blocked for 30 mins with 4% (w/v) 
milk-powder in TBS buffer, with 0.05% Tween-20 and probed with the required 
primary and secondary antibodies in the same buffer. The blots were washed 
well 3-4 times between the steps with TBS buffer + 0.05% Tween-20. Detection 
of species-specific secondary antibodies, covalently attached to horseradish 
peroxidase (HRP), required the addition of enhanced chemiluminescence 
reagents (ECL) for 5 mins and acquisition of phosphorescence images with a 
GeneSnap imager. 
A large fraction of the expressed His6-S25R198T protein was found 
associated with the plasmalemma, as revealed by immunohistochemistry on 
formalin-fixed and methanol-permeabalised cells using an anti-His6 antibody 
detected by an Alexa-488 labeled anti-mouse antibody (Fig. 16). Co-expression 
of the hrGFP and His6-S25R198T in cells infected with the AAV-His6-
S25R198T-IRES-hrGFP virus was confirmed by identification of hrGFP 
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fluorescence and immunodetection of a His6 signal by a phycoerythrin labeled 
secondary (Fig. 16). 
2.2.3. Determining the relative proteolytic activity of BoNT /A, /E and 
/C1 against mutant and wild-type S25 
A highly sensitive assay using digitonin-permeabalised HEK-293 cells 
expressing wtSNAP-25 was used to determine the in vitro potency of the 
different toxins, their EC50 for cleavage of membrane-associated post-
translationally modified SNAP-25 and also to determine the cleavage-resistance 
of the different introduced mutations. Briefly, 5µg of plasmid DNA expressing 
wtSNAP-25, His6SNAP-25RT and His6SNAP-25-MTR was transfected using 
calcium phosphate into 80% confluent HEK-293 cells in a 10cm plate. The cells 
were washed the next day, treated with trypsin-EDTA to dissociate them from 
the plate surface and were seeded into 48-well plates. After another 24 h, the 
cells were treated with the toxin preparations in KGH permeabalisation buffer + 
150µM digitonin (the different toxin preparations were supplemented with 50µM 
ZnSO4 and reduced with 10mM DTT for 10 mins at 37ºC before addition on to 
cells). After 30min incubation, the cells were collected and the toxin’s activity 
stopped by addition of 1mM EDTA. They were freeze-thawed thrice and 
centrifuged at 18,000g for 30min at 4ºC. The membrane enriched sediment was 
denatured in Laemmli gel loading buffer, run on 12% PAGE gels, transferred on 
to a PVDF membrane and probed with a rabbit anti-SNAP-25 antibody. The 
different bands were quantitated by the densitometry software, GeneSnap, and 
analysed (See fig. 17). 
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2.2.4. Culture of chromaffin cells, infection with recombinant AAVs, 
intoxication with BoNT/A and assay of catecholamine release 
Chromaffin cells were isolated from bovine adrenal glands and 
maintained as described previously (Lawrence et al., 1996; O'Sullivan et al., 
1999). Fresh Bovine adrenal glands were cleaned of surrounding fat and 
perfused with Locke’s buffer with a syringe inserted into the portal vein. The 
gland was washed with this solution 4-5 times to ensure that all the blood was 
removed from the gland. Later it was perfused with the same solution containing 
0.1% (w/v) pronase and incubated at 37ºC for 15 mins to digest the connective 
tissue between the adrenal medulla and cortex. The digested glands were 
sectioned and the medulla separated from the cortex using a sterile blade. The 
medulla was minced and incubated with sterile 0.1% collagenase in Locke’s 
buffer at 37oC for 30 mins with vigorous agitation. The dissociated chromaffin 
cells were filtered through two layers of muslin, centrifuged at 500g in a bench 
top centrifuge for 10 mins and resuspended in Locke’s buffer. This process was 
repeated 2-3 times before a final centrifugation on a layer of Locke’s buffer 
containing 4% (w/v) BSA at 300g for 10mins. The essentially RBC-free 
chromaffin cells were counted using a haemocytometer, resuspended in 
chromaffin growth medium and plated at a density 1 X 106 viable cells per well 
on 24-well tissue-culture plates.  If needed the different AAVs were added to the 
media 24 h after plating the cells. 
After a week of growth, the media was changed and the cells were 
incubated at 37oC for 24 h in a low ionic strength medium (LISM) in the absence 
or presence of the BoNT toxins. Cells were re-equilibrated with the toxin-free 
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growth medium for 24 h before experiments were performed. They were 
exposed to 0.3 ml of ‘basal medium’ (Locke’s buffer) at 25ºC for 15 mins 
followed by a similar exposure to a ‘stimulation medium’ (2 mM Ba2+ in Locke’s 
buffer). The non-released catecholamines were extracted through the addition 
of 0.3 ml of ‘remaining medium’ (1% Triton X-100 in Locke’s buffer). The 
amount of catecholamines present in various samples was quantified using a 
fluorometric procedure (von Euler and Floding, 1959). Briefly, 2 ml of 1M 
CH3COONa and 0.1 ml of 0.25% (w/v) K3Fe(CN)6 were added to the collected 
fraction, mixed and incubated for 5 mins, thereby converting adrenaline to 
adrenochrome. This unstable product was then converted to adrenolutin by the 
addition of 1 ml of 0.2% (w/v) ascorbic acid in 5M NaOH. Adrenolutin can be 
quantitated fluorometrically with a Perkin-Elmer spectrophotometer as it emits 
light between 510 - 530 nm when excited at 410 nm. The catecholamine 
content in each of the three fractions was determined and the % of Ba2+-
induced catecholamine release, with respect to the total content, to be 
calculated: 
 
The amounts of release obtained after different viral and toxin treatments 
were then normalized to that in the presence of the toxin and represented as 
mean +/- SD of measurements from 4 different wells for each condition, from 2 
or more sets of experiments. T-tests were used to determine the statistical 
{(stimulated medium) - (basal medium)}
{(stimulated medium) + (basal medium) + (remaining medium)}
X 100
      
 
 
108
significance of all results. 
2.2.5. Stereotaxic intra-spinal administration of AAVs for transfection 
of anterior horn neurons supplying the soleus muscle in rats 
The precise location of the motor neurons innervating the soleus muscle 
was first determined by initial retrograde tracing of injected flourogold and from 
previously published literature (Greene, 1968; Nicolopoulos-Stournaras and 
Iles, 1983).  Rats were anesthetized with medetomidine/fentanyl citrate 
(Medetomidine/Domitor from a stock solution of 1mg/mL – dose  0.4mg/kg 
subcutaneous; Fentanyl/Sublimaze from a stock solution of 0.05mg/mL – dose 
0.45mg/kg IP) and injected with amoxicillin (Amoxycillin/Betamox from a stock 
solution of 150mg/mL – dose 140mg/kg subcutaneous). The surgical field was 
shaved, cleaned using 5% chlorhexidine gluconate (Hibitane) solution or 
Betadine surgical scrub.  To prevent drying out of the eyes, Lacrilube was 
applied periodically.  
The toe pinch and the tail base pinch reflexes were tested to confirm 
complete anethesisa, before the first incision was made over T10-L2 vertebras 
(up to an extra 1 mL of Fentanyl was injected intraperitoneally if the anethesia 
was found to be too shallow). The superficial fascia and the paravertebral 
muscles were separated to expose the vertebral bodies and spines before 
positioning in a stereotaxic frame (Stoelting); rat spinal adapters were used to 
firmly clamp two adjacent vertebras. The vertebral laminas over the T13 and L1 
spinal levels were penetrated using a microdrill taking care not to damage the 
dura or the underlying spinal tissue. Using a 30G beveled needle attached to a 
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Hamilton microsyringe, known quantities of the virus were injected over 5 mins 
at the T13 level; the open bevel was positioned caudo-laterally to prevent any 
leakage into the posterior or contralateral horns. After a further 5 mins, the 
needle was slowly withdrawn and the procedure repeated at L1 and L2 levels; 
in most cases, twitching of the lower limb muscles confirmed the accurate 
placement of the needle. The paraspinal muscles were sutured back together 
with braided, absorbable vicryl sutures (4-0), followed by a similar 
approximation of the superficial fascia reinforced with a Prolene mesh (knitted, 
non-absorbable polypropylene) to strengthen the wound and prevent soft-tissue 
dehiscence. The skin was closed with a non-absorbable prolene (4-0) suture 
and atipamazole (Atipamazole/Antisedan from a stock solution of 5mg/mL – 
dose 1mg/kg subcutaneous) and nalbuphine (Nalbuphine/Nubain from a stock 
solution of 10mg/mL – dose 2mg/kg subcutaneous) administered to accelerate 
recovery from the anesthetic. Carprofen (Carprofen/Rimadyl from a stock 
solution of 50mg/mL – dose 2mg subcutaneous) and bupivacaine (Bupivacaine 
HCL from a stock solution of 0.25% w/v – dose 0.2mL at wound site) were 
injected for systemic and local pain relief. Rats were kept under observation till 
they had fully recovered from anaesthesia and only then were they returned to 
the animal facility.  
Animals were carefully monitored post-operatively and adequate 
analgesia, antibiotics, food and hydration provided as needed. Depending on 
the individual animal, a saline injection to promote hydration was administered. 
A series of criteria was used to determine the post-operative condition of the 
animal, in conjunction with the experience of the regular animal handler.  These 
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include observations of activity, appearance, food and water intake, excretions, 
breathing, vocalisation, weight and the condition of the surgical site.  In general, 
pain is indicated by: "guarding" (protecting) the surgical site; vocalisation 
(squeaking) when the animal moves or if the surgical area is touched; limping, a 
"tucked up" abdomen, or other abnormal stances or posture; reclusive 
behaviour; lack of appetite; increased respiration rate or abnormal breathing 
patterns. In case of any undue distress, animals were euthanized by injection of 
Sodium Pentobarbitone (Dolethal from a stock solution of 20% w/v – dose 
200mg/kg IP). All animals injected with viral vectors were kept in separate 
cages and treated as potential sources of biologically hazardous material.  
2.2.6. In situ electrophysiological recording of the efficiency of 
neuromuscular transmission as a measure of synaptic exocytosis 
remaining after BoNT/A administration 
Three weeks after the intra-spinal injection, these rats were sedated 
using medetomidine, the skin over the posterior part of the lower leg incised and 
~1 mouse LD50 of BoNT/A in 10µL of normal saline (NS)/ BSA injected under 
visual guidance into the belly of the soleus muscle. The incision was then 
sutured, sedation reversed with atipamazole and the animal allowed to recover 
for 16-25 days. Later, they were again deeply anesthetized using 
medetomidine/fentanyl citrate and the Achilles tendon was exposed at the level 
of its insertion. The soleal contribution to this tendon was isolated and ligated to 
a sensitive force transducer (FORT10 – AD Instruments); the gastrocnemius 
and plantaris tendons were severed. The sciatic nerve was exposed at mid-
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thigh level, separated from surrounding fascia and placed on a pair of silver 
electrodes. Two more electrodes were positioned on the belly of the exposed 
soleus muscle followed by stimulation at 1 Hz using 5V for 2 msec with a 
PowerLab 4/20T (AD Instruments). The tension in the muscle and the position 
of the electrodes were adjusted using a micrometer in order to obtain the 
maximal contraction. The nerve was then stimulated at 1Hz using 200 mV for 
0.2 msec and the position of these electrodes adjusted to obtain the largest 
nerve-induced contraction.  The ratio of the force obtained in response to a 
single supra-maximal stimulation of the nerve compared to that for a single 
supra-maximal stimulation of the muscle provided the efficiency of 
neuromuscular transmission (ENT). Stimulation of the nerve and muscle at 60 
Hz provided the ENT at tetanic frequencies.  
 
2.2.7. Immuno-histochemical detection of S25, His6-S25, His6-S25-
R198T and GFP expression 
The rats were euthanized at the end of each experiment with sodium 
pentobarbitone, perfused with 4% formalin, the spinal cord and relevant 
muscles excised and cryoprotected with graded solutions of up to 20% 
glycerol/2% DMSO in phosphate buffered saline (PBS). The tissues were then 
mounted using Tissue-Tek solution and 25 µm sections cut, thawed out just 
before use, washed twice with PBS, permeabalised with ice-cold methanol for 
30 secs, washed again with PBS-T (PBS with 0.05% Tween-20) and blocked for 
up to 30 mins with filter-sterilized PBS-T with 1% BSA/2% goat serum. The 
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sections were then exposed to the primary antibody diluted into the same 
solution (1:50 for SMI-81, anti-NF200 and anti-His6 antibodies; 1:100 for anti-
hrGFP antibodies). After repeated washing at 37 °C, the samples were exposed 
to the relevant secondary antibodies (1:50 Alexa-488 or 1:100 
A546/phycoerythrin labelled goat anti-mouse; 1:50 A564 conjugated goat anti-
rabbit) with or without 1:500 fluorescently-tagged α-BuTx (with Alexa 488 or 
rhodamine).  After further washing, the specimens were mounted under a 
coverslip with PBS/glycerol and visualized with an Olympus IX51 inverted 
fluorescent microscope or, when appropriate, a Zeiss confocal microscope 
(LSM510).  
Protein expression in virally-infected mammalian cells lines or chromaffin 
cells was quantified in the membrane and cytosolic fractions of the lysed cells 
by separation on 12% pre-cast SDS PAGE gels and Western blotting.  The 
blots were probed with different dilutions of the primary (1:5000 SMI-81, 1:1000 
anti-His6, or 1:2000 anti-hrGFP) and relevant secondary antibodies (1:4000 
rabbit anti-mouse or 1:2000 goat anti-rabbit HRP-conjugated), developed with 
West-Dura reagents and chemiluminescence was captured using a cooled-CCD 
camera.  
2.2.8. Determination of the distribution of ACh receptors at NMJs 
using fluorophore-conjugated α-BuTx 
Random sections of soleus muscle from rats injected with BoNT/A alone, 
AAV-His6-S25-R198T then BoNT/A and untreated controls were stained with a 
α-Butx-Alexa 488 conjugate, and  images captured on an Olympus IX51 
      
 
 
113
inverted fluorescent microscope with 10x objective and a fast digital camera 
(Evolution QEi monochrome, MediaCybernetics). A calibrated motorised stage 
and ‘Stage-Pro’ software allowed the serial acquisition and stacking of image-
frames to obtain a picture of the whole muscle area. Scans of 20-40 sections of 
the muscle were acquired per treatment regime and analysed with ‘Image-Pro 
Plus 5.1’ software (MediaCybernetics). The automated ‘count’ function, after 
adjusting the ranges, permitted quantitation of the total endplate area, mean 
endplate area and size of the largest endplate in each section, along with the 
total muscle area. Data from more than 2000 endplates, as determined by the 
program, were quantified per treatment, normalized to the total muscle area, 
averaged over ~20 sections per treatment and compared to untreated and 
toxin-only treated muscles; t-test was used to determine statistical significance. 
Staining with anti-NF200 and fluorescently-tagged α-BuTx allowed monitoring of 
sprouting at NMJs protected by viral-mediated production of BoNT/A-resistant 
S25. 
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Fig. 17: Cleavage resistance of different SNAP-25 mutants to BoNT/A, /E and /C1: A sigmoidal 
dose response curve of SNAP-25 cleavage at different doses of BoNT/A, /E and /C1 is shown 
here. Blue lines represent cleavage of wtSNAP-25, while the black lines show cleavage of 
mutant SNAP-25. (Compared to wtSNAP-25, SNAP-25-R198T was more than 4 log orders 
resistant to BoNT/A mediated cleavage while SNAP-25-MTR was strongly resistant to all three 
serotypes – showing >5 log orders resistance to /A and /E and >2 log orders resistance to /C1). 
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Fig. 18: Quantitation of ENT in the soleus muscle of live rats gives an accurate and 
reproducible measure of the blockade of ACh release induced by different BoNTs. A: The force 
generated by the soleus muscle after single supra-maximal stimulation of the sciatic nerve (0.2 
msec, 200mV) is compared to that developed after direct stimulation of the muscle (2 msec, 5V) 
(Left).  Similarly, peak force generated after nerve and muscle stimulation at tetanic frequencies 
is represented in the right panel. The ratio of the latter, when expressed as a %, defines the 
efficiency of neuromuscular transmission (ENT) – an accurate measure of peripheral 
neuromuscular transmission. In this untreated animal, the force developed by nerve and muscle 
stimulation are virtually identical – ENT is ≈100%. B: The neuroparalytic effects of BoNT/A in 
rat peripheral neuromuscular junctions lasts for a long time and is unaffected by concurrent or 
subsequent /E administration. BoNT/A (10 pg in 10 µL  normal saline/BSA) or BoNT/E (1125 pg 
in 10 µl normal saline/BSA) was injected into the right gasto-soleus region of sedated rats on 
day 0 along with injections of the carrier into the contra-lateral region. ENT measurements were 
performed as described earlier on day 14, 26 and 60 for /A and on day 2 and 14 for /E injected 
animals. The /A then /E animals received BoNT/A as before and were injected with 1125 pg 
BoNT/E 2 days later. /A +/E animals received 10 pg BoNT/A + 112 5pg BoNT/E in 10 µL 
NS/BSA on day 0. ENT measurements on the latter two sets of animals were performed on day 
26. Each bar represents the mean +/- SD of three measurements after stimulation at tetanic 
frequencies. 
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2.3. Results 
Initial testing in HEK-293 and bovine chromaffin cells was performed to 
prove concept of botulism gene therapy. Later,  the rat soleus muscle was 
chosen as an in vivo system to study the effects of viral vector-induced 
prophylaxis for subsequent blockade of Ach release by BoNT/A. The efficiency 
of neuromuscular transmission (ENT) – the ratio between the force of 
contraction elicited by nerve stimulation alone to that by direct muscle 
stimulation – provides an accurate and sensitive means to determine the 
progress of, and recovery from, toxin-induced neuromuscular paralysis. Direct 
spinal injection, which yields the best MOI for any virus was tested first, followed 
by peripheral intra-muscular injection. The results of these experiments, and 
others, are presented below. 
2.3.1. Cleavage resistance of different SNAP-25 mutants to BoNT/A, /E 
and /C1 
The induced mutations confer substantial resistance from cleavage by 
their respective BoNT toxins. Eukaryotically produced SNAP-25, which is post-
translationally modified and membrane bound, is the natural substrate for the 
CNTs (O'Sullivan et al., 1999). While protease assays can be done with SNAP-
25 fragments produced in E.coli, the availability of the natural substrate, 
produced in HEK-293, with its inherently higher BoNT susceptibility produces 
more physiologically relevant data. In addition, the relative absence of any 
natural SNAP-25 in these cells enables a clear determination of the different 
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toxin’s enzymatic properties. While BoNTs cannot enter HEK-293 cells in 
sufficient quantity naturally, digitonin permeabalisation enables them to easily 
access their substrates.  
SNAP-25-R198T is more than 4 log orders resistant to BoNT/A cleavage 
than the wtSNAP-25. SNAP-25-MTR is strongly resistant to all three serotypes 
– showing >5 log orders resistance to /A and /E and >2 log orders resistance to 
/C1 (See fig. 17). While only the R198T mutant was used in the following 
experiments, the proven ability of the MTR mutant, and the presence of similar 
flanking restriction sites, should enable an easy transfer to the latter, if multi-
toxin-resistance becomes necessary. 
2.3.2. Longevity of neuromuscular paralysis induced by BoNT/A and 
BoNT/E in rats models of botulism 
Human cases of botulism, caused by BoNT/A, show a persistant 
neuromuscular paralysis that can last more than 6 months. While mouse 
models have been shown to suffer from exocytotic blockade for 4-6 weeks, the 
situation in rats was not yet fully clarified. There was also some controversy 
regarding the effect of BoNT/E administration with or after BoNT/A injection 
(See (Meunier et al., 2003) and (Adler et al., 2001)). For this reason a detailed 
dose-response study of the effects of BoNT/A, administered without/with/before 
BoNT/E was done. DAS provide an easy, non-invasive, repeatable, yet 
moderately inaccurate method of quantifying the function of the small muscles 
in rat hind limbs. When used in conjunction with an end-point ENT 
determination, a complete picture of the effects the different BoNTs, and the 
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utility of their treatments, can be obtained. 
In rat models of botulism, BoNT/A shows a prolonged neuromuscular 
paralysis that persists for more than 60 days (See fig. 18 and 19). While there 
was some recovery by day 60, it did not reach the pre-injection levels. On the 
other hand, injection of BoNT/E alone caused a near total blockade of 
exocytosis 2 days after injection, with a complete recovery seen by day 14. 
Simultaneous or subsequent administration of BoNT/E did not cause any effect 
on the BoNT/A-mediated neuromuscular blockade.  
Interestingly, the time-course of paralysis was strongly age-dependent 
(See fig. 19). Injection of weight-normalised doses of BoNT/A into younger 
animals resulted in a far shorter duration of exocytotic blockade at the NMJ. 
While not unexpected, this finding can still have exciting implications in the 
search for therapeutics against BoNT/A, as it is possible that a juvenile animal 
produces factors either enabling it to recuperate faster from the paralysis, by 
sprouting quicker or more profusely, or due to intra-cellular proteases or 
ubiquitinases that shorten the lifespan of the toxin’s LC in the pre-synaptic 
terminals.  
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Fig. 19: Longevity of BoNT/A-mediated neuromuscular paralysis is age-dependent in rats: A:  
DAS scores after IM injection of BoNT/A or /E. 10pg of BoNT/A (~2.5 mLD50) was injected into 
the soleus of 8-week old rats (~180-200gms, wistar female). Similarly, 5pg of BoNT/A (~1 
mLD50) was injected into 3-week old rats (~60-70gms, wistar female). The far shorter activity of 
BoNT/E (1125 pg) was also compared in this study. Younger rats show an accelerated recovery 
from BoNT/A as compared to older, adult, animals. B:  ENT measurements confirm the shorter 
duration of action of BoNT/A in juvenile rats.  
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Fig. 20. AAV-mediated expression in chromaffin cells of cleavage-resistant S25, but not wild-
type, antagonises inhibition of stimulated catecholamine release by BoNT/A. AAVs (107 GCs 
per well or multiples thereof) expressing either His6-S25WT, His6-S25R198T, His6-S25R198T+ 
hrGFP or vehicle only were added to chromaffin cells and maintained for 7 days before further 
manipulations. Fluorescence microscopy demonstrated a high level of infection by AAVs, as 
reflected by expression of  hrGFP (A); Western blotting confirmed co-expression of hrGFP and 
His6-S25R198T (B).  Infected and control cells were exposed to 10 nM BoNT/A for 24h before 
stimulating exocytosis with 2mM Ba2+ and quantifying evoked catecholamine release over 15 
mins (see Methods). BoNT/A reduced the amount of evoked catecholamine release from non-
infected cells by 70% compared to non-intoxicated controls [data not shown and (O'Sullivan et 
al., 1999)]. The average amounts of release from virus-treated cells are plotted (C) relative to 
those from cells exposed to vehicle alone (S.D.; n = 4). All the cells treated with clevage-
resistant S25 containing virus showed a statistically significant increase in catecholamine 
release (* = P<0.01, as determined by a t-test) compared to untreated controls. 
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Fig. 21. Stereotaxic intra-spinal injection of therapeutic AAVs results in strong local expression 
and subsequent delivery of cleavage-resistant S25 and hrGFP proteins to the peripheral NMJs. 
A, Spinal cord sections from rats injected with AAVs expressing hrGFP and His6-S25-R198T 
(5µL of 1011 GC/ml) were probed with an anti-His6 antibody followed by a goat anti-mouse 
Alexa-568 conjugate. The green fluorescence of hrGFP and His6-S25-R198T (red) co-localised 
in a circumscribed area in the right L1-L2 anterior horns. There is some vertical columnar 
diffusion of the injected virus, as revealed by similar fluorescence and co-localization at L3-L4. 
(scale bars = 200 µm). B, Delivery of hrGFP (green) to the presynaptic terminals is 
demonstrated by its co-localization with the post-synaptic ACh receptor, identified with a α-
BuTx-rhodamine conjugate (red), in a soleal muscle section from a rat injected with AAV-hrGFP 
(scale bars = 20 µm). C, Soleal muscle sections from animals injected with AAV-His6-S25-
R198T probed with anti-His6/goat anti-mouse-A568 antibodies to identify protected NMJs. The 
anatomical structure of the supplying nerve and its presynaptic terminal (red – binding to the 
His6 tag) and the α-BuTx-Alexa488 bound post-synaptic ACh receptors (green) are clearly seen 
in this 63x fluorescent micrograph (scale bars = 20 µm). 
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2.3.3. Expression of BoNT-resistant S25 in mammalian cell lines using 
AAVs as gene transfer vectors 
AAV helper-free vector system based on a non-pathogenic, non-
immunogenic Parvovirus was used to construct recombinant type-2 AAVs 
incorporating the different genes. Initially, control viruses expressing the hrGFP 
marker protein were produced in HEK-293 cells triply-transfected with the 
different viral components. Heparin affinity chromatography (Zolotukhin et al., 
1999) of the cell lysate yielded pure viruses with titers of 108-109 GC/µl, as seen 
on Coomassie-stained SDS-PAGE gels and corresponding Western blots; only 
bands corresponding to the viral surface protein were visualized (See fig. 13 
and 14). Their titer and infectivity were determined in HEK-293 cells (See fig. 14 
and 15). Later, wild-type or mutated S25, engineered to be non-susceptible to 
cleavage by BoNT/A due to a single residue being substituted at the scissile 
bond, were introduced into this vector, produced and purified as before; in some 
cases, the proteins were co-expressed with a hrGFP marker, using an IRES 
segment. These AAV constructs efficiently expressed His6-S25 protein in 
mammalian cells; strong membrane association was confirmed by Western 
blots of the membrane and cytosolic fractions (See fig. 16). Confocal 
microscopy with an anti-S25 antibody revealed association of a large fraction of 
the expressed His6-S25R198T protein with the plasmalemma (See fig. 16B). 
Co-expression of the hrGFP and His6-S25R198T in cells infected with the AAV-
His6-S25R198T-IRES-hrGFP virus could be demonstrated by visualizing hrGFP 
fluorescence and immuno-detecting the His6 signal, using a phycoerythrin 
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labeled secondary antibody (See fig. 16C). Success with viral-mediated 
expression of S25 in HEK-293 cells warranted functional testing in an in vitro 
chromaffin cell model.  
 
2.3.4. Demonstration of dose-dependent protection of stimulated 
exocytosis from BoNT/A-induced blockade by prior expression in 
chromaffin cells of His6-S25R198T but not wild-type S25 
The protective ability of these viruses was assessed in chromaffin 
cultures exposed for 7 days to various concentrations of the recombinant 
viruses before challenge with 10 nM BoNT/A and measurement of 
catecholamine release. Expression of the introduced genes was established by 
fluorescence microscopic detection of viruses co-expressing hrGFP, or Western 
blotting of membrane fragments from lysed cells with antibodies specific for 
His6, hrGFP or S25 (See fig. 20A and B). AAV-His6-S25R198T viruses gave 
~55% protection against BoNT/A-mediated blockade of exocytosis when 
applied at a MOI (multiplicity of infection) of 50 (highest concentration tested – 
which infected ~90% of the cells); this protective effect showed a clear dose-
dependency (See fig. 20C). The AAV-His6-S25R198T-IRES-hrGFP virus 
yielded a lower, yet significant, protection (~23%) while over-expression of wild-
type S25 alone failed to show any effect (See fig. 20C). These strong 
prophylactic outcomes obtained, despite using large numbers (>106 cells per 
well) of post-mitotic neuroendocrine cells, justified progression from in vitro to in 
vivo testing of this gene therapy paradigm for botulism. 
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Fig. 22. Prophylactic treatment with AAV-His6-S25R198T protects against neuromuscular 
paralysis induced by BoNT/A. A, The force of contraction elicited by nerve stimulation was 
compared to that by direct muscle stimulation in animals with and without protection against 
BoNT/A by prior spinal injection of AAVs expressing cleavage-resistant S25 in the right anterior 
T12, L1 and L3 spinal segments. Four groups of animals were used – (i), and (ii) & (iv) were 
injected with AAV-hrGFP and AAV-His6-S25R198T respectively, with a control group (iii) 
injected with just the vehicle. Group iii and iv were injected with BoNT/A 21 days later. After a 
further 16 days, force generated by the soleus muscle after single supra-maximal stimulation of 
the sciatic nerve (0.2 msec, 200 mV) was compared to that after direct stimulation of the muscle 
(2 msec, 5V) (left). This ratio defines the efficiency of neuromuscular transmission (ENT) – an 
accurate measure of neuromuscular transmission. Representative contraction profiles for each 
treatment group, extracted from the recording program “Chart”, are shown in A. The increased 
ratio between muscle and nerve stimulated contractions in virally pretreated (iv) compared to 
the un-protected (iii) animals demonstrates the prophylactic ability of the introduced cleavage-
resistant S25. B, Summarized data showing the protective effect of viral pre-treatment on 
neuromuscular transmission from subsequent paralysis by BoNT/A; each bar represents the 
mean +/- S.D. of values from four animals (* = p < 0.05).  
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2.3.5. Efficient expression of cleavage-resistant S25 in peripheral nerve 
terminals of rats following intra-spinal administration of AAVs 
protects against the neuroparalytic effects of BoNT/A 
Since animal models suffer from large inherent variability, an additional 
internal control was used i.e. ENT in the right muscle after BoNT treatment was 
compared to that for the vehicle-injected contra-lateral left soleus. Similarly, the 
BoNT-attenuating effect of viral pre-treatment of right soleal neurons could be 
accurately assessed by comparing ENT in this muscle with that in a similarly 
paralyzed but unprotected left muscle.  
The stereotaxic co-ordinates to identify the relevant spinal segments, 
T12-L2, were determined; their right anterior horns were injected with AAVs 
expressing marker hrGFP and/or His6-S25R198T.  Localized co-expression of 
hrGFP and His6-S25R198T in the right anterior horn, as determined by 
fluorescence/immuno- microscopy confirmed the accuracy of the micro-surgical 
procedure (See fig. 21); there was some expected vertical diffusion along the 
injected anterior motor column. After 6-7 weeks, the expressed proteins were 
also seen in the periphery at NMJs, identified by co-localization of α-Butx bound 
to ACh receptors (hrGFP & α-Butx in Figure 21B and His6-S25R198T & α-Butx 
in Figure 21). Having confirmed the presence of cleavage-resistant S25 in pre-
synaptic nerve terminals after AAV-mediated gene transfer, its functional 
effectiveness was established by a subsequent BoNT/A challenge. For such 
functional analysis, animals were injected thrice, into the right anterior T12, L1 
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and L3 spinal segments, with 5uL of various AAVs in order to maximize the 
chances of infecting a large portion of neurons supplying the right soleus. A 
precise bilateral injection of ~1 mouse LD50 of BoNT/A in NS/BSA was made 21 
days later into the soleus using a small skin incision; after a further 16 days, 
ENT values were determined. Control animals injected with AAV-hrGFP or 
AAV-His6-S25R198T alone displayed no significant variation in ENT between 
the left and right soleus [See fig. 22A (i) and (ii)]. The expected paralysis of 
nerve conduction in animals injected with BoNT/A alone was confirmed by the 
decreased signals compared with that for direct muscle stimulation. The 
maintenance of near-normal neurotransmission in unchallenged synaptic 
junctions over-expressing hrGFP or S25R198T demonstrates the non-
deleterious nature of these introduced genes, purity of the preparations and the 
minimal trauma caused by the careful stereotaxic technique. Animals pre-
injected with AAV-His6 S25R198T showed a significantly greater retention of 
neuromuscular transmission [See fig. 22A (iv)] compared to the unprotected 
(contralateral) side after a BoNT/A challenge [See fig. 22A (iii)] (p < 0.05); 
summarized data from 4 animals for each group is depicted in Figure 22B. This 
attenuation of BoNT/A-induced neuroparalysis is the first ever demonstration of 
a non-immunological protective therapy in whole animals and establishes the 
functional effectiveness of the virally-delivered cleavage-resistant S25.  
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Fig. 23. Synaptic remodeling in adult soleus muscles exposed to BoNT/A. Confocal immuno-
fluorescence pictures from control (A) and BoNT/A-treated muscles (B-F) show, respectively, 
NMJ (A), axonal sprouting (B and magnified in C), terminal sprouting (D and magnified in E) 
and mixed sprouting [F, axonal sprouting-arrow and terminal sprouting-arrowhead) (scale bars 
= 20 µm); α-NF200, in red with α-Butx-A488 in green]. An automated system was developed for 
the quantification of mean and maximum endplate (EP) sizes and total muscle area in randomly 
chosen 25 µm sections from control and BoNT/A-injected soleus muscles (see Methods).  The 
fraction of the muscle area occupied by the EPs (EP area per unit area), the average EP area 
(the EP area) and the area of the largest EP (Max EP area) in each section of BoNT/A-treated 
muscles were expressed relative to the untreated muscles - average and S.E.M data from 
BoNTA-treated EPs (in grey) and control EP data (in white) are plotted (G). The results shows 
clear and significant (* = p ≤ 0.005 by unpaired t-test) differences in EP area per unit area, the 
EP area and max EP area per section.  
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Fig. 24. Virally-expressed His6-S25R198T attenuates BoNT/A-induced motor endplate 
remodeling in vivo. AAV-His6-S25R198T was injected into the right anterior horn of rats and four 
weeks later ~2 x LD50 BoNT/A was injected bilaterally into both soleus muscles (see Methods). 
After a further 25 days, both soleus muscles were removed, fixed and sectioned (25 µm thick) 
for immuno-histochemical staining. Representative confocal micrographs (detailed in Methods) 
show the pre-synaptic immunofluoresence signals observed with antibodies to NF-200 (red) and 
the distribution of post-synaptic nicotinic ACh receptors revealed with A488-conjugated α-Butx 
(green), in muscles from control (A) and virus-injected sides (B). Additionally, randomly chosen 
sections were stained with Alexa-488-conjugated α-Butx and subjected to automated endplate 
quantification (as described previously) (C). The average and SEM of EP area per unit area, the 
EP area and max EP area per section for virus pretreated muscles (hatched bars) are 
expressed as a % of those for muscles exposed to toxin alone (grey bars). The results shows a 
significant (* = p ≤ 0.005 by unpaired t-test) difference in the EP area in protected muscles. 
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2.3.6. BoNT/A-induced synapse remodelling is reduced by protection 
of neuromuscular transmission with a spinal injection of AAV-His6-
S25-R198T 
Muscle paralysis induced by BoNT/A is known to cause motor axons to 
sprout and form new, functional synapses around the blocked parent terminals; 
in mice, the sprouts start to retract after 7 weeks, around the time when activity 
returns to the synapse (de Paiva et al., 1999). While it has been hypothesized 
that this sprouting is essential for the recovery of the intoxicated muscle (Juzans 
et al., 1996; de Paiva et al., 1999), its absolute contribution is unclear.  For 
these reasons, it was decided to examine the amount of sprouting in ‘protected 
(by AAV-His6-S25-R198T) and challenged (by BoNT/A)’ muscles compared to 
the situation in ‘unprotected and challenged’ or ‘unprotected and unchallenged’ 
muscles. The postsynaptic part of the NMJ was chosen for this quantification as 
it is known that any change there is tightly linked to alterations in presynaptic 
morphology and, as has been noted in published papers, changes in ACh 
receptor density and distribution are more sensitive to perturbations of synaptic 
transmission than modifications in the pre-synaptic compartment (Pestronk and 
Drachman, 1978b). The exquisitely specific binding and the strong fluorescence 
of bound α-Butx-A488 conjugate lends itself to automation (Powell et al., 1984; 
Askmark et al., 1991; Wang et al., 2005), whereas the heterogeneous 
presynaptic changes necessitate a more labour-intensive and subjective 
method of quantification. Using low magnification (to avoid artefacts from 
unfocused planes) and a software-controlled motorized stage, the amount of 
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sprouting evoked by BoNT/A and the effect of viral protection on this process 
could be determined.  
The soleal muscles from BoNT/A-treated and control rats were dissected 
at various times after injection, sectioned and stained using α-Butx-A488 and an 
antibody against neurofilament 200 k isoform (α-NF) to visualize the post-
synaptic and pre-synaptic parts of the NMJ, respectively.  Comparison of 
muscle sections from control and these treated 16 or 25 days earlier with 
BoNT/A revealed a much greater number of sprouts in the latter (See fig. 23 A 
vs B-F).  Additionally, in agreement with published results (Brown et al., 1980), 
it was observed that axonal and endplate sprouting frequently co-existed in the 
same muscle and, sometimes, in the same endplate (See fig. 23F). 
Exceptionally, some minimal endplate sprouting was also visualised in control 
muscles.  When compared to untreated muscles, significant increases were 
found after BoNT/A treatment in the mean endplate area, the area of the largest 
endplates and, probably due to the muscle wasting that accompanies paralysis, 
an enlargement in the endplate space occupied per muscle section (See fig. 
23G). After characterizing BoNTA-induced sprouting in the soleus muscle, the 
effect of protection on this process was determined. Immuno-staining of 16-day 
toxin-treated soleal sections with α-Butx-A488 and anti-αNF, to label endplates 
and axons respectively, showed less extensive sprouting at NMJs of rats that 
received BoNT/A-resistant S25 than those given toxin alone (See fig. 24A and 
B). Furthermore, examination of more than 30 random sections per treatment 
revealed that the average endplate area was significantly reduced in those 
endplates expressing S25 R198T compared to controls (treated with the toxin 
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alone). Lesser, but non-significant, reduction was seen in the maximum 
endplate and in the ratio of endplate to muscle areas (See fig. 24C).  
 
2.3.7. Partial protection against BoNT/A-induced neuroparalysis in 
rats by neuronal expression of His6-S25R198T after peripheral 
injection of its AAV construct 
While intra-spinal AAV injection achieved efficient transduction and 
protection of motor neurons against BoNT/A with minimal effect on normal 
synaptic transmission, a peripherally-deliverable therapy is preferable as it can 
be injected into the affected muscles, thereby, decreasing the dose needed and 
reducing any potential risks. The control AAV-hrGFP virus, which was first 
tested due to the ease of identification of the expressed product, underwent 
retrograde transport to the spinal cord, as confirmed by expression of the 
marker protein in motor neurons of the anterior horn supplying the soleus 
muscle (See fig. 25A). Having confirmed the utility of such an approach, the 
ability of AAV-His6-S25R198T to protect the motor neurons from BoNT/A-
mediated paralysis was next evaluated. Injection of this therapeutic into the 
area encompassing the soleus muscle was followed a week later by toxin 
administration into the same muscle; the contra-lateral muscle was injected with 
the toxin alone. When tested 3 weeks after the viral injection, the protected 
NMJs in the best responding animals showed a 4-6 fold higher retention of 
synaptic transmission [18.5% v 3.2% for single stimulation [See fig. 25C (i)] and 
62.5% v 15.3% for tetanic stimulation [See fig. 25C (ii)]. The combined results, 
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from 6 animals for each treatment, showed that the side injected with the virus 
gave a >2.5-fold increased retention of muscle strength in response to tetanic 
stimulation (27.5% vs 10.5%) (See fig. 25B). These initial investigations provide 
an encouraging demonstration of the potential of minimally-invasive paths to a 
gene therapy for botulism.  
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Fig. 25. Peripheral administration of therapeutic AAVs results in their retrograde transport and 
partial protection against subsequently administered BoNT/A. A, Florescence microscopic 
detection of hrGFP in large spinal motor neurons in the right lumbar spinal cord after peripheral 
administration of AAV-hrGFP. B, Rats were injected with 3x50µl of 1011 GCs/ml of AAV-His6-
S25R198T in PBS into the right soleus muscle; after 7 days, ~2 x LD50 of BoNT/A was injected 
bilaterally. Summarized data from ENT measurements 15 days later shows partial, albeit non-
significant, protection induced by peripheral AAV pre-administration (B). Each bar = mean +/- 
SEM of the ENTs gathered from 6 rats. C, Single stimulus in (i) and tetanic stimulation in (ii) 
from best responding rats show the improvement due to viral pre-injection. 
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2.4. Discussion 
To overcome the prolonged convalescence associated with human 
botulism caused by BoNT/A, a clinically-effective therapy needs to act at 
multiple stages by preventing the toxin’s binding or uptake, inhibiting its 
breakdown of S25 and/or hastening recovery by replenishing truncated S25 
with a functional, BoNT-resistant form (O'Sullivan et al., 1999). While progress 
towards the first two goals can, and is, being achieved by pharmacological 
means using antibodies and peptide or chemical inhibitors of the toxin’s 
protease, a novel gene therapy approach is necessary to attain the final stages, 
especially in light of the extraordinary persistence of /A protease at nerve 
terminals (Adler et al., 1998; Keller et al., 1999; Foran et al., 2003; Meunier et 
al., 2003). The applicability of gene therapy was initially revealed by 
experiments demonstrating the attenuation of this toxin’s inhibition of secretion 
from chromaffin cells following over-expression of a cleavage-resistant form of 
S25, which has a point mutation at the scissile bond (arginine at 198 position to 
threonine) that does not affect its participation in exocytosis (O'Sullivan et al., 
1999). As the classical gene transfection used in that earlier study gave very 
low efficiency (<0.25%), much more effective gene delivery is a prerequisite for 
in vivo therapeutic purposes. To this end, the gene for S25-R198T was 
transferred into an AAV vector yielding a highly efficient, non-pathogenic means 
for transferring genes into non-dividing neurons.  
2.4.1. AAV vectors are highly efficient neuronal gene delivery vehicles 
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when directly injected into spinal cord 
Initial experiments confirmed that over-expression of a poly-His tagged 
version of cleavage-resistant S25 in eukaryotic cells does not overwhelm the 
intrinsic post-translation modification processes, especially palmitoylation, as 
revealed by the membrane association observed for this protein. This is 
important in light of evidence for the failure of free cytoplasmic S25 to take part 
in productive exocytosis (Washbourne et al., 2001) and due to the necessity for 
toxin-resistant S25 to antagonize disabled S25 at the membrane (O'Sullivan et 
al., 1999). The administered viruses infected 90% of ~106 cells and produced 
enough BoNT/A-resistant S25 to overcome the inhibitory effects of the toxin. 
Another outcome is the discovery that AAV-2 vectors can efficiently infect 
adrenal tissue, adding to the list of neuronal and neuro-endocrine types that can 
be targeted by this versatile virus (Burger et al., 2005). 
While the results obtained in vitro validated the rationale behind the 
strategy, it was necessary to establish its applicability to the much more 
complex in vivo system. Paralysis and recovery from BoNT/A treatment can be 
accurately followed by measuring the force of contraction evoked by stimulation 
of the sciatic nerve in the lower limb muscles of rat (Adler et al., 2001); 
expressing this as a ratio to the force elicited by direct muscle stimulation 
reduces variations between animals. The well documented synaptic remodeling 
of rat soleal NMJs following neuroparalysis by BoNT/A (Pestronk and 
Drachman, 1978a; Brown et al., 1980; Son and Thompson, 1995) was another 
reason for choosing this muscle. Direct injection into the spinal anterior horn 
was prioritized for the initial mode of delivery as it results in a more intense 
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infection of motor neurons and, consequently, recombinant protein production 
than intra-thecal administration (Mannes et al., 1998). The controversy in the 
literature about the exact coordinates of the lumbar spinal levels supplying the 
lower limb between (Greene, 1968) and (Nicolopoulos-Stournaras and Iles, 
1983) necessitated retrograde tracing using fluorogold injected into the soleus; 
the results obtained, T13-L2, agree with the latter. Stereotaxic intra-spinal 
injection of cleavage-resistant S25-expressing AAVs resulted in the localized 
expression of this protein in the lumbar anterior horns and, subsequently, their 
peripheral transport to the NMJs supplied by these motor neurons (Fig. 21). 
There was no evidence of any adverse effect on the synapse at the microscopic 
or functional levels; binding of fluorescently-labeled α-Butx showed normal 
distribution of post-synaptic ACh receptors; accordingly, only a small, non-
significant, difference could be detected in ENT values between muscles 
innervated by virally-infected lumbar motor neurons and vehicle-injected control 
neurons. While spinal motor neurons were found to be relatively refractory to 
uptake of this capsid type-2 pseudotyped AAVs compared to other central 
neurons [agreeing with previous reports (Burger et al., 2004)], this was 
overcome by using larger volumes and multiple injections of high titers. 
2.4.2. Delivery of cleavage resistant S25 to the exocytotic terminals 
ameliorates the transmission blockade induced by a later toxin 
challenge 
Significantly, the expressed and peripherally-localized transgenic protein 
successfully substituted for native cleavage-susceptible S25, as clearly 
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demonstrated by enhanced retention of nerve-stimulated muscle contractility in 
pre-protected animals challenged with BoNT/A 16 days later (Fig. 22). This was 
detected using two different modes of stimulation – discrete single supra-
maximal stimuli or trains of tetanic pulses – with the recorded protection being 
more marked when measured using the latter protocol. Such protection against 
a later BoNT/A injection was only observed after pre-injecting AAVs expressing 
His6-S25R198T whereas administering AAVs that produce hrGFP or wild-type 
His6-S25 failed to show any significant difference from vehicle-only controls. 
This is the first report on successful antagonism of BoNT/A action in live 
animals using viral vector-mediated gene delivery. The protection seen 
demonstrates that the produced protein can not only overcome the persistent 
protease activity of the toxin at motor neuron terminals (Adler et al., 1998; Keller 
et al., 1999; Foran et al., 2003; Meunier et al., 2003) but, also, any probable 
inhibition from the truncated native S25 (Dolly and Aoki, 2006). A combination 
of such gene delivery with the recently-described inhibitors (Schmidt et al., 
1998; Schmidt and Stafford, 2005; Park et al., 2006), should yield 
supplementary benefits in providing immediate and prolonged therapy.  
 
2.4.3. The retrograde trafficking ability of AAVs in rats – necessity to 
develop efficient targeting agents 
Published data suggested that AAVs undergo successful retrograde 
transport from mouse NMJs and can efficiently infect anterior horn motor 
neurons supplying the targeted muscles, with efficiencies ~1 in 1000 virions 
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reaching the spinal cell body (Kaspar et al., 2003). While injection of >5x1011 
AAVs into soleal muscle proved necessary to successfully detect infected motor 
neurons, this mode of administration offers advantages of minimal trauma and 
faster recovery from the operating procedure; most notably, in terms of possible 
clinical application, it allows easier access to important respiratory muscles 
(intercostal and diaphragmatic muscle). The functional value of this peripheral 
mode of application is reflected by the promising protection obtained, though 
the intrinsic variability in the responses of whole animals prevented a more 
convincing outcome.  
The large difference in efficacy between published studies in mice and 
this study in adult rats poses fundamental questions about the potential of 
peripheral delivery for motor neuron gene therapy. An average mouse weighs 
20g, compared to 200-400g  for an average rat, and has a sciatic nerve that is 
less than 2cms in length, compared to more than 8 cms for an average rat 
(>100cms in an average human). Any delivered AAV has to negotiate the whole 
length of this nerve in order to reach the spinal motor neuron supplying the 
injected muscle. If an increase of 6cms strongly reduces the retrograde 
transport of AAVs in rats, the possibility of any virus reaching the MN in humans 
seems increasingly miniscule. Also, the greater muscle mass in larger animals 
will probably reduce the amount of virus reaching the NMJ, further complicating 
matters. One way of increasing retrograde transport would be to increase the 
number of AAVs delivered to every NMJ, thus increasing chances that a few will 
successfully navigate up the length of the sciatic nerve (or phrenic nerve and 
intercostals nerves, if the respiratory muscles are to be targeted). Thus 
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targeting with a NMJ specific molecule will be an essential step in graduating 
gene therapy from the laboratory to the clinic. Initial attempts at exploiting the 
known cholinergic specificity of CNTs to target viral vectors are described in 
Section 3. 
2.4.4. Sprouting induced by BoNT/A is a result of exocytotic blockade 
and is reduced by the alleviation of such paralysis 
It is believed that synaptic remodeling after BoNT/A-induced paralysis 
plays an important role in the early phases of recovery (Juzans et al., 1996; de 
Paiva et al., 1999; Meunier et al., 2003). The quantity of sprouts is thought to 
depend strongly on the amount of toxin introduced [for a more detailed 
discussion see (Connold and Vrbova, 1991; Tam and Gordon, 2003)], the kind 
of muscle [fast muscles have lower amounts of mostly axonal sprouting, 
compared to slow muscles which show a higher percentage of terminal sprouts 
(Pestronk and Drachman, 1978b; Brown et al., 1980) and the duration of 
paralysis (long-acting serotypes like /A induce a more extensive pattern of 
sprouting than short-acting /F; the extremely short duration of paralysis induced 
by /E results in no observable sprouts (Meunier et al., 2003)). Further 
complicating this picture is the effect of factors released from perisynaptic 
Schwann cells and muscle (Gomez et al., 1982; Son and Thompson, 1995; De 
Winter et al., 2006; Wright and Son, 2007). The data obtained from the present 
study points to a reduction in synaptic remodeling when the extent of paralysis 
is limited by over-expression of cleavage-resistant S25 in presynaptic nerve 
endings, substantiating the hypothesis that the extent of neurotransmission 
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blockade, along with the duration, are strong determinants of the amount of 
remodeling. The changes in sprouting seen upon treatment with the same dose 
of /A toxin in the presence or absence of viral protection seems to confirm that 
the differential effects on sprouting seen previously with the different toxin 
serotypes are a property of the duration of paralysis and not of the substrate 
cleaved or properties of their proteases. While these results do not reduce the 
importance of the contributions made by other factors towards initiating 
sprouting at a NMJ, it does hint that these are ultimately dependent on, and 
controlled by, the evoked exocytosis from the motor nerve terminals. 
This study reports the attainment of an important milestone in the goal of 
a peripherally-deliverable gene therapy that can be administered after exposure 
to long-acting BoNT serotypes, raising the exciting prospect of a powerful 
means of successfully managing the late stages of botulism which presently 
involve a prolonged, resource-intensive recovery phase. The proof of principle 
obtained provided an encouraging foundation upon which to build more 
versatile vectors based on LVs that could allow the simultaneous transfection of 
neurons with multiple-toxin resistant S25, VAMP-2 and syntaxin for combating 
several toxin serotypes and even novel chimera. Furthermore, this model 
circumvents problems associated with using conventional murine models of 
human motor neuron diseases. The ability to control the extent/severity of 
‘disease’ (i.e. neuroparalysis) when combined with the availability of a sensitive 
assay for measuring peripheral neurotransmission and the knowledge of the 
gene required to protect against the toxin’s effects, allows prediction of the 
response to successful delivery. The elimination of these multiple variables 
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should enable a more focused investigation of the different changes needed to 
obtain a peripherally-deliverable viral vector targeted to motor neurons. 
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3. Targeting viral vectors to cholinergic nerve 
terminals 
3.1.1. Introduction – rationale behind the utilisation of the cholinergic 
targeting property of Clostridial neurotoxins to target therapeutic 
viral vectors to NMJs 
There are two major aspects to peripherally delivered gene therapy for 
motor neurons – the first is to get the virus into the pre-synaptic terminal and 
second is getting internalised virus retrogradely back up the axon to the motor 
neuron nucleus. Indeed, every virus that’s used for gene therapy can, and does 
both, of these things to some extent. But the specialised anatomical aspect of 
the NMJ-axon-spinal motor neuron complicates matters considerably. 
Therefore, peripherally delivered gene therapy for spinal motor neurons is 
relatively inefficient – the best case scenario in mice needs a >1000 fold excess 
of viruses for efficient transduction compared to direct delivery (Kaspar et al., 
2003). Indeed, the present study in rats showed it is more than three log orders 
less efficient than in mice. Therefore there is an urgent need to funnel the 
delivered viruses towards NMJs thereby, increasing the delivery of viruses that 
can undergo retrograde transport and thus successfully infect the supplying 
motor neurons. This also decreases the number of viruses infecting muscle and 
connective tissue, reducing substantially the hazard of insertional mutagenesis 
and oncogenesis and also any transgene induced toxic effects. Another 
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advantage is the reduced proliferation of the introduced viruses into the blood 
and lymphatic systems, thereby avoiding sensitizing the immune system for 
viral components.  
There are many potential ways of achieving these goals. The easiest is 
to use viruses that are naturally motor neuron specific and modify them to 
eliminate their pathogenicity (Keir et al., 1995). But such a procedure is 
laborious and discards the huge amount of work that has already gone into 
making safe and efficient general viral vectors. Another potential method is 
pseudo-typing an existing virus with the components of a motor neuron specific 
virus – e.g. lentivirus with a rabies virus glycoprotein (Mazarakis et al., 2001). 
Pseudo-typing is a well-established strategy to modfy viral, expecially lentiviral, 
specificity (Cronin et al., 2005). Indeed the current generation of lentiviruses use 
the envelope protein from the Vesicular stomatitis virus (VSV-G) (Zufferey et al., 
1998). But, rabies virus glycoprotein pseudo-typing for NMJ targeting suffers 
from some disadvantages – this can only be used in lipid-enveloped viruses, 
like retrovirally-derived vectors, and while it does induce retrograde transport 
once inside the nerve terminal, it does not seem to substantially increase the 
chances of the virus entering such a terminal. This method of targeting also 
complicates assignment of a valid bio-safety profile to these viruses, containing 
as they do components of two different, and potentially dangerous, viruses. 
Another alternative is attaching immune, or immune-derived, molecules specific 
for NMJ surface constituents to the therapeutic viruses (Hedley et al., 2006). 
The advantage with this method is that it can be modified relatively easily, with 
suitable adapters, for use with enveloped or non-enveloped viruses. While this 
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method does increase the chances of the virus encountering and sticking to a 
cholinergic terminal, it does not increase the probability of viral endocytosis or of 
retrograde transport.   
The natural cholinergic specificity of CNTs is an attractive option to 
achieve vector concentration on nerve-terminals. The bi-partite mechanism for 
cholinergic binding and internalisation inherent in all CNTs results in their 
exquisite specificity (See section 2.1). Exploitation of this specificity to deliver 
cargo is an attractive means of achieving motor nerve targeting. The ready 
availability of protease-inactive BoNT/E (BoTIM) led to its choice as the first 
candidate NMJ targeting molecule. An early decision was made to construct 
flexible NMJ-targeting molecules that can, with very little effort, be used to 
target various cargo, small molecules, liposomes or viral vectors, to NMJs. For 
this reason, BoTIM was conjugated at the genetic level to core-streptavidin 
(CS). This hybrid molecule should bind any biotinylated cargo while retaining 
the cholinergic specificity of BoTIM, thereby successfully delivering the bound 
cargo to NMJs. Some of the preliminary proof of principle studies in this regard 
are present in the following sections. 
3.1.2. Core-Streptavidin 
The high affinity of avidin, derived from egg-white, and streptavidin, 
produced by Streptomyces avidinii, for biotin has long been exploited in 
histological and biochemical applications (Bayer and Wilchek, 1990). Native 
streptavidin is a nonglycosylated, 52Kda tetramer with a near-neutral isoelectric 
point, that binds 4 moles of biotin per mole of protein with high selectivity and 
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affinity (Kd~10-15M) (Bayer and Wilchek, 1980). The minimal, biotin binding part 
of a streptavidin molecule is called the core-streptavidin. The latter was chosen 
over the former, as it is far smaller, ~13Kda, and therefore easier to clone into 
the BoTIM gene without greatly perturbing its cholinergic binding abilities.  
There are some potential problems with the use of CS. These molecules 
retain a strong tendency to tetramerize, and reconstitute the parent streptavidin, 
which could cause problems later with, potentially insoluble, aggregates of CS-
BoTIM. In addition, the position of the CS in BoTIM, N- or C-terminal, could 
destabilise either the CS or the BoTIM leading on to a loss of biotin-binding or 
cholinergic-binding abilities. Also, because a complete biotin binding site in each 
CS subunit requires the contribution of tryptophan 120 from a neighboring 
subunit, a forcible monomerization, due to the attachment of a large BoTIM 
molecule, can reduce affinity towards biotin (Qureshi et al., 2001; Wu and 
Wong, 2005). But the high starting affinity results in a lot of leeway in biotin-
binding affinity and indeed, a reduced affinity might be useful in allowing a 
targeted cargo to escape from the targeting molecule. While some monomeric, 
minimal streptavidins are now available (Qureshi and Wong, 2002), their 
performance in large chimeric hybrids are, as yet, unknown. 
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9495bppMD-2G
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pWPT-GFP
pCMV-d-8.74
11921bp
 
Fig. 26: Constituents of the LV production system: A: The VSV-G containing plasmid – pMD-
2G: An annotated plasmid map, generated using Gene Construction Kit (GCK 2.5) showing the 
important constituents and unique restriction site. AMP – beta-lactamase gene; CMV – 
cytomegalovirus promoter; hu-globin pA – human globin poly-adenylation site. B: The transfer 
construct, pWPT-GFP, containing the essential cis-acting sequences. LTR – Long terminal 
repeats; SA/SD – splice acceptor and splice donor; RRE – reve responsive element; cPPT – 
central poly-purine tract; EF1 – elongation factor 1 promoter; SIN – self-inactivating. C: The 
trans-acting construct, pCMV-d-8.74. GAG – group specific antigen; Pro – protease; POL – 
polymerase; dVpu. dVpr and dENV – deleted viral protein U, viral protein R and envelope 
proteins; hInsulin pA – human insulin polyadenylation sequence. For more details about all 
these different proteins and sequences, please see section 3.1.3. 
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Fig. 27: Creating LVs expressing wt and mutant SNAP-25: A: A pictorial representation of 
different plasmids, showing the relative positions of the important constituents and the cloning 
site for any introduced transgene (See Fig. 26 and section 3.1.3 for more details). B: Cloning 
His6-tagged multi-toxin resistant SNAP-25 into the cis-transfer construct, pWPT-GFP, by 
replacing the original GFP gene. PCR, with BamHI and XhoI containing primers, followed by 
restriction digestion with the relevant enzymes yielded His6-SNAP-25-MTR [(i) and (iii)]. This 
was then cloned into a pWPT plasmid [(ii) and (iii)], digested with BamHI and SalI, and 
transformed into Dh5α chemically competent E.coli. Colony PCR with bglob-For and WPRE-
Rev primers enabled the selection of only those clones containing the right insert (iv). These 
were then expanded into giga-preps and purified to yield highly pure plasmids, suitable for 
transfection of HEK-293 cells in culture (v). 
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3.1.3. Lentiviral vectors (LV) 
The LV system is a replication-deficient, hybrid viral vector system made 
from the core proteins and enzymes of human immunodeficiency virus type I 
(HIV-1) and the envelope of a vesicular stomatitis virus glycoprotein (VSV-G) 
(reviewed in (Zufferey et al., 1998; Rohll et al., 2002)). These gene transfer 
vectors can mediate efficient integration of the transgene into the host genome, 
do not express any viral genes, are not affected by pre-existing immunity in the 
recipient and demonstrate the ability to infect non-dividing cells. Their biosafety 
profile has been improved by the separation of cis-acting sequences required 
for the transfer of the transgene to target cells, from the trans-acting sequences 
encoding the essential viral proteins, thus rendering them replication-deficient. 
Furthermore, the complete deletion of the native lentiviral envelope proteins and 
their replacement by a heterologous, VSV-G, envelope protein (pseudotyping), 
increases their infectivity towards a wide spectrum non-immune target cells and 
increases their safety, by reducing the chances of recombination with any native 
HIV viruses. While other retroviruses, like the feline, simian, bovine or equine 
immunodeficiency viruses, have been modified to suit gene delivery, the HIV 
based one is the most widely used and studied (reviewed by (Delenda, 2004)). 
The most widely used Lentiviral system utilises the simultaneous transfection of 
HEK-293 cells by three different plasmids to produce lentiviral particles (See 
Fig. 26). The essential cis-acting elements are found in the pWPT or pWPI 
plasmids, with the latter containing an IRES sequence for the co-expression of 
GFP with the gene of interest. It contains the two long terminal repeats (LTR), 
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encapsidation signal (psi), major splice donor (SD), rev responsive element 
(RRE), major splice acceptor (SA) and a central polypurine tract (cPPT). LVs 
have a large packaging capacity of approximately 8kb (see Fig. 26-27). The 
gene of interest in this plasmid is driven by a very efficient eukayotic promoter 
(elongation factor 1a or its minimal domain - EF-1a or short EF-1) and is flanked 
at its C-terminal by a woodchuck post-translational regulatory element (WPRE), 
which promotes the efficiency of polyadenylation of the nascent transcript and 
increases its total amount in the cells. These constructs are self-inactivating, 
with a major deletion in the U3 region of the LTR, containing the viral enhancer 
and promoter sequences. When infected into target cells, they duplicate this 
deletion, resulting in the transcriptional inactivation of the LTR. Such a self-
inactivating vector diminishes the risk of oncogene activation, by promoter 
insertion and further reduces the chances of vector mobilization and 
recombination with wild-type virus. Also, self-inactivation of the LTRs eliminates 
the possibility of their interference in transgene expression, enabling the 
insertion of desirable promoters for tissue specific or regulatable activity. 
The second plasmid is pCMV-d8.74 containing the GAG, pro, POL and 
Tat/Rev coding sequences. The complete deletion of the ENV sequence, 
coding for the surface glycoprotein, and Vif/Vpu/Nef/Vpr sequences, coding for 
additional non-essential deleterious proteins, further reduces the viral 
pathogenicity. The Tat protein acts as a transcriptional activator and Rev is 
required for expression of unspliced, packageable transcripts from the transfer 
vector construct. The GAG gene, which is codon optimized for optimum 
efficiency, provides the viral matrix proteins, RNA genome binding proteins and 
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the major proteins comprising the nucleoprotein core particle. The codon 
optimised POL gene encodes the reverse transcriptase, integrase and RNase H 
activity. Addition of the third plasmid, pMD2G, coding for an envelope G-
glycoprotein from vesicular stomatitis virus increases the vectors’ tropism (but 
could be limiting intracellular transport to relatively short distances). The use of 
this heterologous envelope protein strongly limits the theoretical possiblilty that 
multiple recombination events can join the viral cis-acting sequences in the 
transfer vector to trans-acting viral genes in packaging constructs to generate 
replication competent recombinants (RCR). While further gains in biosafety can 
be achieved by removing the Tat gene and separating the Rev gene into a 
separate plasmid, the compromised expression resulting from this is not 
considered a viable payoff for the concomitant increase in safety.  
The LV system has a higher gene delivery capacity than AAV; with a 
capacity of ~8kb, it can accommodate most genes and tissue specific 
promoters. An additional advantage is the relative ease of swapping out the 
VSV-G surface glycoprotein for another - e.g., rabies virus (for retrograde 
transport (Mazarakis et al., 2001; Wong et al., 2004)), Ross River (more 
efficient on glial cells than neurons (Kang et al., 2002)), lymphocytic 
choriomeningitis virus (preferentially transduce murine neural stem cells and 
human glioma cell lines (Steffens et al., 2004; Stein et al., 2005)). One can also 
modulate its activity by attachment of molecules providing specificity for certain 
cell types, e.g., by IgG fragments or by clostridial toxins.  However, since LVs 
are derived from pathogenic viruses, i.e, HIV-1, it is crucial that sufficient 
precautions be maintained to ensure adequate biosafety both during production 
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and administration; the AAV virus, a naturally non-pathogenic strain does not 
suffer from this drawback. The un-modified viruses also differ in their propensity 
to infect neurons over glia, with the ratio changing depending on the site of 
administration. But in general, transduction of most neurons has been 
demonstrated in vivo in rodent and primate models, using both the systems 
(Galimi and Verma, 2002; Azzouz et al., 2004). Neuronal gene transfer could be 
compromised by innate or induced immunity against viral proteins or the 
transgene products. This is more problematic for the AAV system, as AAVs can 
exist as a widespread and quiescent infection in certain populations (Peden et 
al., 2004). Innate immune responses are not problematic for LVs as only 
minimal and asymptomatic inflammation has been observed in animal models 
after their administration (Kordower et al., 2000). The problem of transgene 
induced immunity, while theoretically present, can be resolved by the judicious 
choice of proper proteins from the same, or highly homologous, species. A 
greater problem is that of transgene induced toxicity – the large gene capacity 
of the LV system, with their predictable copy numbers and low silencing effects, 
allows the introduction of regulated gene expression derived from bacterial 
operons such as the Tet repressor or engineered eukaryotic transcription 
factors (Vigna and Naldini, 2000; Pluta et al., 2005).  
Gene delivery for neurological disorders often requires intricate and 
highly invasive surgery; therefore, long-term, stable expression at therapeutic 
levels is essential. Expression of transgenes after in vivo LV administration lasts 
for up to 16 months and these animals usually maintain expression without 
silencing after the first month (Kordower et al., 2000; Bienemann et al., 2003). 
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The biology of LV infection strongly indicates that there would be a reduction in 
transgene expression over time – initially there is a high level of mRNA 
production from all the LVs that manage to enter the nucleus, but later, only the 
integrated forms (in permissive environments) are capable of producing 
transgene mRNA while the untegrated ones are culled through natural cellular 
processes. The level, timescale and duration of this slump are not fully studied. 
3.2. Experimental strategies employed 
Many of the tools and techniques below are described in greater detail in 
section 2.2. The constituents of all the buffers and solutions can be found in 
Appendix 1. Animal surgery protocols are described in sections 2.2.1 and 2.2.5. 
3.2.1. Development of LVs carrying marker EGFP and/or S25 mutants 
resistant to /A or /A, /E and /C1 
SNAP-25 mutants described in section 2.2 were cloned into the pWPT-
GFP plasmid, after the excision of GFP (See Fig. 27). In addition, SNAP-25-197 
and SNAP-25-180, mimicing the residual cleavage products after BoNT/A and 
/E proteolysis) were cloned into pWPT-GFP. These purified plasmids, in 
addition to control plasmid pWPT-GFP and pWPT-SNAP-25 wt, were triple 
transfected into HEK-293 cells (20µg per 10cm plate) along with pMD2G (5µg 
per 10cm plate)  and pCMV-d-8.74 (10µg per 10cm plate). After 12-24 h, the 
cells were washed 2-3 times and the media replaced. The LVs, secreted into 
the cellular supernatant, were concentrated using protocols modified from 
(Zufferey et al., 1998). The supernatant was harvested 24 h after media 
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change, spun down at ~500-1000G and filtered through a 45µm filter, before 
storage at 4ºC. Another batch of the supernatant was harvested after a further 
24 h and treated as before. The two supernatant were mixed together, layered 
on 20% sucrose in PBS solution and centrifuged at 45,000 G for 2 h. The visible 
pellet was resupended in more PBS, pooled and centrifuged once again at 
45,000G. The final pellet was resuspended in either PBS/5% BSA or DMEM 
medium, aliquoted and frozen at -80ºC. 
3.2.1.1. Titration of produced LVs by p24 ELISA 
LVs were titered using a modified HIV-1-p24 ELISA kit obtained from 
Aalto Bio-reagents Ltd. This is a twin-site sandwich ELISA based on the capture 
of p24 antigen, from a detergent lysate of virions, onto a polyclonal antibody 
adsorbed onto a solid phase. The bound p24 is then detected with an alkaline 
phosphatase-conjugated anti-p24 monoclonal antibody and read using the 
luminescent detection system (Moore et al., 1990). Briefly, a sheep polyclonal 
anti-HIV-1-p24-gag antibody, diluted 1:400 into 100mM NaHCO3 pH 8.5 buffer, 
is coated onto ELISA plates. After an overnight incubation, the plates are 
washed and blocked with 2% milk in TBS and stored at -20ºC till use. In the 
mean time, viral samples are inactivated by adding Empigen zwitterionic 
detergent to a final concentration of 1%. These inactivated viruses were then 
added to washed plates prepared as described previously and incubated for 3 h 
at room temperature. A standard curve, prepared from dilutions of HIV-1-p24 
protein obtained from Aalto, is run in parallel with every ELISA reaction. After 
washing the plates, a 1:7500 dilution of the secondary antibody, anti-HIV-1-p24 
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mouse monoclonal alkaline phophatase conjugate, is added for a futher 1hr. 
The plates are washed again with PBS/0.1% Tween-20, tapped dry and 
developed with a Tropix system. The Tropix-ELISA cheimiluminescent detection 
system from Applied Biosytems uses CSPD 1, 2-dioxetane substrate to enable 
the rapid, sensitive and linear detection of alkaline phosphatase in ELISAs. The 
plates are rinsed with a 1x solution of the Tropix wash buffer, before addition of 
a CSPD substrate. The luminescence emitted from each well is calculated using 
a luminescene plate reader. Plotting the standard curve and extrapolating the 
values of the unknown samples onto the curve yields the p24 concentrations of 
the viral preparation (See Fig. 28). In addition, estimation of the total protein 
content, with a BCA assay, and viral infectivity, by a series of limiting dilutions 
on camptothecin treated HEK-293 cells, yields additional data about the titer, 
purity and infectivity of the viral preparation (See Fig. 28. The viral particle titers 
are obtained by multiplying the p24 values in ng/ml by a factor of 107).  
3.2.1.2. Biotinylation of purified LVs  
Biotinylation of the surface proteins in LVs is a relatively simple chemical 
procedure that can enable the later addition of different targeting moieties, via 
CS, to its surface. The EZ-Link Sulfo-NHS-SS-Biotin reagent (sulfosuccinimidyl-
2-[biotinamido]ethyl-1,3-dithiopropionate) from Pierce, a thiol-cleavable amine-
reactive biotinylation reagent, enables the attachment of a biotin that is 
separated by an extended spacer arm from the LV surface, thus reducing any 
steric hindrances (Altin and Pagler, 1995). This water-soluble, and lipid-
insoluble, reagent only biotinylates the surface proteins, thereby preventing any 
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potential interference in the activity of the important packaged enzymes in the 
viral core. The N-hydroxysulfosuccinimide (NHS) ester group on this reagent 
reacts with the ε-amine of lysine residues to produce at neutral to basic pH 
values. Release of N-hydroxysulfosuccinimide and hydrolysis of the NHS-ester 
completes the reaction. A 5-20 fold-molar excess of the reagent was used in 
order to adequately biotinylate the surface VSV-G. The exact molar excess of 
this reagent needed is difficult to calculate and varies from viral prep to prep; if 
the prep is relatively clean with few contaminating proteins or cellular debris, a 
1-5 fold excess is chosen in order to prevent over-biotinylation. On the other 
hand impure preps, with other competing proteins for the NHS group, need the 
higher figure. In any case, the reagent was freshly constituted in PBS before 
addition to the viral prep for 15-30 mins at RT. The reaction was then stopped 
by the addition of an excess of TBS or serum containing culture media. The 
viruses were spun down over a sucrose cushion as before to yield pure LVs, 
uncontaminated with any Ez-link reagent. In very case, multiple molar excesses 
of the reagent were used and LV viability tested for each batch to determine if 
the reaction had severely compromised LV infectivity or titer. A small aliquot of 
the final, purified LV was tested with a HABA-avidin kit (Sigma) to determine the 
number of biotin molecules per LV (Green, 1965).  
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Curve Formula A B R R²
Log(Y) = A*Log(X)+B 0.701 5.01 0.985 0.97
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Name Amount of p24 No. of Lentiviral particles No. of Infectious Units
Lenti-hisS25 Unconcentrated 100 ng/ml 1.00 x 109 LVs/ml 1.00 x 107 IUs/ml
Lenti-hisS25 Concentrated 2550 ng/ml 2.55 x 1010 LVs/ml 2.55 x 108 IUs/ml
Lenti-hisRT Unconcentrated 90 ng/ml 9.00 x 108 LVs/ml 9.00 x 106 IUs/ml
Lenti-hisRT Concentrated 2700 ng/ml 2.70 x 1010 LVs/ml 2.70 x 108 IUs/ml
Lenti-hisMTR Unconcentrated 70 ng/ml 7.00 x 108 LVs/ml 7.00 x 106 IUs/ml
Lenti-hisMTR Concentrated 1800 ng/ml 1.80 x 1010 LVs/ml 1.80 x 108 IUs/ml
Lenti-GFP H1 Concentrated 24693 ng/ml 2.47 x 1011 LVs/ml 2.47 x 109 IUs/ml
Lenti-GFP H2 Concentrated 31633 ng/ml 3.16 x 1011 LVs/ml 3.16 x 109 IUs/ml
Lenti-hisS25180 Concentrated 1647 ng/ml 1.65 x 1010 LVs/ml 1.65 x 108 IUs/ml
Lenti-hisS25197 Concentrated 1844 ng/ml 1.84 x 1010 LVs/ml 1.84 x 108 IUs/ml
 
Fig. 28: p24 ELISA to determine LV titers: A: p24 standard curve plotted against the 
luminescence detected. On the X-axis is the concentration of p24 in ng/ml and on the Y-axis is 
arbitrary luminesnce units acquired. B: Concentration of some important LV preparations used 
for later experiments. (IU – infectious units; LV – lentiviral particles). 
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3.2.2. Isolation of cerebellar granule neurons (CGNs) from neonatal 
rat cerebellum 
Cerebellar granule neurons are the most abundant type of homogenous 
neurons in mammalian CNS. First described by Ramón y Cajal, these small 
neurons are found in the granular layer of the cerebellum. They receive 
afferents from mossy fibers while sending out glutaminergic efferent axons 
which are in turn organised into a parallel network synapsing with Purkinje cells. 
These cells, an ideal neuronal model system, were cultured as per protocols 
derived from (Foran et al., 2003). 
Briefly, coverslips were inserted into the necessary number of wells and 
coated overnight with poly-L-lysine (0.25 mg/ml in dH2O). After removal of the 
poly-l-lysine, the wells were rinsed briefly with dH2O and dryed in CO2 
incubator. Rat pups, 6 – 10 days old, were killed with sodium pentobarbital and 
the cerebelli dissected out into cold basal media eagle (BME). The isolated  
cerebelli were finely minced and resuspended into fresh BME. They were then 
spun down at 150-200G for 5 mins at 4ºC, resuspended in PBS and dispersed 
into a 1:1 trypsin-EDTA (Invitrogen – 1x) and PBS mixture. The cells were 
triturated with a 5ml pipette and incubated at 37ºC for 20 mins with frequent 
agitation. Benzonase was added to dissociate any clumps and obtain a clear 
suspension. The cells were spun at 200G for 5 mins, resuspended in 15ml 
partial cerebellar growth medium (PCGM) and filtered through a 100µm filter. 
The single cell suspension of predominantly cerebellar granule neurons, free of 
contaminating RBCs, was plated at a density of 1.5 X 106 /well for a 24-well 
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plate and grown at 37ºC in a CO2 incubator. The PCGM was replaced with a 
complete cerebellar growth media (CCGM), containing the mitotic inhibitor 
AraC, after 24-48 h in order to prevent the overgrowth of micro and macro glial 
cells. After a further 5-6 days in CCGM, the cells exhibit profuse axo-dendritic 
proliferation, express synaptic proteins abundantly and secrete glutamate in 
response to an action potential.  Cells could be kept alive easily for 10-12 days, 
and if needed longer, by replacing half of the existing media every 7-10 days. 
3.2.2.1.  Radioisotopic measurement of K+-evoked, and Ca2+-
stimulated, 14C-glutamate release from CGNs 
To measure the functional exocytosis present in these neurons, a 
radioisotopic measurement of K+-evoked, and Ca2+-stimulated, 14C-glutamate 
release from CGNs was used. A representation of the processes involved in a 
typical glutamatergic synapse is shown in Fig. 29.  Cells, cultured for more than 
5 days, were exposed to 0.25 µCi/ml of C14-L-Glutamine in 0.5ml of warmed-
oxygenated Hepes basal buffer (HBB). After 60mins incubation at 37ºC, the 
supernatant was removed and the cells were washed thrice with HBB. The 
basal, unstimulated, glutamate release was measured by the addition of 0.5ml 
of HBB for 5mins at 37ºC. A high K+-containing Hepes stimulation buffer (HSB) 
was added for a similar period to elicit K+-evoked, and Ca2+-stimulated 
exocytosis. Finally, addition of HBB with 1% triton enabled the extraction any 
remaining glutamate. The fractions were centrifuged at 14,000G for 15mins at 
4ºC and 200µL of supernatant from each was added to 2ml of EcoScint-H 
scintillation fluid, mixed and counted using a Beckmann-Coulter counter. 
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Fig. 29: A typical glutamatergic synapse: Free cytoplasmic glutamate, synthesized 
metabolically or from breakdown of glutamine, is actively transported into synaptic vesicles by 
VGluT. Upon release, glutamate binds to the post synaptic ionotropic or metabotropic receptors 
(labelled) or to pre-synaptic autoreceptors. Any free glutamate is rapidly taken up by glial cells 
or by transporters in the pre-synaptic membrane. Glial glutamate is converted to glutamine by 
glutamate synthase enzyme and transported back into the pre-synaptic neuron, thus completing 
the cycle. (Glu – glutamate; Gln – glutamine; PAG – phosphate activated glutaminase; EAA – 
excitatory amino acid transporter; VGluT – vesicular glutamate transporter). Adopted from 
(Squire et al., 2003) 
      
 
 
160
3.2.3.  In vitro and in vivo assays of LV function  
As CGNs were found to be relatively refractory to AAV or LV infection 
after more than 48 h in culture, only protection studies can be done with these 
cells. LVs were added to cultures 2-4 h after plating and were washed out 48 h 
later. BoNT/A were added 7 or 11 days after plating and removed before 
continuation with the release assay. Some of the cells were not treated with the 
toxin and were instead used for immunohistochemical localisation of expressed 
SNAP-25 variants (Fig. 30 A-D). The basal release was subtracted from the 
evoked C14-glutamate release and expressed as a fraction of the total content of 
neuronal glutamate (basal + stimulated + total). In order to quantify the absolute 
effect of viral-mediated SNAP-25 variant expression, the evoked component 
from toxin-and-LV treated cells was normalised to that from LV-only treated 
ones and plotted as a graph (Fig. 30 E). 
The effect of SNAP-25-197 and SNAP-25-180 on stimulated exocytosis 
was quantified in cells that were exposed to the relevant LVs for 8 or 12 days. 
LVs expressing wtSNAP-25 were used as a control (Fig. 31). In addition, the 
effect of increasing MOI on the final protein expression was quantified by 
western blots of lysed cells probed with anti-His and anti-SNAP-25 antibodies 
(Fig. 31).  
The in vivo effects of direct LV-His6-SNAP-25 injection into the spinal 
cord anterior horn was tested as before in 8-week old Wistar rats. Animals were 
euthanized 8, 15 or 21 days after injection, the spinal cords cryo-preserved, 
sectioned, immuno-probed and examined under a fluorescent microscope (the 
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best expression level, seen 8 days after injection, is shown in Fig. 32). 
3.2.4. Development of core-streptavidin tagged protease-inactive and 
active BoNT/E targeting chimeras  
BoNT/E with a E12Q mutation in its HEXXH-E protease domain has 
been shown to be inactive (Agarwal et al., 2004). This molecule, henceforth 
termed BoTIM (Botulinum toxin inactive mutant) has been proposed as a 
putative targeting agent to deliver cargo to motor neuron terminals. A version of 
this molecule available in our laboratory, with an N-term His6 tag and a C-term 
Strep tag, was used to generate core-streptavidin tagged protease-inactive 
BoNT/E targeting chimeras (See Fig. 33 for a schematic of the cloning process). 
This molecule also had PreScission protease recognition sites between the LC 
and HC and between the tags and BoTIM (the enzyme is a genetically 
engineered human rhinovirus 3C protease and was acquired from GE 
healthcare. It recognises the amino acid sequence LFQ/GP (Cordingley et al., 
1990)).  
Briefly, the two existing tags were removed and replaced by a single His6 
tag at the C-terminal. In addition, convenient restriction sites, BamHI before the 
LC at the N-terminal and XhoI before the His6 tag at the C-term just, were 
introduced. The created molecule, BoTIM-His6, was used for subsequent 
cloning procedures. A codon-optimised synthetic CS with long, flexible glycine-
serine linker and suitable restriction sites at both ends was designed (pI of 6.7 
and Mr of 17.4kDa – the sequence was based on that used in (Schmiedl et al., 
2000) and (Sano et al., 1995)). This was synthesized at Eurofins Medigenomix 
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and cloned into BoTIM as shown in Fig. 33. The orientation of the inserts in the 
new plasmids created, pQE-CS-BoTIM-His6 and pQE-BoTIM-CS-His6, was 
checked by sequencing. The sequence confirmed plasmids were transformed 
into chemically competent M16(pREP4) E.coli strains. These transformed 
bacteria were grown in 2TY media (Sigma) overnight and 1 ml of this dense 
culture seeded into 120ml of fresh 2TY in a 2L baffle flask. They were allowed 
to grow at 37 °C for 3 h before induction with 100µM IPTG. After the addition of 
IPTG, the temperature was turned down to 21 °C and the culture grown 
overnight with vigorous shaking. The bacteria were then harvested by 
centrifugation at 6000G, resuspended in a Tris-NaCl buffer containing 
1xProtease inhibitor cocktail type 3 (Calbiochem). The cells were lysed using 
lysozyme and several freeze/thaw cycles and the insoluble material was 
removed by centrifugation. The different BoTIMs, and CS-His6, were trapped by 
immobilized metal affinity chromatography (IMAC) on TALON resin, eluted with 
500mM imidazole, and fractions rich in the eluted proteins were pooled into 
HEPES-NaCl buffer (pH 8.1) using a Zeba-Spin desalt column (Pierce) (See 
Figs. 34 and 35). These were then aliquoted and stored at –80 °C. Some of SC 
BoTIM molecules were proteolytically nicked by PreScission protease 
(20units/mg of BoTIM) for 1 h at 25 °C to create a di-chain version free of the 
His6 tag (See Fig. 36).  All long term storage was in HEPES-NaCl buffer (pH 
7.4). The expression, purity and nicking of these proteins was monitored on 
Coomassie-stained SDS-PAGE gels and by Western blotting with primary 
antibodies followed by horseradish peroxidase-conjugated anti-species 
secondary antibodies and visualized using an ECL protocol (See Fig. 34, 35 and 
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36 for more details). The protein concentrations were determined using the 
Bradford assay and purity assessed based on Coomassie-stained SDS-PAGE 
gels.  
After the confirmation of the producibility of CS-tagged BoTIMs, versions 
with an active LC were created by PCR cloning techniques. These were 
expressed and purified as described for their inactive relatives.  
3.2.5. Testing the targeting abilities of different CS-tagged BoTIMs 
The protease-active CS-tagged BoNT/Es are a valuable proxy to 
measure the targeting of CS-tagged BoTIMs (since they differ in only one single 
amino acid from the latter). They were applied at different concentration to 8 
day old CGNs in culture for 1hr at 37C, washed out and the cells were lysed 
and blotted the next day. ECL estimation of the amount of SNAP-25 cleavage at 
different concentrations provided an accurate and quantitative assessment of 
the perturbation, if any, caused by the attached CS-tag to the various processes 
that underlie toxin-mediated SNARE cleavage – binding, internalisation, 
extravasation from the lysosome, target finding and finally cleavage. Nicked and 
un-nicked versions of the tagged BoNT/Es, along with LCE and BoNT/E DC 
provided valuable controls to fully asses this process (See Fig. 37). In addition, 
the lethal dose of the toxin in mice was determined by the intra-peritoneal 
injection of various concentrations, followed by monitoring for 5 days (See 
section 2.2.1 more more details). The amount of toxin that killed 50% of mice 
within 4 days was taken as one minimal lethal dose – for some SC versions the 
maximum dose injected, which did not kill the animal, is represented in Fig. 37. 
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Another important test was measuring the ability of CS-tagged BoTIMs to 
antagonise the activity of BoNT/E in CGN cultures. Various concentrations of 
the BoTIMs were added to CGN cultures 1hr before the addition of 500pM 
BoNT/E. They were allowed to act for a further hour, before replacement of the 
media with fresh CCGM. After an overnight incubation, the cells were tested for 
glutamate release and SNAP-25 cleavage (See Fig. 38). 
3.2.5.1. Immuno-histochemical determination of binding of CS-
tagged BoTIMs to CGNs 
The tagged BoTIMs were applied at various concentrations to 4 day old 
CGNs in culture. They were allowed to bind overnight and the cells were 
repeatedly washed using PBS the next day to get rid of any unbound proteins. 
They were then fixed with ice-cold 4% paraformaldehyde in PBS, 
permeabalised with methanol and PBS/0.1%Tween and probed with a rabbit 
anti-streptavidin antibody. Probing with a goat anti-rabbit-A546 fluorescent 
conjugate releaved the binding pattern of CS-BoTIM and BoTIM-CS (See Fig. 
39). To elicit the microscopic details of this binding, some of the slides were 
counter-stained with a mouse anti-SNAP-25 antibody and a goat anti-mouse-
A488 fluorescent conjugate (See Fig. 40).  
3.2.6. Testing the ability of CS-tagged BoTIMs to bind various 
biotinylated cargo 
Biotinylated horse radish peroxidase (biot-HRP – Sigma) was extensively 
used to not just quantify the binding of the CS-tagged proteins, but also as a 
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screening tool to identify high-producing colonies during the cloning process 
(See Fig. 41). In brief, a 1:1500 dilution of biot-HRP (5mg/ml - Pierce) was 
diluted into PBS/5% BSA and used to probe aliquots of the different stages of 
the BoTIM purification process blotted onto nitrocellulose. After repeated 
washing, a commercial ECL kit (Millipore) was used to identify and quantitate 
the amount of bound biot-HRP. A similar procedure was used to elucidate the 
effect of pH, buffer constituents and detergents on the affinity of the CS tag to 
biot-HRP (See Fig. 41). 
3.2.7. Chromatographic analysis of CS-tagged BoTIMs 
A 50cm chromatographic column filled with Superose 6 resin (GE 
Healthcare – useful fractionation range of 5kDa-5000kDa, particle size of 13µm 
and flow rate of 0.1-0.5ml/min) was used to measure the molecular weights of 
the different CS-tagged BoTIMs in PBS. Initially, the characteristics of the 
column were determined by running different protein and non-protein standards 
(GE Healthcare; See Fig. 42). The protein concentration in the different 
fractions was analysed by Bradfords assay and the peak elution volume for 
each standard calculated. A standard curve was generated, showing the 
relationship between the Kav and Mr, and used to calculate the molecular 
weights of the CS, BoTIM and CS-BoTIM (See Fig. 43). 
3.2.8. Assessment of the ability of CS-tagged BoTIMs to bind larger 
cargo – biotinylated microspheres and LVs 
Two, prototype, large cargos were chosen – biotinylated fluorescent 
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microspheres – bFM (FluoSpheres from Invitrogen - biotin-labeled 
microspheres, 0.2µm in diameter, containing yellow-green fluorescent cargo 
with 505nm excitation and 515nm emission, comprising a suspension of 1% 
solids) and biotinylated LVs described previously. Chromatographic analysis of 
the binding of CS-BoTIM to bFM was performed, as before, on a superose 6 
column. In addition to protein content estimation of the different fractions, the 
fluorescent content was estimated on a plate reader and plotted (See Fig. 44).   
Biotinylated LVs, with ~2000 biotins per LV, were the second large cargo 
tested. CS-BoTIM, un-nicked and still containing the His-tag, was passed 
through a column containing 50ul of TALON resin. Once the resin was saturably 
bound with CS-BoTIM, a solution of biot-LVs was passed through the column. 
After repeated washing, PBS/1mM EDTA was used to dislodge the bound CS-
BoTIM and a western blot of this probed with antibodies against streptavidin 
and p24, identifying the fractions containing CS-BoTIM and biot-LV respectively 
(See Fig. 44). A parallel and related experiment was to test the effect of bound 
cargo on CS-tagged BoNT/E’s exocytotic blockade activity. CGNs were treated 
overnight to a mixture of the CS-tagged BoNT/Es bound to different cargo – 
from the biotin (0.4kDa), biot-HRP (60kDa) and bFM (>5000kDa). The cells 
were then washed repeatedly, lysed and contents run on a western blot. The 
amount of SNAP-25 cleavage was quatified for each mixture and plotted (See 
Fig. 45).  
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3.2.9. Effect of bound CS-BoTIM on biot-LV infectivity 
HEK-293 and CGNs in culture were treated with a mix of biot-LVs and 
CS-BoTIM (or BoTIM-CS). Untargeted biot-LV and non-biotinylated LVs were 
used as controls. The mixture was washed off after an overnight incubation and 
the cell were allowed to grow for 48 h (HEK-293) – 96 h (CGN) before imaging 
the expressed GFP fluorescence. A fluorescence plater reader was also used to 
obtain quantitative data, by measuring, and summating, fluorescence readings 
from 25 different points in each of the wells (See Fig. 46 and 47). 
      
 
 
168
Lenti-hisS25 Lenti-hisS25MTR
A B
C D
-20
0
20
40
60
80
100
120
hS25/250pM
BoNTA
hRT/250pM
BoNTA
hMTR/250pM
BoNTA
 -ve/250pM
BoNTA
 -ve/0pM BoNTA
C
14
gl
ut
am
at
e 
re
le
as
e 
as
 %
 u
nt
re
at
ed
 c
on
tro
l
Evoked release 12d after infectionE
 
Fig. 30: Evaluation of LV-mediated wt, RT and MTR SNAP-25 expression in CGNs: 
Immunohistochemical detection of expressed SNAP-25 variants in 5 day old CGN cultures 
probed with a anti-His6 antibody (in red), anti-VAMP antibody (in green) and the nuclear stain 
DAPI (in blue). The extensive colocalisation of His6-SNAP-25 (A: 10x and C: 40x) and His6-
SNAP-25-MTR (B: 10x and D: 40x) with VAMP is clearly seen. E: Functional evaluation of 
expressed cleavage-resitant SNAP-25 mutants in CGNs challenged with 250pM of BoNT/A. 
The purely evoked component of the K+-evoked Ca2+-mediated C14-glutamate exocytosis in 
CGNs treated with LV+toxin was normalised to that from toxin-free controls, treated with just the 
virus, and plotted on a graph. (Three replicates each were calculated for each viral and toxin 
dose. 107 IUs of LV was added to the wells) 
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Fig. 31:  Effect of His6-SNAP-25-197 and -180 expression on K+-evoked Ca2+ mediated 
exocytosis in CGNs: A and B: Normalised evoked release 8 or 12 days after infection with the 
relevant LVs shows a slight, non-significant, decrease in the evoked component of release in 
cells expressing the 197 or 180 isoforms. In contrast, cells expressing the full-length, wild-type 
SNAP-25 show no difference in exocytotic release compared to untreated cells. C: The 
introduced SNAP-25 variant does not overwhelm the native SNAP-25. A significant  quantity of 
wt-SNAP-25 persists in CGNs. Even infection with a high dose dose not lead to a significantly 
higher protein expression level – a plateau effect that may be mediated at the level of viral 
infectivity, integration or mRNA expression. 
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Fig. 32: Spinally-injected LVs efficiently infect and rapidly produce the introduced transgene in 
spinal neurons. A: Assembled low magnification images show the spread of injected LVs and 
the relatively wide area of transgene expression. B: A higher magnification enables the 
identification of the characteristically large anterior horn motor neurons among the infected 
cells. 
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3.3. Results 
3.3.1. LVs are an efficient tool to deliver genes into neurons – in vivo 
and in culture 
 
A second generation lentiviral-vector system, obtained from Prof. Trono, 
was used to create LVs expressing GFP, wtSNAP-25, SNAP-25-RT, SNAP-25-
MTR, SNAP-25-197 and SNAP-25-180 (See Fig. 26-28). GFP containing 
viruses were produced to control for the effects of viral infection, if any, on cell 
viability and exocytotic processes. Similarly, wtSNAP-25 is a valuable control to 
elicit the effects of SNAP-25 over-production, if any, on the efficiency of 
synaptic exocytosis. The BoNT/A resistant SNAP-25-RT and the /A, /E and /C1 
resistant SNAP-25-MTR are the therapeutic genes that has been proven to 
introduce resistance to the exocytotic blockade by the respective serotypes. 
The process of creation of these two has been shown in Fig. 27. A 
commericially available p24 ELISA kit, based on a sandwich ELISA utilising a 
sheep anti-p24 capturing antibody and a alkaline phosphotase tagged mouse 
monoclonal anti-p24 secondary was used to detect the titers of the produced 
lentiviruses. Standard curves were generated using known quantities of a 
recombinant p24 protein and the estimated yields extrapolated, using published 
figures, to obtain the viral particle and infectious unit yields (See Fig. 28). High 
titers were obtainable with LVs expressing GFP; the introduction of SNAP-25 
into the system resulted in a lower, yet sufficient for most in vitro and in vivo 
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procedures, titer. These viruses were further tested by application of serial 
dilutions onto HEK-293 cells, treated with camptothecin to limit overgrowth, 
followed by visual/immunohistochemical examination of expressed transgene 
products. 
The functionality of the RT and MTR SNAP-25 carrying viruses was 
tested in CGNs. Application of 10-20 MOIs of the virus onto CGNs resulted in 
strong production of the SNAP-25 variants that could be identified 
immunohistochemically and functionally (See Fig. 30 and 31). GFP and mutant 
SNAP-25 products produced by LV based gene-delivery were identifiable after 
2-3 days and showed a strong expression 5 days after infection. Examination of 
radio-labelled glutamate release enabled a quantitative, and sensitive, 
observation of the effect of the mutant SNAP-25s on BoNT/A mediated 
exocytotic blockade (see Fig. 30). There was a strong protective effect, with the 
amount of exocytosis increasing to ~60% and ~40% of the normal controls; in 
contrast, CGNs treated with wtSNAP-25 showed no perceivable improvement.   
CGNs were found to be relatively refractory to AAV or LV infection after more 
than 48 h in culture; while this restricts the experiments that can be performed 
with these cells to protection studies only, they still offer a valuable model 
system to study the perturbation of exocytosis by CNTs.  
In a parallel experiment, the total amount of recombinant protein 
produced as a percentage of the total natural protein was examined using LVs 
expressing the truncated SNAP-25 isoforms. These, due to the difference in 
molecular weights, can be easily differentiated from the native SNAP-25, yet 
probed with the same antibody. The results obtained show that the introduced 
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protein is produced at levels that rival the natural protein (See Fig 31 C). But 
beyond a certain level, increasing the MOI does not lead to an increase in the 
produced protein. In addition, the effects of these truncated mutants on normal 
exocytosis in CGNs was tested - the application of SNAP-25-197 and -180, 
resulted in a reduction, albeit non-significant, in exocytotic activity of CGNs 
when measured after 8 or 12 days (See Fig. 31 A and B). 
The in vivo activity of these viruses was tested by direct injection into rat 
spinal cord anterior horns. When the cords were dissected after 8 days and 
observed, the viruses were found to be very active in vivo and had transduced a 
large area of the spinal cord. Viral-mediated SNAP-25 and GFP expression 
kicked in by day 8 and seemed to strongly infect, the anatomically identifiable, 
motor neurons (See Fig 32). Interestingly, the viruses had also diffused 
vertically along the spinal cord and had infected muti-verterbral levels spanning 
anterior horns. 
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Fig. 33: Schematic of the creation of CS-BoTIM and BoTIM-CS. PCR based modification of a 
N-term His6 and C-term Strep tagged BoTIM yielded the single C-term His6 tagged BoTIM-E-
His6. Insertion of the designed and synthesized CS in the N- and C-terminals of this molecule 
yielded CS-BoTIM-His6 and BoTIM-CS-His6 respectively. Long, flexible gycine-serine linkers 
were introduced at the junctions between CS and BoTIM and between CS and His6. (Pre – 
PreScission site; LCE-M – light chain of BoNT/E with E212Q mutation; HCE – heavy chain of 
BoNT/E; FL – flexible linker; CS-mod – designed core streptavidin) 
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Fig. 34: Expression and purification of CS-His6 and SC BoTIM-His6. A: Coomassie stained 
SDS-PAGE gels (left) and corresponding Western blot (right) with an anti-His antibody of 
aliquots from the different stages of purification of CS-His6. The arrow points to the sharp single 
band visible below 15kDa in both the panels. B: Coomassie stained SDS-PAGE gels (left) and 
corresponding Western blot (right) with an anti-His antibody of aliquots from the different stages 
of purification of BoTIM-His6. The arrow points to the sharp single band visible at 150kDa in 
both the panels. (L – lysate; FT – flow-through from the TALON resin column; E1-4 – elute 
fractions; M – pre-stained protein molecular weith marker from Pierce) 
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Fig. 35: Expression and purification of SC CS-BoTIMHis6 and SC BoTIM-CS-His6. A: 
Coomassie stained SDS-PAGE gels (left) and corresponding Western blot (right) with an anti-
His antibody of aliquots from the different stages of purification of CS-BoTIM-His6. The arrow 
points to the largest and most abundant band visible higher than 150kDa in both the panels. B: 
Coomassie stained SDS-PAGE gels (left) and corresponding Western blot (right) with an anti-
His antibody of aliquots from the different stages of purification of BoTIM-CS-His6. The arrow 
points to the largest and most abundant band visible higher than 150kDa in both the panels. (L 
– lysate; P – resuspended cellular pellet; FT – flow-through from the TALON resin column; E1-4 
– elute fractions; M – pre-stained protein molecular weith marker from Pierce) 
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Fig. 36: Nicking of CS-BoTIM-His6 and CS-BoNT-E-His6 to generate His-tag free dichains. A: 
Coomassie stained SDS-PAGE gels (left) and corresponding anti-LCE Western blot (right) of 
aliquots, PreScission nicked and un-nicked and reduced and unreduced, of CS-BoNT-E-His6. 
The arrows on the left panel point to the SC, HC and LC respectively, while the arrows on the 
right panel point to the SC and LC. The HC and LC are seen clearly in the reduced and nicked 
fractions. B: Western blots of PreScission nicked and un-nicked, and reduced and unreduced, 
CS-BoTIM-His6 aliquots probed with anti-LCE (left) and anti-His (right) antibodies. The arrows 
on the left panel point to the SC and LC forms, while the one on the right points to the SC form. 
The arrow in the right panel points to the SC form. The absence of free LC in the un-nicked 
fractions and absence of His-tag in the nicked fractions confirm the totality of nicking 
(PreScission scission was carried out using 10units/µg protein with 1mM DTT; Red: reduced 
with 50mM DTT) 
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3.3.2. CS-tagged BoTIMs retain the properties of both their parent 
molecules 
Having proved the ability of LVs to infect the target cell types, the next 
step was to produce the prototype targeting agent. BoTIM, the inactive version 
of BoNT/E, was conjugated at the genomic level to a small CS tag. Initially, the 
synthetic CS-His6 gene was introduced into the pQE-60 plasmid and its 
expression and biotin binding abilities were tested. This minimal-biotin binding 
fragment expressed well and bound free biotin and biotin-HRP well (See Fig 34 
and 41). Crucially, neither the His tag nor the included long, flexible glycine-
serine linker seemed to interfere with the properties of this protein. Later, this 
was cloned into different parts of, the already developed, BoTIM. Attempts were 
made to develop four different versions, with the CS tag at the N-terminus, C-
terminus, between the HC and LC and with a tandem linked version with two 
CS molecules at the C-terminus (see Fig 33). Of these, only the first two 
expressed well enough and showed minimal degradation; production 
procedures were then optimised to obtain relatively pure protein (See Fig 33-
36). Utilisation of small culture volumes, reduction of production temperature to 
20ºC and rapid shaking enabled production of quantities sufficient for in vitro 
and in vivo use (see Fig 35). After IMAC purification, these single-chain 
molecules were then treated with PreScission to convert them into di-chain 
version, thereby also removing the His6 tag (see Fig 36). In order to test the 
effects of the attached CS, active versions of these BoTIMs were then prepared 
– a useful and sensitive proxy to track the properties of the inactive-mutant. 
PCR-based mutagenesis using primers to restore the essential glutamic acid, at 
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position 212 within the Zn2+-dependent protease active site of the LC yielded 
active versions of CS-tagged BoTIMs. These were then produced, purified and 
nicked as before to yield CS-BoNT/E (see Fig 36a) and BoNT/E-CS. In total, 13 
different proteins were produced and tested – CS-His6, BoTIM-His6 SC, BoTIM 
DC, CS-BoTIM-His6 SC, CS-BoTIM DC, BoTIM-CS-His6 SC, BoTIM-CS DC, 
BoNT/E-His6 SC, BoNT/E DC, CS-BoNT/E-His6 SC, CS-BoNT/E DC, BoNT/E-
CS-His6 SC and BoNT/E-CS DC. 
An initial and essential test was to determine if the addition of the CS-tag 
has destabilised the natural neuronal and cholinergic specificity of BoTIM. Two 
different approaches were undertaken for this purpose – the first was to use the 
active LC in CS-tagged BoNT/E as a reporter (differing in only one single amino 
acid from the corresponding BoTIMs) and the second was to test the binding of 
CS-tagged BoTIMs themselves. The former yields highly relevant and 
quantitative data, while the latter yields a corroborative and qualitative 
confirmation. CGNs were used as neuronal model systems for the former test 
and the CS-tag seemed to be pretty innocuous and the CS-tagged active 
BoNT/E showed properties similar to their unmodified counterpart (See Fig. 37). 
While the CS-tagged di-chains plateau early compared to the non-tagged 
BoNT/E, it still was found to be many order of magnitude more active than just 
the LC on its own or the un-nicked single chains.  
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Fig. 37: CS-tagged BoNT/E variants show similar activity to their un-modified counterparts in 
neuronal/cholinergic model systems: A: SNAP-25 cleavage in CGNs exposed to various 
concentration of the BoNT/E and its CS-tagged variants. The clear demonstration of targeting, 
binding, internalisation and pathfinding properties of the DC forms shows that the presence of 
the tag has only a small effect on the toxin’s natural properties. While the SNAP-25 cleavage 
does plateau earlier compared to the un-modified toxin, the comparitively low cleavage seen 
with just the LC, or with the SCs, clarifies that the tagged toxins still demonstrate an active, 
specific and efficient neuronal targeting property. B: Summarised data of the EC50, EC25 and 
mLD50 values of the different toxins. Due to the very low activity of the SCs and the LC, not all 
data could be obtainable.  
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Fig. 38: The various CS-tagged BoTIMs show only a small competitive antagonism of the un-
modified toxin’s activity in CGNs. 500pM of BoNT/E applied to CGNs in combination with 
various concentrations of CS-tagged BoTIMs and BoTIM. The amount SNAP-25 cleavage and 
the amount of evoked C14-Glutamate release was quantitated, normalised and plotted here. 
While there is some inhibition of cleavage, which corresponds to an increase in glutamate 
relase, there does not seem to be a significant effect with any of the concentrations tested. 
(Four replicates were performed per dose and the SD are shown). 
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One test to determine if the addition of the CS-tag has destabilised 
BoTIMs properties is to attempt a competitive antagonism of BoNT/E action by 
molar excesses of CS-BoTIM and BoTIM-CS. In this test however, these 
inactive molecules were not able to significantly antagonise the activity of native 
BoNT/E (See Fig. 38). But when BoTIM on its own was tested, it also showed a 
similar lack of significant competitive antagonism. One of the reasons for this 
could be the previously described dual-receptor dual-affinity mode of uptake in 
neurons. The presence of such a large number of binding sites, actively 
undergoing recycling, could be the cause of this absence of competitive 
antagonism. 
When tested on its own, CS-tagged BoTIM bound strongly and 
specifically to neurons in culture – a property similar to BoTIM, and BoNT/E, 
and missing in CS. This binding was even identifiable at very low protein 
concentrations, reflecting the specificity of BoTIMs natural neuronal targeting, 
and the sensitivity of the detection method employed (See Fig 39). The 
availability of a highly sensitive anti-streptavidin antibody significantly aided in 
this analysis.  Investigation of the microscopic details of this binding in CGNs, 
with co-staining by a SNAP-25 antibody, revealed that the tagged BoTIMs 
bounds predomionantly to the neuronal cell bodies, with a large component 
bound to the axo-dendritic proceses (See Fig. 40). This is significant as the 
native BoNT/E binds and internalises at the active-zones in the axonal 
processes of neurons. 
The addition of immunohistochemical data to that obtained by the use of 
CS-BoNT/E and BoNT/E-CS conclusively proves that most of the properties of 
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BoTIM have been retained by its derivatives. 
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Fig. 39: CS-tagged BoTIMs strongly and specifically bind to CGNs: A 12hr incubation of 
various concentrations of CS (A), CS-BoTIM DC (C), CS-BoTIM SC (E), BoTIM-CS DC (D) and 
BoTIM-CS SC (F) with 4 day old CGNs in culture was probed with an anti-Streptavidin primary 
and revealed with an anti-Rabbit-A546 secondary (red). The abundant signals found in cells 
treated with the CS-tagged BoTIMs and their absence in cells treated with just CS on its own 
demonstrates the strength and specificity of binding. Untreated cells were probed with just the 
antibodies as a negative control (B). (Scale bar 100 µm) 
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Fig. 40: The CGN binding of the CS-tagged BoTIMs is detectable even at single-digit nM 
concentrations. CGNs were treated, as before, with CS-BoTIM DC (4nM – A & B and 2nM - C) 
and BoTIM-CS DC (2nM – D & E and 1nM - F). Probing with rabbit anti-streptavidin and mouse 
anti-SNAP-25 antibodies followed by a goat anti-rabbit-A546 (red) and goat anti-mouse-A488 
(green) antibodies revealed the microscopic details of binding. The cells were then counter-
stained with DAPI and the images overlaid. Representative fluorescent micrographs at 20x (A & 
D), 40x (B & E) and 60x (C & F) magnification are shown here. (Scale bar 20µm) 
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A detailed gel-filtration analysis of the effects of the CS-tag on BoTIM 
was undertaken to determine the conditions of efficient biotin, and biotinylated 
cargo, binding and to examine if there was any polymerisation of the molecules 
in solution. The efficacy of biotin-binding was not compromised, with biotin-HRP 
being bound strongly to CS and CS-tagged BoTIMs in solution (See Fig. 41). 
Most physiological buffers, at physiological pH, were found to be acceptable for 
such binding; one interesting finding was that the presence of even small 
quantities of detergent in the buffer could destabilise and inhibit biotin binding. 
These results prove that the presence of BoTIM does not subvert the properties 
of CS.  
In order to determine the degree, or presence of polymerisation of the 
molecules in solution, a detailed gel-filtration analysis was undertaken. This is 
important for later experiments in vivo, as large multi-molecular aggregates 
could be inactive in vivo despite being active in vitro. The characteristics of the 
home-made column were determined using a variety of protein molecular 
weight standards and phenol red/blue dextran (see Fig. 42). The elution peaks 
of CS, 37.8 – 39.6ml, corresponds to a tetramer of ~50-60kDa compared to its 
native molecular weight of 13.4 kDa. BoTIM elutes from the column between 
35.5-36.5ml corresponding to a Mr of ~130-170kDa, while the elution peaks of 
CS-BoTIM, at 27, 29, 32 and 33 ml, corresponds to a complex multimer ranging 
from >660 to 150kDa (see Fig. 43). Thus there is some degree of 
polymerisation of CS-BoTIM – a strong contributor for this effect could be the 
propensity of CS on its own to form tetrameric aggregates.  
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Fig. 41: CS and CS-tagged BoTIMs efficiently bind to biot-HRP. A: Aliquots from the IMAC 
purification process were blotted onto a nitrocellulose membrane and probed with biot-HRP. 
The blots show the strong and efficient binding of CS, and CS-tagged BoTIMs, to biot-HRP and 
the efficient concentration afforded by IMAC purification. (L – lysate; FT – flow-through from the 
TALON resin column; E1-4 – elute fractions; M – pre-stained protein molecular weith marker 
from Pierce). B: CS, and CS-tagged BoTIMs, are capable of binding biot-HRP at physiological 
pH. Various concentrations of CS and CS-tagged BoTIMs were blotted onto nitrocellulose 
membranes, blocked with PBS/5% BSA and probed with a 1:1500 dilution of biot-HRP in PBS 
buffers of pH 6.0 to 8.0. After development with an ECL reagent, the luminescence values were 
calculated with GeneSnap software, normalised to the maximum for each protein and plotted. 
C: The effect of different buffers and dertergents on the binding of biot-HRP to CS was 
determined. While binding is efficient in the physiological buffers tested, PBS, HBS and TBS 
(pH 7.2), the presence of even small quantities of a mild detergent (Tween 20) is enough to 
strongly inhibit such binding. 
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Fig. 42: Characterisation of the properties of a Superose 6 column: A: Elution profiles of 
proteins of different Mr superimposed on that of Blue dextran and phenol red. B and C: The 
relationship between protein Mr, Ve and, the calculated, Kav. A table with the individual values 
and a semi-log graph of the same is represented here.  
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Fig. 43: Chromatographic determination of the molecular weights and conformation of CS, 
BoTIM and CS-BoTIM in solution. The elution peaks of CS, 37.8 – 39.6ml, corresponds to a 
tetramer of ~50-60kDa. BoTIM elutes from the column between 35.5-36.5ml corresponding to a 
Mr of ~130-170kDa, while the elution peaks of CS-BoTIM, at 27, 29, 32 and 33 ml, corresponds 
to a complex multimer ranging from >660 to 150kDa.  
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Another query that needs to be clarified if the relative efficiency of 
binding to larger biotinylated cargo is different that from smaller ones – an 
aspect that is important in determining if there is an in-built limit to CS-tagged 
BoTIM’s targeting capacity. The prototype cargo chosen was commercially 
available biotinylated fluoromicrospheres. This large, multi-molecular, cargo 
was efficiently bound and, most importantly, not dislodged by repeated washing 
with physiological buffers (see Fig. 44A). In addition, the actual cargo that will 
be used, biotinylated LVs was also tested – due to the hazards involved in using 
large amounts of LVs on the bench, a modification of the gel-filtration 
experiment was used. Un-nicked CS-BoTIM was bound to an IMAC column and 
biotinylated LVs were passed through this. As expected, these LVs bound 
strongly to the immobilised CS-BoTIM and could be eluted using EDTA (see 
Fig. 44B). 
Another test to measure the effect of bound cargo on the native targeting 
ability of BoNT, was to measure SNAP-25 cleavage in CGNs after attaching 
various biotinylated molecules, of increasing sizes, to CS-BoNT/E and BoNT/E-
CS. There was a small effect on LC entry, and thus SNAP-25 proteolysis, which 
seemed to be directly proportional to the size of the attached cargo – 
interestingly, activity was retained even in molecules handicapped with bFM 
(see Fig. 45). The position of CS on BoTIM did not strongly affect the amount of 
SNAP-25 proteolysis, probably due to the fact that most of the cargo is 
detached in the acidic lysosomal environment. 
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Fig. 44: CS-BoTIM binds efficiently to large biotinylated cargo. A: The elution profiles of 
biotinylated fluoromicrospheres (bFM) – bound to CS-BoTIM (ii) or free (i). Panel (ii) shows the 
strong and specific association between the biotin on bFM and CS on CS-BoTIM. (The 
normalised fluorescence readings are plotted in red and protein concentrations, measure by a 
Bradford’s assay, are shown in green. B: CS-BoTIM can bind specifically to Biotinylated 
decorated. A crude mixture of an excess of CS-BoTIM (30ug) and biotinylated lentiviruses 
(~2x1011 VPs) was loaded onto a mini-clumn containing 20µl TALON resin (1). Samples from 
the flow-through (2), wash with 1 ml PBS pH7 (3), FT after adding more CS-BoTIM (30ug) (4) 
wash with 1 ml PBS pH7 (5), first elute (10mM EDTA) (6) and 2nd elute (50mM EDTA) (7) were 
then run on an SDS-PAGE gel and blotted with an anti-streptavidin and anti-p24 antibodies. The 
presence of viral and protein bands in the 2nd elute clearly shows the specific binding of CS-
BoTIM to biot-LVs.[Biot-LV concentrations: starting p24 ELISA – 2x1011; 2nd Elute p24 ELISA - 
~1011)]. 
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Fig. 45: The effect of bound cargo on the cleavage of SNAP-25 in CGNs by CS-tagged 
BoNT/Es. A: The effect of saturably bound biotin (biot – 50 and 100µM), biot-HRP (50 and 
100µM) and biotinylated microspheres (biot-micro – 50 and 100µM equivalent) on the cleavage 
of SNAP-25 in CGNs by N-terminally CS-tagged BoNT/E (CS-E). B: The effect of previously 
described cargo binding on the cleavage of SNAP-25 in CGNs by C-terminally CS-tagged 
BoNT/E (E-CS). 
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Preliminary tests were then done on targeting LVs – the prototype large 
cargo chosen. HEK-293 cells were the chosen non-neuronal cells and CGNs 
were the chosen neurons. While a more rigorous test would have been that 
using muscle cells and cholinergic spinal motor neurons in the same dish, there 
were difficulties in creating such a co-culture system. Attachment of CS-BoTIM 
and BoTIM-CS to the surface of biot-LVs strongly reduced its promiscuity to 
non-neuronal cells (see Fig 46), while having a minimal effect of the viruses 
natural neuronal affinity (see Fig.47). The effect of targeting on viral infectivity to 
HEK-293s was very evident, at least at higher concentrations of the targeting 
molecule, while there was no obvious improvement in their neuronal infectivity. 
While the reasons for this are yet to be determined, it must be noted that LVs 
strongly and readily infect neurons in culture and increasing this pronounced, 
pre-existing, neuronal affinity might not be easily achieved. The achieved 
decrease in non-neuronal promiscuity does realize the same result as 
increasing neuronal infectivity and is an integral part of the goal of cholinergic 
targeting. 
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Fig. 46: Partial ablation of the promiscuous infectivity of LVs by attachment of CS-tagged 
BoTIMs: HEK293 cells used as a prototype non-neuronal cells. GFP expression after infection 
with un-targeted LVs [A(i) shows unmodified and A(ii) biotinylated] is compared to that after 
targeting with bound CS-BoTIM [B(i)] and BoTIM-CS [B(ii)]. Pre-incubation with a 10-fold molar 
excess of CS-BoTIM and BoTIM-CS reduces the number of cells expressing GFP after 48 h. 
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Fig. 47: LV infectivity towards neurons is not affected by attachment of CS-tagged BoTIM. The 
cell counts after treatment with biot-LV (targeted or untargeted – as described previously) are 
shown in A, while representative photomicrographs are shown in B. The cumultive counts from 
4 different wells, obtained with a scanning plate readers are plotted along with their SDs.  
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3.4. Discussion 
The extra-ordinary specificity of CNTs to NMJs creates formidable 
problems that need to be overcome if a successful therapy against botulism is 
to be devised. On the other hand, if this very same specificity can be exploited 
to deliver therapeutic molecules to NMJs, and their supplying motor neurons, 
novel, highly effective, peripherally deliverable and minimally-invasive 
treatments can be developed. 
The deliverable therapeutic could be a small peptide molecule, a 
medium-sized protein/antibody, a virus or even a liposome. Having targeting 
molecules that are flexible enough to target all, or atleast many, of these varied 
therapeutics, would substantially advance and expand, the currently limited, 
area of spinal cord treatments. Attachment of biotin, a small 0.4kDa molecule 
should not strongly affect the therapeutic potential of the delivered cargo – 
indeed this biotin could have a long, cleavable linker, between itself and the 
attached cargo, further minimising deleterious effects. Attaching such a 
modified cargo via a streptavidin linker to the CNT based targeting molecule will 
bring to fruition the proposed versatile targeting strategy. Thus the currently 
study uusing a CS-tagged BoTIM based targeting molecule delivering a 
biotinylated LV to neuronal/cholibergic terminals, while limiting its promiscuous 
infectivity to non-neuronal cells, was formulated.  
Of course, during these involved processes, a large number of things 
could go wrong – the cargo could be inactivated by biotinylation, the targeting 
properties of BoTIM could be destroyed by the attachment of CS or the biotin 
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binding property of CS destabilised by the attachment of BoTIM. In addition, the 
final, assembled, multi-molecular conglomerate might not work as proposed, 
despite the individual components being perfectly functional. This study was 
primarily aimed at solving the first three set of problems and in only obtaining 
some proof-of-principle for the final, and ultimate, goal. 
A LV system was chosen for this part of the project, in preference to an 
AAV, as is has a larger cloning capacity, easier production of high titers and 
since the functional protein core is separate from the protein-studded lipid 
envelope. The large amount of work done in re-targeting LVs, albeit by pseudo-
typing rather than targeting, was another reason for its choice. The obtained 
LVs performed as described by others and was able to replicate important 
results obtained with AAVs – protection from a later application of BoNT/A in 
CGNs. In addition, the devised biotinylation protocols worked efficiently while 
not perturbing the LV’s infectivity or titer.  
The CS-tagging of BoTIMs was another success, with a total of 13 
different molecules generated. The molecules not only bound small biotinylated 
proteins like biot-HRP, but also larger cargo like Biotinylated LVs and 
microspheres. One, expected, result from the chromatographic analysis of CS-
BoTIM was the finding that it exists as a di-tri-tetrameric mixture in physiological 
buffers. But this seemed to not have any strong, or identifiable, effects in the in 
vitro tests conducted. A crucial finding was the retention of exocytotic blockade 
activity by CS-tagged BoNT/Es – validating all the processes that lie behind this 
blocklade i.e., specific binding, internalisation, extra-vasation into the cytoplasm, 
path-finding to membrane bound SNAP-25 and its disablement by cleavage of a 
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27 AA fragment. The difference of only one single a between the active and the 
inactive versions, connotes that all the CS-tagged BoTIMs also undergo the 
same steps and therefore are valid as targeting agents.  
The final series of tests was the attempted targeting of biot-LVs – this 
can be achieved by either increasing their affinity to neurons or by decreasing 
their affinity to non-neuronal cells. An ideal targeting molecule should 
accomplish both the aspects. But since the LVs seem to naturally prefer 
neurons, it was always doubtful if any significant increase in neuronal infectivity 
could be conferred by targeting, or indeed if this could be identified by the end-
point assays available. The results obtained demonstrate a clear reduction in 
viral infection of HEK-293 cells, with no identifiable effects on their infectivity 
towards CGNs in culture. 
Targeting peripherally delivered viruses into spinal motor neurons is an 
exceptionally difficult proposition (for reasons discussed in the introduction). 
The targeting molecule has to overcome the virus’s natural properties till it 
reaches the motor neuron nucleus and then has to immediately give way for the 
viral properties to come to the fore, to enable successful infection. This inherent 
conflict might be difficult to resolve using the currently available tools and 
techniques. However, the procedures developed during this study demonstrate 
that some aspects of this strategy can be successfully attained, at least in in 
vitro model systems. Futher refinements of this protocol, with different targeting 
molecules and/or viruses, might soon enable the acquisition of a complete, 
clinically-applicable, therapy. 
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4. General Discussion and future prospects 
Counter-measures for botulism must contend with several difficulties 
posed by the toxins’ intracellular action, the persistence of the protease activity 
of some serotypes (e.g. /A, /C1) for months inside neurons and the extended 
time required to restore normal neuromuscular transmission (including 
replacement of the truncated SNARE and completion of the endplate 
remodeling that follows paralysis by most serotypes). To cope with these 
challenges, a multi-pronged strategy utilising conjunctive therapies must be 
used – an immediate active/passive immunisation based mopping up of the 
toxin from systemic circulation, direct interventions at the NMJ including delivery 
of protease inhibitors to limit the exocytotic blockade and, finally, delivery of 
resistant SNARE genes to obtain sustained rescue from neuro-paralysis. The 
exquisite specificity and extreme activity of the BoNTs will probably necessitate 
that all these three modes be developed in order to obtain a clinically relevant 
treatment for botulism.  
The present study, which investigates the most optimal way of delivering 
resistant SNAP-25 genes to motor neurons, is an attempt to accomplish the 
final facet in this holistic BoNT therapy strategy. The use of viral vectors to 
deliver and expressed resistant SNAREs has many advantages – once 
infected, there is long-term expression, sustained production and delivery to 
presynaptic terminals.  The multiple serotypes of BoNTs found in nature, each 
highly potent, complicates any potential therapy – especially considering that 
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the main application would be to counter malicious and deliberate dispersal of 
such toxins. But, when used in conjunction with neutralizing antibodies that 
sequester BoNTs in the extracellular environment preventing further uptake and 
inhibitors delivered to cholinergic terminals that counteract the internalized 
toxin, viral vector based delivery of multi-toxin resistant SNAREs, and even 
multiple SNAREs, could result yield such a versatile treatment. The biggest 
problem with viral vector mediated delivery is the amount of time taken by the 
virus to infect the neurons, integrate into the chromosome and to start 
producing the resistant SNAREs. Indeed in rats and mice, the true value of such 
therapy cannot be measured as the toxin’s natural half-life only slightly overlaps 
with the viral-vector’s optimal expression time period. It is for these reasons that 
protection based assays were chosen to prove the efficacy and utility of gene 
delivery as a mode of treatment. Indeed, it is possible that the real value to 
gene delivery can only be gauged in larger animals, with their longer paralytic 
time periods. But the effect of size on the efficiency of viral delivery and 
infection is a factor that could confound such effectiveness. Another potential 
roadblock is the known side-effect of insertional mutagenesis seen in many 
gene therapy trials. Therefore, limiting viral entry to only those neurons that are 
affected will prove to be a critical aspect of a successful therapy. This will 
necessitate the development of a virus specific for motor neurons. 
Direct spinal delivery is currently the most effective mode of ensuring 
viral infection of anterior horn motor neurons. But this is a highly invasive and 
time consuming procedure that might not find much use outside a lab 
environment. Peripheral delivery, by intravenous/intramuscular injection, will be 
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far easier and, therefore, more clinically applicable – especially in treatments of 
mass epidemics of botulism. But since the viruses, AAV and LV, will infect all 
cells, the previously described insertional mutagenesis will be a bigger problem 
for peripheral delivery. In addition, not enough virus will enter the nerve 
terminals and therefore not provide adequate resistant SNARE proteins to 
enable measurable rescue. Targeting viruses to the pre-synaptic cholinergic 
terminals will materially advance prospects of peripherally delivered gene 
therapies for botulism. In addition, such a method, will have great potential in 
the treatment of other biological threats that often affect peripheral nerve 
endings.  
The specificity of CNTs, especially BoNTs, for nerve terminals, which till 
now has been the prime stumbling block, has been harnessed here to 
therapeutic effect.  The proof of principle already obtained for the prophylaxis of 
BoNT/A-induced neuromuscular paralysis in rodents by Adeno-associated viral 
(AAV) delivery of a gene encoding SNAP-25 mutant resistant to BoNT/A 
(Raghunath et al. 2007) when combined with the work that has been started on 
targeting viruses has the potential to yield such a therapy. The ultimate goal is a 
therapy that utilises the properties of LVs and BoNTs to create a hybrid virus 
and also contains larger gene inserts necessary for achieving rescue from all 
relevant BoNT serotypes, incorporates a cholinergic promoter to give absolute 
specificity and uses regulatory elements for controlling expression.  
The next phase leverages the novel tools and techniques developed in 
this project to further modify the existing and proven delivery vehicles and 
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assess the effects of such changes on their targeting efficiency. Building on the 
initial success with AAV-mediated expression of cleavage-resistant SNAP-25, 
the newly-developed second-generation LV gene delivery system adopted has 
proven more flexible – with its larger insert capacity, facility for bi-cistronic 
production of two genes from the same virus, potential for inserting specific and 
regulatable promoters and ease of modifying viral specificity by 
introducing/modifying/pseudotyping the surface glycoproteins. Three sequential 
experimental strands will be investigated to promote LV mediated gene delivery 
after peripheral injection. Firstly, the ability of these LVs to seek and 
preferentially bind to nerve terminals will be enhanced by the addition of 
cholinergic targeting molecules, thereby, increasing motor neuron expression of 
introduced genes whilst decreasing the deleterious effects of non-neuronal viral 
integration. The second strand will be the incorporation of promoters that, in 
case the LVs enter non-neuronal cells, limit gene expression; another track in 
this endeavour will be the incorporation of regulatable promoters that can be 
switched off once the toxin’s effects have been effectively countered. Finally, in 
order to leverage the maximum scope for treating different outbreaks of 
botulism or exposure to the commonly encountered toxins, LVs will be modified 
to co-express in neurons multi-toxin resistant (MTR) SNAP-25 and VAMP2 – 
two major BoNT targets. Current investigations of LV have shown that, even 
unmodified, they preferentially infect neurons and the introduced genes are 
transcribed at a highly accelerated pace. Additionally, their surface 
glycoproteins have been successfully biotinylated, with long, reducible, linkers 
between biotin and the viral surface; such biotinylated LVs retain infectivity. 
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MTR SNAP-25, proven to be resistant to cleavage by BoNT/A, /E and /C1, has 
already been successfully incorporated; LV-induced expression of this protein in 
cultured neurons has been shown to confer protection of glutamate exocytosis 
against a subsequent challenge by BoNT/A or /E. 
The previously developed, CS-tagged, toxin- and immune-based 
targeting molecules will be attached to these viruses and their infectivity plus 
specificity tested in pure neuronal and mixed neuron/glia/muscle cultures. The 
neuronal specificity imparted by the targeting agents will be estimated by 
immuno-fluorescent tracking of trans-gene expression. In addition, the 
availability of fluorescent Taqman-based real-time quantitative PCR assays will 
allow a rapid measurement of the number of viral particles entering the target 
neurons. Compartmentalised cultures of neurons will be used to track the 
retrograde transport of applied targeted-LVs after application to the terminals. 
While targeting should enhance motor neuron infection, there will still be some 
LVs that promiscuously bind to non-neuronal cells (which grossly outnumber the 
motor terminals). Eliminating their expression of the introduced cleavage-
resistant SNAREs should allow the injection of even higher LV doses, thereby, 
increasing chances of motor neuron infection. The best optimised promoter is 
the choline acetyl-transferase promoter (CHAT – 2-4kb), which is only active in 
cholinergic neurons (though, the smaller and proven human synapsin promoter 
will also be tried) – it will be used to replace the native elongation factor-1 
promoter. RT-QPCR after LV application to cerebellar granule neurons, motor 
neurons and myoblasts in culture (or mouse cholinergic neuronal SN6 line, 
mouse non-cholinergic neuronal LAN5 line and rat fibroblast FR3T3 line) will 
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facilitate the assessment of introduced cholinergic specificity. 
 An alternative/additional sophistication is the use of regulatable 
promoters. While multiple choices exist (eg. Ecdysone, RU486 and rapamycin 
based regulation), the tetracycline-induced regulatable system (TiRS) offers 
advantages of rapid induction and minimal promoter leakage, with up to a 
1,000-fold dose-dependent induction of gene expression from the basal state. 
The TiRS system uses a rtTA (reverse tetracycline-controlled transactivator 
attached to 3 repeats of a minimal VP16 transcription activation domain) and a 
TRE (tet-responsive element containing the modified tet-operator in conjunction 
with a minimal CMV promoter driving cleavage-resistant SNARE expression). 
Only upon binding to the tetracycline derivative, doxycycline, is the TRE 
activated and cleavage-resistant SNAREs produced. While the TiRS system 
originally required two different viruses to provide rtTA and TRE systems, use of 
LV and WPRE (Woodchuck hepatitis virus post-translational regulatory 
element) permits their incorporation into a single viral molecule. Once again, the 
use of RT-QPCR will facilitate the measurement of gene induction upon 
introduction of doxycycline; use of a human synapsin promoter to drive rtTA 
expression would add neuron-specificity to this TiRS based regulatable 
promoter. 
 The existence of several toxin serotypes with different SNARE 
substrates/cleavage sites and the potential to create chimeric toxins demand 
the introduction MTR SNAREs into susceptible neurons. An important 
demonstration of the practicability of such an advance is the proven ability of 
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MTR SNAP-25(mutated at D179K, M182T and R197T) to resist cleavage by 
BoNT/A, /E and /C1 in protease assays in vitro and by BoNT/A and /E in 
neuronal cultures. To complement this, MTR forms of VAMP2 will be created – 
with mutations at Q76V conferring resistance to BoNT/B (and TeNT) and K59A 
to /F (and possibly /D).  This MTR-VAMP2 will be tested in vitro and in vivo 
before incorporation into the LV system. Its capacity to participate in productive 
synaptic exocytosis and to resist BoNTs will be determined in neurons infected 
with the virus, and treated with or without BoNTs. If successful, MTR-VAMP2 
will be integrated into the existing LV-MTR-SNAP25 viral system. Co-
expression of MTR-SNAP-25 and MTR-VAMP2 from the same promoter 
(neuron-specific and/or regulatable) can be ensured by addition of an IRES 
sequence (internal ribosome entry site) before the second gene. The bi-cistronic 
MTR-SNARE expressing LVs will be tested, as before, in neuronal model 
systems.  
      While not all of the modifications will succeed, the multi-pronged 
approach described should lead to improvements that could later be adapted in 
clinically-applicable pre- or post-exposure therapies for botulism. 
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Appendix 1 
 
Buffers and Solutions: 
 
Locke’s buffer: 154 mM NaCl; 2.55 mM KCl; 2.13 mM K2HPO4.2H2O; 0.88 mM 
KH2PO4.2H2O; 10 mM glucose; 15 mM HEPES pH 7.4; 1x Antibiotic/Antimycotic mix 
from Invitrogen 
 
Phosphate buffered Saline (PBS): 0.17 mM NaH2PO4.2H2O, 1.76 mM Na2HPO4, 150 
mM NaCl, 2.6 mM KCl 
 
Chromaffin growth medium: DMEM  with 2 mM L-glutamine; 2 mM Na pyruvate; 
25 mM HEPES pH7.4; 1x Antibiotic/Antimycotic mix from Invitrogen; 10 µM cytosine 
arabinofurinoside; 8 µM fluorodeoxyuridine; 10 µM dibutyryl cAMP; 5 µM 
dexamethasone-2-1 phosphate; 50 µg / ml sodium ascorbate; 10% (v/v) heat-inactivated 
FCS 
 
Low ionic strength media (LISM): 5 mM NaCl; 4.8 mM KCl; 2.2 mM CaCl2.2H2O; 
1.2 mM KH2PO4; 1.2 mM MgSO4; 5.6 mM glucose; 220 mM sucrose; 0.5% (w/v) 
BSA; 20 mM HEPES pH 7.4; 1x Antibiotic/Antimycotic mix from Invitrogen 
 
Laemlli gel loading buffer: 8% SDS; 20% glycerol; 0.012% (w/v) bromophenol blue; 
4% 2-mercaptoethanol; 0.5 M Tris HCl; pH 6.8 
 
Western transfer buffer: 25 mM Tris HCl; 192 mM glycine 
 
Tris buffered saline (TBS): 150 mM NaCl; 25 mM Tris-HCl pH 7.0 
 
KGH media for permeabilisation: 140mM Potassium glutamate; 1mM MgCl2; 6mM 
Glucose; 20mM HEPES; pH 7.2 
 
Pre-Scission buffer: 50mM Tris-HCl; 150mM NaCl; 1mM EDTA; 1mM DTT; pH 7.0 
 
Cerebellar mix: 40mM HEPES-NaOH; 20mM NaCl; 80mM KCl; 3.7mM d-Glucose; 
2.8mM CaCl2.2H2O; 1.6mM MgSO4; 1mM NaH2PO4.2H20; pH 7.4 
 
HEPES basal buffer for glutamate release (HBB): 40mM HEPES; 240mM NaCl; 
10mM KCl; 4mM MgCL2.6H2O; 2.5mM CaCl2.2H2O; 10mM d-Glucose; pH 7.4; 300-
310mOSM 
 
HEPES stimulation buffer for glutamate release (HSB): 40mM HEPES; 110mM 
NaCl; 140mM KCl; 4mM MgCL2.6H2O; 2.5mM CaCl2.2H2O; 10mM d-Glucose; pH 
      
 
 
226
7.4; 300-310mOSM 
 
 
Partial cerebellar growth media (PCGM): 375 ml Basal Media Eagle (Sigma); 125ml 
cerebellar mix; 5ml N2 supplement (Invitrogen); 5ml 100xAntibiotic/Antimycotic 
solution (Invitrogen); 10ml dialysed Horse serum; 5ml Glutamax (Invitrogen) 
 
Complete cerebellar growth media (CCGM): PCGM with 40 µM Ara-C (Cytosine β-
D-arabinofuranoside) 
 
Western stripping buffer: 4.9g Tris-HCl (pH 6.7); 3.52ml 2-β-mercaptoethanol; 10g 
SDS; Make upto 500ml with dH2O 
 
TBS/Tween: 50mM Tris; 138mM NaCl; 2.7mM KCl; 0.05% Tween-20 
 
Protease buffer:  20mM Hepes; 100mM NaCl; 10µM ZnSO4 
 
PCR master mix 2x: 10µl NEB Taq polymerase; 10µl 25mM dNTP mix; 100µl NEB 
PCR buffer; 50µl 50mM MgCl2; 330µl dH2O 
 
SDS for colony blot: 100g SDS in 1000ml dH2O 
 
Denaturing buffer for colony blot: 500mM NaOH; 1.5M NaCl 
 
Neutralisation buffer for colony blot: 1.5M NaCl; 500mM Tris-HCl; pH 7.4 
 
20xSSC for colony blot: 87.65g NaCl; 50.25g TriSodium.Citrate.2H2O; 500ml dH2O 
 
2xHBS for transfection: 50mM HEPES; 280mM NaCl; 1.5mM Na2HPO4 
 
CaCl2 for transfection: 300mM CaCl2.2H2O 
 
1X PBS for transfection: NaCl 8.05g; KCl 0.195g; Na2HPO4 1.42g; KH2PO4 0.245g; 
1000ml dH2O; pH 7.4  
 
10xTE: 100 mM Tris pH 7.5; 10 mM EDTA pH 8.0 
 
10x TAE: 400 mM Tris-acetate; 10 mM EDTA 
 
HEPES-NaCl buffer: 50mM HEPES; 150mM NaCl 
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Brief Communications
Adeno-Associated Virus Transfer of a Gene Encoding
SNAP-25 Resistant to Botulinum Toxin A Attenuates
Neuromuscular Paralysis Associated with Botulism
Arvind Raghunath,1 Francesc Perez-Branguli,1 Leonard Smith,2 and J. Oliver Dolly1
1International Centre for Neurotherapeutics, Dublin City University, Dublin 9, Ireland, and 2Integrated Toxicology Division, United States Army Medical
Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702-5011
Advances in viral gene therapy have opened new possibilities for treating a range of motor neuron diseases, but these have not yet been
translated into clinically applicable therapies because of difficulties in delivery to susceptible/damaged neurons, ambiguities in the
identity of gene(s) implicated, and a paucity ofmeans to quantify any physiological improvement.Most of these hurdles can be overcome
by using the neuromuscular paralysis induced by botulinum neurotoxin type A (BoNT/A) as a prototype disease. Furthermore, because
human botulism, occasionally fatal, causes prolonged muscle disablement as a result of the intraneuronal persistence of the toxin’s
SNAP-25 (S25)-cleaving protease, development of a genetic approach could lead to a potential treatment for this debilitating disease.
Adeno-associated viral delivery of a cleavage-resistant S25 gene (S25-R198T) to chromaffin cells in vitro yielded exocytotically active
S25-R198T that diminished subsequent blockade by BoNT/A of evoked catecholamine release. Evaluation in vivo, by administering this
virus into rat spinal cordbefore injectingBoNT/A, showedadecreased inhibitionof acetylcholine release as reflected in elevated retention
of neuromuscular transmission. A similar, although smaller, protection of synaptic transmission from the toxin was seen after periph-
erally injecting the therapeutic virus. Such therapy also curtailed nerve sprouting normally induced byBoNT/A. This first demonstration
of the utility of a DNA-based therapy for botulism paves the way for further advances in its treatment and for application to genetic
disorders of motor neurons.
Key words: botulinum; gene transfer; neuromuscular junction; motor neuron; SNARE proteins; sprouting
Introduction
A major challenge facing gene therapy for motor neuron disor-
ders, a group of rare yet debilitating and ultimately fatal diseases
affecting spinal motor neurons, is targeted, minimally traumatic
delivery. Because of the limited number of motor neurons (e.g.,
rat sciatic nerve has only 2000 efferents) (Nicolopoulos-
Stournaras and Iles, 1983), insults that are merely sublethal in
other cells can be extremely deleterious [e.g., in superoxide-
dismutasemutantmice, which ubiquitously express the damaged
protein, motor neurons are the most affected (Bruijn et al.,
2004)]. Their anatomical structure, with a relatively inaccessible
cell body in the spinal column and an elongated axon, compli-
cates therapies including gene transfer by viral vectors. Those that
transfect motor neurons [adeno-associated virus (AAV), lentivi-
rus, and herpes virus] do so most efficiently when in direct con-
tact with the cell body (Mannes et al., 1998). Because intraspinal
injection is difficult under clinical conditions, the use of periph-
erally deliverable vectors would be desirable; moreover, such an
advance requires a model that allows accurate measurement of
the graded improvements currently achievable.
An ideal system to evaluate such therapies is the blockade of
neuromuscular transmission by botulinum neurotoxin type A
(BoNT/A). Its light chain Zn2-dependent endoprotease causes
irreversible blockade of acetylcholine (ACh) exocytosis by spe-
cific cleavage of SNAP-25 (S25), a protein essential for this fun-
damental process (Blasi et al., 1994). Importantly, protection
from inhibition by BoNT/A can be achieved by expression of a
toxin-resistant S25 mutant gene (O’Sullivan et al., 1999). Fur-
thermore, because current treatments are ineffective in combat-
ing botulism, it is imperative that a refined therapy is designed
with the ability to abrogate the prolonged convalescence and high
mortality and morbidity associated with this condition.
Herein, sustained neuromuscular paralysis by BoNT/A was
attenuated using AAV vectors that give long-term expression of a
cleavage-resistant S25 mutant (S25-R198T), having all the prop-
erties of thewild type, including ability to substitute for truncated
S25 and recover exocytosis in intoxicated chromaffin cells
(O’Sullivan et al., 1999). AAV vectors provide an efficient and
relatively safe way to ensure prolonged expression of genes in
neurons (Burger et al., 2005), and botulism in rats provides a
much more valid model for evaluating this gene therapy. Injec-
tion of AAVs encoding S25-R198T into the spinal anterior horn
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innervating the soleus muscle protected neuromuscular trans-
mission from subsequent inhibition by BoNT/A. Moreover,
muscles treated in this way showed a decreased amount of nerve
sprouting compared with unprotected controls. Finally, admin-
istering the therapeutic AAVs directly into the soleus muscle re-
sulted in their retrograde transport to motor cell bodies and a
consequential reduction of BoNT/A-mediated blockade of neu-
rotransmission at peripheral synapses. These findings provide the
first evidence for the potential applicability of gene therapy to the
intractable problems posed by botulism and, possibly in the
longer-term, genetic disorders of motor neurons.
Materials andMethods
Construction, production, and purification of recombinant AAVs expressing
BoNT-resistant S25. PCR, using the S25BamH1His6-For and S25XhoI-
Rev primer pair, generated aHis6-tagged S25 fromamouse S25 gene; this
was inserted into the pAAV-MCS plasmid to generate the pAAV-His6-
S25 plasmid [96% homologous to human S25 (for primer sequences,
see supplemental material, available at www.jneurosci.org)]. A similar
technique, with the substitution of S25RTXhoI-Rev for S25XhoI-Rev,
created pAAV-His6-S25-R198T encoding a BoNT/A-resistant S25. These
different plasmids, along with AAV-hrGFP, were used to create their
respective replication-deficient AAVs and purified on heparin-agarose,
as described previously (Zolotukhin et al., 1999). Viral (protein) yield
and purity were assessed on Coomassie-stained SDS-PAGE gels by com-
paring the surface proteins (VP1, VP2, and VP3) to a bovine serum
albumin (BSA) standard. Real-time quantitative PCR, with appropriate
primers, quantified the number of genomic copies (GCs) per prepara-
tion, and a dilution series applied toHEK-293 cells yielded the number of
transducing units.
Culture of chromaffin cells, infection with recombinant AAVs, intoxica-
tion with BoNT/A, and assay of catecholamine release. Bovine adrenal
chromaffin cells were isolated as described previously (Lawrence et al.,
1996), infected with AAVs, and 7 d later exposed for 24 h to 10 nM
BoNT/A under conditions that promote its uptake. Ba2-evoked cate-
cholamine release was measured after different viral treatments and nor-
malized to that in the presence of the toxin alone and presented as
mean SD (n 4), from two or more sets of experiments. t tests were
used to determine the statistical significance.
Stereotaxic intraspinal administration of AAVs for transfection of ante-
rior horn neurons supplying the soleus muscle. Rats were anesthetized with
medetomidine/fentanyl citrate, and the T10-L2 vertebrae were exposed
and positioned in a stereotaxic frame using spinal adapters (Stoelting,
WoodDale, IL). After careful penetration of the vertebral lamina over the
T13 spinal level using a microdrill, known quantities of the virus were
injected over 5 min with a Hamilton microsyringe attached to a 30 ga
beveled needle. After a further 5 min, the needle was withdrawn and
the procedure repeated at L1 and L2 levels; twitching of the lower limb
muscles confirmed the accurate placement of the needle. The paraspi-
nal muscles and the superficial fascia, reinforced with a polypropylene
mesh, were sutured with vicryl sutures, and the skin was closed with
Prolene sutures before injection of atipamazole/nalbuphine and
carprofen/bupivacaine.
In situ recording of neuromuscular transmission after BoNT/A adminis-
tration. Three weeks after the intraspinal injection, 1 mouse LD50 of
BoNT/A in 10 l of normal saline (NS)/BSA was injected into the soleus
muscle. After a 16–25 d recovery, the rats were anesthetized, and the
soleal contribution to the Achilles tendon was isolated and ligated to a
sensitive force transducer (FORT10 and PowerLab 4/20T; ADInstru-
ments, Castle Hill, New South Wales, Australia). The sciatic nerve, ex-
posed at midthigh level, and the belly of the soleus muscle were stimu-
lated at 1 Hz/200 mV/0.2 ms and 1 Hz/5 V/2 ms, respectively; 60 Hz
stimulation provided the response at tetanic frequencies.
Immunohistochemical detection of S25, His6-S25, His6-S25-R198T, and
GFP expression. Serial 25 mmuscle and spinal cord sections were per-
meabilized before exposure to the primary antibody (1:50 for anti-NF200
and anti-His6) diluted in PBS with 0.05% Tween 20/1% BSA/2% goat
serum and, after washing, to the relevant secondary antibodies (1:50
Alexa-488 or 1:100 A546/phycoerythrin-labeled goat anti-mouse) with
or without 1:500 fluorescently tagged -bungarotoxin (-BuTx; with
Alexa 488 or rhodamine). These were visualized with an Olympus (To-
kyo, Japan) IX51 inverted fluorescent microscope or, when appropriate,
a Zeiss (Thornwood, NY) confocal microscope (LSM510).
Determination of the distribution of ACh receptors at neuromuscular
junctions using fluorophore-conjugated -BuTx. Random soleal sections
from rats injected with BoNT/A alone, AAV-His6-S25-R198T, and then
BoNT/A and untreated controls were stainedwith an-BuTx–Alexa-488
conjugate; for determination of muscle parameters, see supplemental
material (available at www.jneurosci.org). Staining with anti-NF200 and
fluorescently tagged -BuTx allowed visual monitoring of sprouting at
neuromuscular junctions (NMJs) protected by viral-mediated produc-
tion of BoNT/A-resistant S25.
Results
Protection of stimulated exocytosis from BoNT/A-induced
blockade by prior expression of His6-S25-R198T, but not
wild-type S25, in chromaffin cells
AAV helper-free vector system based on a nonpathogenic parvo-
virus was used to construct recombinant type-2 AAVs incorpo-
rating different genes. Initially, control viruses expressing the
hrGFP marker protein were produced; heparin affinity chroma-
tography yielded pure viruses containing only viral surface pro-
teins (Fig. 1A,B). Their activity was established from expression
of hrGFP fluorescence in infected chromaffin cells (Fig. 1C).
Later, wild-type ormutated S25, engineered to be nonsusceptible
to cleavage by BoNT/A, were introduced into this vector. In some
cases, the proteins were coexpressed with an hrGFPmarker using
an IRES segment (AAV-His6-S25-R198T-IRES-hrGFP); coex-
pression was demonstrated by immunodetection of His6, S25,
and hrGFP in lysed cells (Fig. 1D).
Their protective abilities were demonstrated in chromaffin
cells exposed for 7 d to various concentrations of the recombi-
nant viruses before challenge with 10 nM BoNT/A (the 150 kDa
neurotoxin free of accessory proteins was used throughout).
AAV-His6-S25-R198T viruses gave a dose-dependent relative in-
crease in exocytosis of 55% compared with the level recorded
for cells treated with toxin alone (Fig. 1E). The highest concen-
tration of viral particles tested, equivalent to a multiplicity of
infection  50, infected 90% of the cells. The AAV-His6-S25-
R198T-IRES-hrGFP virus yielded a lower, yet significant, relative
protection (23%), whereas overexpression of wild-type S25
failed to show any effect (Fig. 1E). This extent of prophylaxis,
despite using large numbers (106 cells per well) of postmitotic
neuroendocrine cells, justified progression to in vivo testing of
this gene therapy paradigm. Moreover, infection of chromaffin
cells with viral particles expressing toxin-resistant, but not wild-
type, S25 gave appreciable rescue of evoked catecholamine exo-
cytosis that had been inhibited by preexposure to BoNT/A (see
supplemental material, available at www.jneurosci.org).
Efficient expression of cleavage-resistant S25 in peripheral
nerve terminals of rats after intraspinal administration of
AAVs protects against the neuroparalytic effects of BoNT/A
Published data (Adler et al., 2001) determined the choice of rat
soleus muscle as an in vivo system to study the effects of viral
vector-induced BoNT prophylaxis. The efficiency of neuromus-
cular transmission (ENT; the ratio of the force of contraction
elicited by nerve stimulation to that elicited by direct muscle
stimulation) provides an accurate and sensitive means to deter-
mine the progress of, and recovery from, toxin-induced paralysis.
Stereotaxic injection of AAVs expressing marker hrGFP and/or
His6-S25-R198T into the right anterior T12, L1, and L3 spinal
3684 • J. Neurosci., April 2, 2008 • 28(14):3683–3688 Raghunath et al. • Botulism Combated by Gene Transfer of Mutated S25
horns, containing the cell bodies of neurons supplying the soleus,
resulted in a localized coexpression of hrGFP and His6-S25-
R198T, confirming the accuracy of the microsurgical procedure
(Fig. 2A). After 6–7 weeks, the expressed proteins were also seen
in the periphery at NMJs, identified by colocalization with
-BuTx (hrGFP and-BuTx in Fig. 2B andHis6-S25-R198T and
-BuTx in Fig. 2C). The functional effectiveness of this cleavage-
resistant S25 was established by bilateral injection of 1 mouse
LD50 of BoNT/A in NS/BSA into the soleus 21 d after viral
injection, followed by ENT measurements after a further 16 d.
The expected reduction in transmitter release after injecting
BoNT/A alone was confirmed, whereas the maintenance of
near-normal neurotransmission in synaptic junctions overex-
pressing hrGFP or S25-R198T demonstrates purity of the
preparations and the minimal trauma caused by the stereo-
taxic technique (Fig. 2Di,Dii). Animals preinjected with AAV-
His6 S25-R198T showed a significantly greater retention of
neuromuscular transmission (Fig. 2Div) compared with the
unprotected (contralateral) side after a BoNT/A challenge
(Fig. 2Diii) ( p  0.05); summarized data from four animals
for each group are depicted in Figure 2E. This attenuation of
BoNT/A-induced neuroparalysis is the first ever demonstra-
tion of a nonimmunological protective therapy in whole ani-
mals and establishes the functional effectiveness of the periph-
erally delivered cleavage-resistant S25.
BoNT/A-induced synapse remodeling is reduced by
protection of neuromuscular transmission with a spinal
injection of AAV-His6-S25-R198T
Sections of soleal muscles from BoNT/A-treated and control rats
were stained with -BuTx-A488 and the anti-NF200 antibody to
visualize the postsynaptic and presynaptic parts of the NMJ, re-
spectively. Comparison of images from control and those treated
16 or 25 d earlier with BoNT/A revealed a much greater number
of sprouts in the latter (Fig. 3, compare A with B–F). Addition-
ally, in agreement with published results (Brown et al., 1980), it
was observed that axonal and endplate sprouting frequently co-
existed in the same muscle and, sometimes, in the same endplate
(Fig. 3F). After characterizing BoNT/A-induced sprouting, the
effect of protection on this process was determined. Immuno-
staining of soleal sections treated with toxin for 16 d showed less
extensive sprouting at NMJs of rats that received BoNT/A-
resistant S25 than those given toxin alone (Fig. 3G,H). To quan-
tify these changes, the amount of sprouting in “protected (by
AAV-His6-S25-R198T) and challenged (by BoNT/A)” muscles
were compared with “unprotected and challenged” or “unpro-
tected and unchallenged” muscles. Because changes in ACh re-
ceptor density and distribution are highly sensitive to perturba-
tions of synaptic transmission, an automated quantitation of
-BuTx–fluorophore conjugate binding to the postsynaptic part
of the NMJ was chosen (Pestronk and Drachman, 1978; Wang et
Figure 1. AAV-mediated expression in chromaffin cells of cleavage-resistant S25, but not wild-type, antagonizes inhibition of catecholamine release by BoNT/A.A,B, Coomassie-stained gel (A)
and Western blot (B) of aliquots from stages of the production of AAV-hrGFP. M, Markers; Lys, lysate; De, deoxycholate extract; Ft1, flow-through from heparin-agarose column; E, eluate; Ft2,
flow-through from concentrator; Conc, concentrated AAV-hrGFP. Arrows show surface proteins VP1, VP2, and VP3 withMr 87,000, 73,000, and 62,000, respectively. C, Fluorescent microscopy
demonstrated extensive infection by AAVs. D, Western blotting confirmed coexpression of hrGFP and His6-S25-R198T. E, Chromaffin cells were infected with AAVs (10
7 GCs per well or multiples
expressing His6-S25WT, His6-S25-R198T, or His6-S25-R198T plus hrGFP) or vehicle and 7 d later exposed to 10 nM BoNT for 24 h before quantifying Ba
2-evoked catecholamine release. Averaged
relative release fromvirus-treatedandcontrol cellsSD is plotted (n4). Cells expressing cleavage-resistant S25 showeda significant increase in catecholamine release (*p0.01, asdetermined
by a t test) compared with controls.
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al., 2005). Relative to untreated muscles, significant increases
were found after BoNT/A treatment in the mean endplate area,
the area of the largest endplates and, probably because of the
muscle wasting that accompanies paralysis, the endplate space
occupied permuscle section (Fig. 3I). However, interestingly, the
average endplate area was significantly reduced in those end-
plates expressing S25 R198T compared with controls [treated
with the toxin alone (Fig. 3J)]. A lesser, nonsignificant reduction
was seen in themaximum endplate and in the ratio of endplate to
muscle areas (Fig. 3J).
Partial protection against BoNT/A-induced neuroparalysis in
rats by neuronal expression of His6-S25-R198T after
peripheral injection of its AAV construct
Although intraspinal AAV injection achieved efficient transduc-
tion and protection of motor neurons against BoNT/A, a periph-
erally deliverable therapy is still preferable. The control AAV-
hrGFP virus underwent retrograde transport to the spinal cord,
as confirmed by expression of the marker protein in motor neu-
rons of the anterior horn supplying the soleus muscle (Fig. 4A).
Having confirmed the utility of such an approach, the ability of
AAV-His6-S25-R198T to protect themotor neurons fromBoNT/
A-mediated paralysis was next evaluated by its injection into the
soleus muscle, followed a week later by toxin administration; the
contralateral muscle was injected with the toxin alone. When
tested 3 weeks after the viral injection, the protected NMJs in the
best responding animals showed a fourfold to sixfold higher re-
tention of synaptic transmission [18.5 vs 3.2% for single stimu-
lation (Fig. 4Bi) and 62.5 vs 15.3% for tetanic stimulation (Fig.
4Bii)]. The combined results, from six animals for each treat-
ment, showed that the side injected with the virus gave a 2.5-
fold increased retention of muscle strength in response to tetanic
Figure2. Treatmentwith AAV-His6-S25-R198T protects against neuromuscular paralysis induced by BoNT/A.A, Spinal cord sections from rats injectedwith AAVs (5l of 10
11 GC/ml) expressing
hrGFP (green) and His6-S25-R198T (red) show colocalization in the right L1/L2 and L3/L4 anterior horns. Scale bar, 200 m. B, C, Delivery of hrGFP (green; B) and His6-S25-R198T (red; C) to
presynaptic terminals demonstrated by colocalization with the postsynaptic ACh receptor (-BuTx, red in B, green in C), in soleal sections from rats injected with AAV-hrGFP (B) or AAV-His6-S25-
R198T (C). Scale bars, 20m.D, Effect on ENT of spinal injection of AAV-hrGFP (i) andAAV-His6-S25-R198T (ii, iv) or vehicle (iii) into animals, someofwhichwere challengedwith BoNT/A 21 d later
(iii, iv). Representative contractions after a further 16 d from single supramaximal stimulation of the sciatic nerve (right) and direct stimulation of themuscle (left) are shown. E, Summarized data
showing that viral pretreatment protects ENT from subsequent paralysis by BoNT/A; each bar represents the mean SD of values from four animals (*p 0.05).
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stimulation (27.5 vs 10.5%) (Fig. 4B). These investigations pro-
vide an encouraging demonstration of the potential of minimally
invasive paths to a gene therapy for botulism.
Discussion
To prevent the prolonged convalescence associated with human
botulism caused by BoNT/A, a clinically effective therapy needs
to act at multiple stages by antagonizing the toxin’s binding or
uptake, inhibiting its breakdown of S25, and/or hastening recov-
ery by replenishing truncated S25 with a functional, BoNT-
resistant form (O’Sullivan et al., 1999). Althoughprogress toward
the first two goals is being achieved by pharmacological means
using inhibitors of the toxin’s protease, a novel gene therapy
approach is necessary to attain the final stages, especially in light
of the extraordinary persistence of BoNT/A protease at nerve
terminals (Keller et al., 1999; Foran et al., 2003;Meunier et al., 2003).
The applicability of gene therapy was initially revealed by demon-
strating the attenuation of this toxin’s inhibition of secretion from
chromaffin cells after overexpression of a cleavage-resistant S25
(O’Sullivan et al., 1999). Because the classical gene transfection used
in that earlier study gave very low efficiency, much more effective
gene delivery is a prerequisite for in vivo therapeutic purposes. To
this end, the gene encoding S25-R198T was inserted into an AAV
vector yielding a highly efficient, nonpathogenic virus for transfer-
ring genes into nondividing neurons.
Initial experiments confirmed that overexpression of a His6-
tagged cleavage-resistant S25 in eukaryotic cells does not over-
whelm the posttranslational processes, especially palmitoylation,
as revealed by the membrane association of this protein (see sup-
plemental results, available at www.jneurosci.org as supplemen-
tal material). This is important in light of the failure of free cyto-
plasmic S25 to take part in productive exocytosis (Washbourne et
al., 2001) and because of the necessity for
toxin-resistant S25 to antagonize disabled
S25 at the membrane (O’Sullivan et al.,
1999). The administered viruses infected
90% of 106 chromaffin cells and pro-
duced enough BoNT/A-resistant S25 to
overcome the toxin’s inhibitory effects.
Although the in vitro results validated
this therapeutic strategy, it was necessary
to establish its applicability to the more
complex in vivo system. BoNT/A-induced
paralysis can be measured by decrease in
force of contraction evoked by stimulation
of the sciatic nerve in rat limb muscles
(Adler et al., 2001). The synaptic remodel-
ing of rat soleal NMJs after neuroparalysis
(Pestronk and Drachman, 1978; Brown et
al., 1980) was another reason for choosing
this muscle. Direct injection into the spi-
nal anterior horn was used initially be-
cause it gives a more intense infection of
motor neurons and, consequently, recom-
binant protein production than intrathe-
cal administration (Mannes et al., 1998).
Intraspinal injection of cleavage-resistant
S25-expressing AAVs resulted in a local-
ized expression of this protein in the lum-
bar anterior horns and, subsequently, pe-
ripheral transport to their synaptic
terminals (Fig. 2). Significantly, the ex-
pressed and peripherally transported
transgenic protein successfully substituted
for native cleavage-susceptible S25, as demonstrated by enhanced
retention of nerve-stimulated muscle contractility in prepro-
tected animals later challenged with BoNT/A (Fig. 2), detected by
single supramaximal stimuli or tetanic pulses with protection
being more marked with the latter. Only AAVs expressing His6-
S25-R198T, and not those that produce hrGFP orwild-typeHis6-
S25, proved effective. This is the first report on successful antag-
onism of BoNT/A action in live animals using viral-mediated
gene delivery. The protection seen demonstrates that the recom-
binantly produced protein cannot only overcome the persistent
protease activity of the toxin at motor neuron terminals, but also
any probable inhibition by the truncated native S25 (Dolly and
Aoki, 2006). A combination of such gene delivery with effective
inhibitors of the protease should help provide both immediate
and prolonged therapy.
Published data suggested that AAVs undergo successful retro-
grade transport from mouse NMJs and can efficiently infect the
supplyingmotor neurons, with1 in 1000 reaching the cell body
(Kaspar et al., 2003). Although injection of5 1011 AAVs into
soleal muscle proved necessary to detect infectedmotor neurons,
thismode of administration offers advantages ofminimal trauma
and faster recovery from the operating procedure; most notably,
in terms of possible clinical application, it allows easier access to
important muscles. The potential of peripheral application is re-
flected by the promising protection obtained.
It is believed that synaptic remodeling after BoNT/A-induced
paralysis plays an important role in the early recovery (de Paiva et
al., 1999;Meunier et al., 2003). The quantity of sprouts is thought
to depend strongly on the amount of toxin, the kind of muscle
[fast muscles have lower amounts of mostly axonal sprouting,
compared with slow muscles, which show a higher percentage of
Figure3. Influence of virally expressedHis6-S25-R198T on synaptic remodeling in rat soleusmuscles induced byBoNT/A.A–F,
Immunofluorescent images fromcontrol (A) andmuscles injectedwith2 LD50 units of BoNT/A (B–F ) showingaxonal sprouting
(B, magnified in C), terminal sprouting (D, magnified in E), and mixed sprouting [F; axonal sprouting (arrow) and terminal
sprouting (arrowhead)]. Scale bars, 20 m. -NF200 is shown in red with -BuTx-A488 in green. G, H, The effect of having
administered AAV-His6-S25-R198T 21 d before BoNT/A injection (H ) compared with the muscle given the toxin only (G). I, J, An
automated quantitation of sprouting determined the various parameters plotted (as average SEM) in I formuscle treatedwith
BoNT/A (shaded) or vehicle (open) and in J those receiving BoNT/A alone (shaded) or BoNT/A plus AAV-His6-S25-R198T (hatched)
(*p 0.005 by unpaired t test).
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terminal sprouts (Pestronk and Drachman, 1978; Brown et al.,
1980)], and the duration of paralysis (Meunier et al., 2003). The
data herein revealed a reduction in synaptic remodeling when
paralysis is limited by overexpression of cleavage-resistant S25 in
nerve endings, substantiating the hypothesis that the extent of
neurotransmission blockade, along with the duration, are strong
determinants of synapse remodeling. The changes in sprouting
seen after treatment with the same dose of BoNT/A toxin in the
presence or absence of viral protection seem to confirm that the
differential effects on sprouting seen previously with the different
toxin serotypes are a property of the duration of paralysis and not
of the substrate cleaved.
This study attained an important milestone in devising a pe-
ripherally deliverable gene therapy that can counteract the pro-
longed paralysis by BoNT serotypes. The proof of principle ob-
tained provides an encouraging foundation on which to build
more versatile vectors based on lentiviruses that could allow the
simultaneous transfection of neurons with multiple-toxin-
resistant S25, VAMP-2, and syntaxin for combating several sero-
types and even novel chimera. Furthermore, botulinization
solves problems associated with using murine models of human
motor neuron diseases. The ability to control the extent/severity
of “disease” combined with the availability of a sensitive assay for
measuring peripheral neurotransmission and knowledge of the
gene required to protect against the toxin’s effects, ought to allow
meaningful assessment of successful delivery. Such elimination
of these multiple variables should enable a more focused and
successful optimization of a peripherally administered viral vec-
tor that can target therapeutic genes into motor neurons.
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